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Abstract 
 
Migrant South Asian populations in Europe, North America the Westernised 
countries have a greater cardiovascular disease (CVD) risk than their respective 
indigenous populations.  Both overall and premature CVD morbidity and 
mortality is significantly higher in migrant South Asians than in white populations 
in the UK and globally. Despite this, the role of ultrasound as a screening tool for 
CVD risk assessment in South Asians has not been studied extensively. Data also 
suggest that increased susceptibility to the adverse effects of insulin resistance 
and type 2 diabetes mellitus (T2DM) may contribute to the increased CVD risk.  
 
South Asians  living in the United Kingdom also have a 3-5 fold increased 
prevalence of T2DM, developing the disease around a decade earlier and at a 
lower body mass index (BMI) compared to white Europeans.  Furthermore, non-
diabetic South Asians have higher fasting glycaemia and are more insulin 
resistant than Europeans. Liver fat is also associated with insulin resistance and 
T2DM risk and is considered to play a causal role in diabetes. Limited data 
suggest that South Asians have higher liver fat content than age- and BMI-
matched Europeans, but it is not currently clear whether this contributes to the 
observed ethnic difference in insulin resistance. 
 
The first aim was to determine the extent to which increased insulin resistance 
and fasting glycaemia in South Asian, compared to white European men, living in 
the UK, was due to lower cardiorespiratory fitness (maximal oxygen uptake 
[VO2max]) and physical activity. The second aim was to determine whether South 
Asians have increased liver fat compared to Europeans and the extent to which 
any such differences can explain the increased insulin resistance observed 
between these groups. The final aim was to determine whether South Asians had 
a difference in carotid intima-media thickness (cIMT) or carotid plaque presence 
compared to Europeans; and if so, whether any measured risk factors (if any) 
could account for any such observed differences in cIMT and/or carotid plaque 
disease. 
 
100 SA and 100 age and BMI-matched European men without diagnosed diabetes, 
aged 40-70 years, had fasting blood taken for glucose concentration, insulin, plus 
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other risk factors, and underwent 2-dimensional carotid ultrasound for 
measurement of intima-media thickness and carotid plaque analysis, assessment 
of physical activity (using accelerometry), VO2max, body size and composition, 
and demographic and other lifestyle factors. For addressing the first aim of this 
thesis, 13 South Asian and 1 European man had HbA1c levels >6.5% indicating 
potential undiagnosed diabetes and were excluded from the analyses relating.  
Linear regression models were used to determine the extent to which body size 
and composition, fitness and physical activity variables explained differences in 
insulin resistance (assessed by Homeostasis Assessment Model of Insulin 
Resistance, HOMAIR) and fasting glucose between SA and Europeans. For the 
second aim, 28 South Asian and 24 European participants were chosen at random 
(but matched for age) within 4 months of their original main study visit to 
undergo magnetic resonance spectroscopy for quantification of liver fat. 
 
HOMAIR and fasting glucose were 67% (p<0.001) and 3% (p<0.018) higher, 
respectively, in South Asians than Europeans.  Lower VO2max, lower physical 
activity and greater total adiposity in SA individually explained 68% (95% 
confidence interval [CI], 45-91%), 29% (95% CI, 11-46%) and 52% (95% CI, 30-80%), 
respectively, and together explained 83% (95% CI, 50-119%) (all p<0.001), of the 
ethnic difference in HOMAIR. Lower VO2max and greater total adiposity 
respectively explained 61% (95% CI, 9-111%) and 39% (95% CI; 9-76%) (combined 
effect 63% (95% CI 8-115%); all p<0.05)) of the ethnic difference in fasting 
glucose.  Unadjusted mean liver fat content did not differ significantly between 
South Asians compared to Europeans (5.28 (standard deviation [SD], 2.11)% vs 
5.41 (SD,2.35)%, p=0.913), but following adjustment for alcohol consumption 
was significantly lower in South Asians than Europeans (5.30 (SD, 2.10)% vs 9.03 
(SD, 2.22)% p=0.017).  Adjustment for alcohol-adjusted liver fat did not 
attenuate the difference in HOMAIR between ethnic groups. There were no 
significant differences in unadjusted or age-adjusted in mean cIMT between 
South Asians and Europeans.  There was an increased odds ratio for the presence 
of plaque disease in South Asians compared to Europeans, however this was not 
significant (OR 1.57, 95% CI 0.89-2.77, p=0.13). 
 
Lower cardiorespiratory fitness is a key factor associated with the excess insulin 
resistance and fasting glycaemia in middle-aged South Asian compared to 
 4 
 
European men living in the UK.  Also, whilst clear associations between liver fat 
and insulin resistance were observed in South Asians and Europeans, these 
results challenge the notion that excess liver fat per se explains the greater 
insulin resistance observed in South Asians. Finally, cIMT is similar between 
South Asian and European men and there is also currently no clear evidence for 
more carotid plaques in South Asian compared to European men living in the UK. 
This important negative finding highlights the need for further studies on carotid 
plaque or research in alternative screening methods for CVD which are more 
sensitive in identifying subclinical CVD. 
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Chapter 1 
Introduction and Literature Review 
 
1.1 Cardiometabolic disease and associated risk factors 
 
Cardiovascular disease (CVD) due to coronary heart disease (CHD) and 
cerebrovascular disease, accounted for nearly 180,000 of the 561,666 deaths in 
the UK in 2010, making it the second highest cause of death behind cancer (1) 
and is the leading cause of death in western Europe and North America. Whilst 
age-standardised deaths from CVD are falling, absolute deaths due to CVD have 
risen between 1990 and 2010 – in 2010 CVD accounted for 25 % of global deaths, 
having accounted for 20% in 1990 (2). Further, recent large scale longitudinal 
data (>800,000 people) largely from Europe and North America examining the 
association of diabetes mellitus (DM) with CVD mortality showed that after 
adjustment for age, sex, smoking status, and body mass index (BMI), the hazard 
ratio (HR) among persons with DM as compared with persons without DM was 
2.32 (95% confidence interval [CI], 2.11-2.56) for death from CVD (3). Further, 
middle-aged adults with DM but without known vascular disease died about 6 
years younger than people without DM - around 58% of this survival difference at 
50 years of age can be attributed to excess vascular deaths (3). 
 
Following the very first publication from the Framingham Study over 60 years 
ago (4), prevention of CVD (primary or secondary) has focused on the 
management of established modifiable risk factors. These traditional or 
established risk factors include  blood cholesterol, tobacco smoking, 
hypertension, diabetes mellitus (DM) and more recently, reduced physical 
activity (5).  Interest has grown in additional ‘novel’ risk factors, such as insulin 
resistance and cardiorespiratory fitness (6). It is also well recognised that the 
risk of morbidity and mortality from CVD is influenced by ethnicity.   
 
 
1.2 South Asians and risk of cardiometabolic disease 
 
People of South Asian origin (people from India, Pakistan, Bangladesh and Sri 
Lanka) were one of the first ethnic groups recognised to have increased CHD 
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risk.  One of the first studies published on CHD and South Asians (using autopsy 
data), showed that migrant Asian Indian males in Singapore had seven times the 
CHD prevalence of Chinese men (7).  Subsequently, this increased risk has been 
confirmed by a number of reports indicating that migrant South Asian 
populations in the UK and North America and elsewhere in the world have a 
greater CHD risk than their respective indigenous populations (8).  The global 
INTERHEART study, found that myocardial infarction (MI) occurred on average 10 
years earlier in South Asians than in white populations based on case-control 
data from 52 countries (9). Furthermore, the age-standardised CHD mortality in 
South Asians living in the UK has been around 50% higher than the indigenous 
white population (10). More recently the age-standardised mortality of migrant 
South Asians in the UK shows persistence of increased mortality from ischaemic 
heart disease (IHD), with Indian men having a standardised mortality ratio (SMR) 
increased by 31%, Pakistani men by 62% and Bangladeshi men by 75% (Table 1.1) 
(11). Similarly, the same study showed that deaths from cerebrovascular disease 
remain in excess for migrant South Asian men.  Also, CHD mortality in young 
migrant South Asian men and women (aged <40) is over double that of Europeans 
(12;13).  
 
 
Table 1.1 Deaths from IHD in the UK for men 2001-2003.  
 
Country Number of IHD 
Deaths 
SMR (95% CI) 
England and Wales 149,950 96   (96-97) 
Scotland 3813 104 (100-107) 
India 2528 131 (126-137) 
Pakistan 1044 162 (152-172) 
Bangladesh 409 175 (158-193) 
 
 
The increased CHD burden in the migrant South Asian population is not entirely 
explained by traditional CVD risk factors, such as cholesterol, blood pressure 
and smoking (14-17). The largest dataset comparing the traditional risk factors 
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in South Asian compared to European men comes from the 2004 heath survey for 
England (18). Data from the survey confirmed that with the exception of the 
increased prevalence of DM and increased prevalence of smoking (Bangladeshi 
men only), there were little differences in traditional risk factors between South 
Asians and the general population (Table 1.2). A systematic review comparing 
blood pressure between South Asians, even indicated that blood pressure levels 
may be lower in Pakistanis and Bangladeshis compared to Europeans living in the 
UK (19).  
 
 
Table 1.2 Differences in CVD risk factors between South Asian men and the 
general population living in the UK. (Health Survey for England 2004 (18)) 
 
 Indians Pakistanis Bangladeshis General 
Population 
Current smoking (%) 20 29 40 24 
Cholesterol 5.3 5.3 5.3 5.5 
Systolic blood 
Pressure (mmHg) 127 124 121 130 
Diabetes (%) * 9.8 17.9 19.0 3.8 
 
* Self-reported history 
 
The data in Table 1.2 show similar total cholesterol values in South Asian and 
European men, with similar data reported the Southall study in 1991 and in 
more recently in patients with diabetes living in Scotland (20). Although LDL 
levels are similar, it has been found that South Asians have smaller and more 
dense LDL cholesterol particles, which are considered to be more atherogenic 
(21;22). Further, HDL cholesterol, which is known to be predictive against CVD 
(23) was lower in the South Asian group in the Southall study. Further, HDL 
cholesterol may be less protective in South Asian, as particle size (which is 
positively associated with reduced CVD) is previously been found to be smaller in 
South Asians (22). 
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The Southall study was the first large cross-sectional study to compare measured 
metabolic data from Indian and Pakistani subjects with that from age and BMI-
matched European subjects (24).  This showed that migrant South Asians have a 
higher prevalence of DM (19% versus 4%), and this figure is similar for South 
Asians living in the USA (Figure 1.1) (24;25). More recent data from Scotland 
showed that the prevalence of DM in South Asians has little changed, with the 
prevalence remaining 3-4 times higher compared to Europeans (20). In terms of 
undiagnosed type 2 diabetes mellitus (T2DM) in South Asians in the UK, data 
suggest that this might be as high as 20% in adults aged 20-75, with a further 
28% having impaired glucose tolerance (26). This figure for hidden T2DM is 14 
times higher than the suggested 1 in 70 prevalence for the general UK 
population (27). Additionally, South Asians living in Scotland are diagnosed with 
diabetes more than a decade earlier compared to Europeans (45.9 years v 57.3 
years) (28). Similar findings have been demonstrated in the 20-year follow-up 
data from the Southall cohort (as well as subjects in the Brent study) (29). The 
follow-up data (collected until 2011) showed that incident T2DM in South Asians 
was 33% - nearly 2.5 times higher that of Europeans (14%) over the 20 years. 
Further, the average age of diagnosis was 66-67 years of age in Europeans, but 5 
years earlier in South Asians.  
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Figure 1.1 Prevalence of DM in South Asians 
Reproduced from (25) with permission of Future Medicine Ltd 
 
 
Previous prospective (~16yr) UK follow-up data from Southall & Brent studies 
also suggest that South Asians are more sensitive to the adverse CVD 
complications from T2DM (14). The data described an age-adjusted HR for male 
CHD mortality for South Asians of 1.64 (95% CI 1.24-2.16), compared to 
Europeans, increasing to 2.14 (95% CI, 1.56–2.94) after adjustment for smoking 
and cholesterol. Further analysis using multivariable models that adjusted for 
conventional risk factors and diabetes and/or impaired glucose regulation, 
features of insulin resistance, or the metabolic syndrome showed that CHD 
mortality remained significantly higher in South Asian men (HR 1.6–1.9).The 
South Asian diabetic subgroup suffered nearly half of all the South Asian CHD 
deaths, but only 13% of European CHD deaths occurred in the European 
diabetics. Further, in the South Asian group, diabetes was associated with nearly 
threefold higher mortality risk compared with South Asians without diabetes at 
baseline, yet in Europeans, the excess mortality associated with diabetes was 
only 1.5-fold. 
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To summarise, whilst South Asians have more atherogenic lipid profiles and a 
higher prevalence of diabetes associated with poorer glycaemic control, 
differences in traditional cardiovascular risk factors still fail to fully explain the 
increased CVD risk in South Asians. There has been suggestion that quantifying 
the increased risk can be achieved by adding 10 years to the age of the person 
when using the Framingham Risk Score (FRS) (30), whilst newer UK-based risk 
factor scoring engines now factor in ethnicity when predicting future CHD risk 
(31). Regardless of what method is used for scoring CHD or CVD risk, it is clear 
the reasons for ethnic disparities remain unanswered, and the traditional 
cardiovascular risk factors of blood pressure, smoking, blood cholesterol and DM 
fall short in fully accounting for this increased CVD risk. Thus pre-clinical disease 
states such as insulin resistance and the role of novel cardiometabolic risk 
factors including cardiorespiratory fitness, physical activity and liver fat as 
potentially mediating as well as independent factors deserve exploration in 
South Asians given the size of this high-risk ethnic group locally and worldwide. 
Further, in parallel to this exploration, the role and evaluation of various pre-
existing ultrasound-based screening methods for subclinical CVD is of merit if 
one is to maximise screening potential in South Asians who experience 
premature cardiometabolic disease. 
 
Sections 1.4 to 1.8 will discuss some of these potentially relevant and more 
novel risk factors particularly those which have little or no published data on 
South Asians, including cardiorespiratory fitness, objectively-measured physical 
activity and liver fat measurement. Finally section 1.9 will discuss the role of 
ultrasound-based carotid plaque scoring as a potentially more sensitive 
screening tool for CVD in South Asians. 
 
 
1.3 Insulin resistance  
 
1.3.1 Insulin resistance and cardiometabolic risk 
 
Insulin resistance can be defined as ‘the inability of a known quantity of 
exogenous or endogenous insulin to increase glucose uptake and utilization in an 
individual as much as it does in a normal population’ (32). In other words an 
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individual with insulin resistance requires more insulin to have the same effect 
on controlling blood glucose, or the body cannot produce enough insulin to 
control blood sugar, leading to impaired glucose regulation and ultimately T2DM 
(33). 
 
Briefly, insulin resistance is strongly associated with an increased adiposity state 
such as obesity. The connection between obesity and increased levels of 
circulating insulin was first described in the 1960s (34) with the research 
showing that, in systemic insulin resistance, there was compensatory activity by 
insulin-secreting beta cells. It is also recognised that obese individuals have 
increased circulating levels of free fatty acids and this is associated with insulin 
resistance and dysglycaemia. Finally it is known that obese normoglycaemic 
individuals have increased beta-cell function (34;35). Thus obesity-induced 
glucose intolerance appears to reflect failure of beta cell activity (36). 
 
Several mechanisms have been suggested to explain why obesity causes insulin 
resistance and subsequently T2DM. These include increased production of 
adipokines/cytokines which contribute to insulin resistance (37); ectopic fat 
deposition (mainly in the liver but also in skeletal muscle), and the resulting 
effect on glucose/insulin homeostasis (described in more detail in section 1.7.1) 
(38); and impaired mitochondrial activity (39). Impaired mitochondrial activity 
(reflected by reduced mitochondrial mass and/or function) could be one of many 
important pathologies connecting obesity to diabetes, both by decreasing insulin 
sensitivity and by compromising beta-cell function. Though it is recognised that 
impaired mitochondrial activity is not a consistent finding as demonstrated in a 
small cohort of Indian men with diabetes compared to Indian men without 
diabetes (13 in each group) (40) 
 
Insulin resistance is adversely associated with a number of traditional CVD risk 
factors (41).  Longitudinal data also supports the role of the severity of insulin 
resistance with CVD risk in subjects with pre-existing T2DM (42). Longitudinal 
data directly linking Insulin resistance to incident CVD has been demonstrated in 
Italians from the Bruneck study, which followed up 839 subjects without CVD at 
baseline for 15 years (43). Results showed a significant association between 
increased insulin resistance at baseline and incident CVD even in subjects 
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without diabetes after adjustment for traditional as well as several novel 
cardiovascular risk factors (HR 2.2, 95% CI, 1.3 –3.7, p<0.05). 
 
 
1.3.2 Insulin resistance in South Asians 
 
Several studies in addition to the Southall study (which demonstrated increased 
fasting and 2-hour post 75g glucose load insulin levels in South Asians) have 
confirmed that South Asians are more insulin resistant (determined by HOMA-I; 
hyperinsulinaemic euglycaemic clamp; insulin sensitivity index; and fasting and 
2-hour post 75g glucose load insulin levels respectively) than their European 
counterparts (14;44-46). Further, studies have shown that even after adjustment 
for BMI, waist-hip ratio (WHR), and skin fold thickness, insulin levels (both 
fasting and post glucose-load) remain significantly higher in South Asians (45-47), 
thus greater insulin resistance is not fully explained by excess adiposity. Despite 
the increased prevalence of insulin resistance in South Asians, follow-up data 
from the Southall and Brent Studies, showed that the increased CVD mortality 
observed in the South Asians was little influenced after adjustment for insulin 
resistance (as determined by HOMA-IR) (14). 
 
 
1.4 Adiposity 
 
1.4.1 Adiposity and cardiometabolic risk 
  
Worldwide the prevalence of DM in 2010 was estimated at 285 million people 
(48). In 2012, the UK prevalence of DM was estimated to be 4.6% - giving three 
million people a diagnosis of diabetes in the UK (49). Around 90% of adults with 
DM have T2DM (49). Both the prevalence and incidence of T2DM have been 
increasing the UK. The prevalence has increased from 2.8% in 1996 to 4.5% in 
2011 (49;50). The growing incidence of DM is nearly all T2DM in aetiology - the 
incidence of T2DM increased from 2.60/1000 person-years in 1996 to 4.31/1000 
person-years in 2005, whilst the incidence of type 1 diabetes remained relatively 
constant (50). This growing incidence and prevalence of T2DM being linked to 
the increasing prevalence of obesity - the proportion of individuals newly 
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diagnosed with T2DM who were obese increased from 46% to 56% over the 10-
year period.  
 
This adverse metabolic effect of obesity is expected, as it is recognised that 
weight gain is an important proven risk factor in developing T2DM (51-54).  For 
example, a 5-year follow-up of over 50,000 healthy men aged 40–75 years, found 
that men with a BMI >35 were at 42-fold higher risk of developing T2DM than 
men with a BMI <23 (52). Moreover, the landmark data from Hillier and 
colleagues illustrated how severity of obesity lowered the age of onset of T2DM. 
Defining early onset of T2DM as a diagnosis before the age of 45, they calculated 
the mean BMI in this group to be 39, however the usual group (age >45), had a 
mean BMI of 33 (55). There was also a significant (p<0.0001) inverse linear 
relationship between BMI and age at diagnosis of T2DM (Table 1.3). Research is 
also confirming the belief that with growing numbers of younger people 
becoming obese, the number of younger adults being diagnosed with T2DM is 
also on the rise (56).  Thus obesity is a key, if not the main driver for the 
growing (and premature) prevalence of T2DM.  
 
 
Table 1.3 Relationship between age of diagnosis of T2DM and BMI. 
 
Age at Diagnosis T2DM BMI 
<30 38.3 
31-35 37.1 
36-40 38.3 
41-45 36.3 
46-50 35.9 
51-55 35 
56-60 33.9 
61-65 31.7 
66-70 31.1 
>70 28.8 
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The relationship between obesity or increased BMI and CVD/CHD is not as clear 
as the relationship obesity has with T2DM. It is well-known that an obese state is 
associated with higher blood pressure, higher non-HDL cholesterol, lower HDL 
cholesterol and a higher prevalence of diabetes (57). However studies have 
argued that these are the mediators by which BMI is thought to affect 
cardiovascular mortality (58;59). Nonetheless,  equally contemporary 
prospective data including a meta-analysis showed a 40% increase in CHD 
mortality for every 5Kg/m2 increase in BMI above 25Kg/m2, confounding factors 
such as traditional risk CVD risk factors, medication and intentional weight loss 
due to disease were not adjusted for (57;60). One recent prospective study 
assessed the independent association of obesity separately for fatal or nonfatal 
CHD over a 15-year period by accounting for traditional risk factors and 
deprivation in a cohort of over 6,000 previously healthy middle-aged men living 
in the west of Scotland (West of Scotland Coronary Prevention Study, WOSCOPS) 
(61). A minimally adjusted model (age, sex, treatment with statins) and a 
maximally adjusted model (including known CVD risk factors and deprivation) 
were generated, using BMI 25–27.4 kg/m2 as the reference BMI. The risk of fatal 
CHD events was increased in obese men (BMI 30.0–39.9 kg/m2) in both the 
minimally adjusted model (HR=1.75, 95% CI, 1.12, 2.74) and the maximally 
adjusted model (HR=1.60, 95% CI, 1.02, 2.53).  
 
A possible additional pathological effect of obesity, beyond its association with 
traditional factors, is that of inflammation. Adipose tissue is considered an 
endocrine organ that releases proinflammatory cytokines (62), rendering obesity 
a low-grade inflammatory state (63;64). Recent data have suggested that in 
established CVD, markers of inflammation—namely C-reactive protein (CRP) and 
interleukin 6 (IL-6) - are more strongly associated with fatal than non-fatal 
events (65). Therefore if inflammation increases the risk of CHD mortality, the 
same might be hypothesised about the role of adiposity – a source of circulating 
inflammatory markers.  
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1.4.2 Adiposity in South Asians  
 
Much of the aforementioned data in relation to obesity and risk of T2DM comes 
from populations predominantly of European extraction. Yet much of the 
projected increased global prevalence of T2DM is attributable to Asia, namely 
the Indian subcontinent, China and the Middle East (48). The prevalence of 
diabetes is expected to rise 54% between 2010 and 2030, however the 
prevalence is expected to rise by 72% in South Asian countries. Conversely, the 
prevalence in Europe is only expected to rise by 20%. India, China and Pakistan 
will provide 63 million of the 145 million extra people who will have diabetes by 
2030, with India alone contributing 37 million people. 
 
In light of these epidemiological data, is it possible that obesity, or indeed 
weight gain in general has a stronger association with onset of T2DM in such high 
risk populations? As described earlier adiposity does not fully explain the 
increased insulin resistance seen in South Asians. A recent review plotted the 
relative risk of T2DM against BMI for people of South Asians and European origin 
(Figure 1.2) (25). The graph illustrates clearly that the BMI threshold associated 
with the exponential increase in diabetes risk occurs at markedly lower BMI 
range (18.5-25 at 22-23 for South Asians), whereas the increase in Europeans 
occurs at a BMI in excess of 30.  
 
Similarly, a landmark study from Canada looking at a multiethnic population 
(South Asian, Chinese, Aboriginal and Europeans) calculated ethnic-specific BMIs 
for an equivalent risk of impaired glucose control akin to risk of diabetes (66). 
They calculated the risk for a European with a BMI of 30, and subsequently 
calculated the equivalent BMI that would give the same risk in the other ethnic 
groups. The equivalent BMIs in the South Asian, Chinese and Aboriginal 
populations were 21.0, 20.6 and 21.8 respectively. More recently a similar larger 
study performed in the UK comparing migrant South Asians with the indigenous 
white European population (ADDITION-Leicester cohort), calculated risk 
equivalent BMIs for T2DM of 22.6 for men and 21.5 for women (67). 
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Figure 1.2 Association of BMI with risk of T2DM in South Asians and 
Europeans 
Reproduced from (25) with permission of Future Medicine Ltd 
 
 
One possible explanation is that the current BMI categories for weight are not as 
useful or sensitive in other ethnicity groups in relation to metabolic risk. For 
example, though South Asians have similar absolute waist circumferences 
compared to BMI-matched Europeans (68;69), South Asians have an increased 
WHR (24), thus indicating that South Asians have more adiposity concentrated 
centrally. Increased WHR is recognised as a stronger predictor of risk of T2DM 
compared to BMI in Asians (70). Similarly, BMI-matched South Asians have more 
body fat compared to Europeans (44;47;71). Also, for a given BMI, South Asians 
have significantly lower muscle mass (44;47), with increased abdominal adiposity 
(44), larger adipocyte size (44;68) and greater amounts of adipose tissue in the 
deep subcutaneous compartment than Europeans (72), although interestingly 
increased visceral fat is not a consistent finding (44;46).  Thus relative adiposity 
as opposed to BMI appears more influential for T2DM risk in South Asians 
compared to Europeans. 
 
The greater adverse effects of adiposity observed in South Asians have led to 
recent consensus statements, including the recommendation that the threshold 
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for obesity should be lowered to BMI 25 kg.m-2 (normal 18–22.9 kg.m-2, 
overweight 23–24.9 kg.m-2) in South Asian populations (73-75) .  Similarly,  
findings from the ADDITION cohort from Leicester UK, suggested South Asian-
specific waist circumferences (a surrogate for WHR) for equivalent glycaemic 
and lipid factors compared  to Europeans for the central obesity cut off points - 
South Asian women and men required waist circumferences of 69 and 84 cm 
respectively for the glycaemic factor, and 74 and 91 cm respectively for the lipid 
factor. This in contrast is much lower than the all-encompassing 88/102 cm for 
European women/men. Further, prospective data from Mauritius and AusDiab 
surveys indicated that South Asian women and men required waist 
circumferences of 70/80 cm for diabetes equivalent risk to Europoid women and 
men with waist 88/102 cm (76). Accordingly, the waist circumference threshold 
criterion for diagnosis of the metabolic syndrome lower is South Asian (80/90 
cm) than in European (88/102 cm), women and men respectively (77). 
 
 
1.5 Cardiorespiratory fitness  
 
1.5.1 Cardiorespiratory fitness and cardiometabolic risk 
 
Exercise tests can provide a number of indices of in vivo skeletal muscle and 
whole body oxidative capacity.  It has been reported that maximal oxygen 
uptake, or VO2max (i.e. a measure of whole-body oxidative capacity, which 
correlates strongly with skeletal muscle oxidative enzyme activities in 
heterogeneous populations (78;79)) is a strong predictor of whole-body insulin 
sensitivity in Europeans independent of visceral adiposity in both higher-risk as 
well as normal subjects (79-82). Moreover epidemiological data report a 2.6-fold 
increased risk of incident T2DM, independent of BMI, in men with low compared 
to high cardiorespiratory fitness levels (83). 
 
Data from a large meta-analysis which aimed to define quantitative relationships 
between cardiorespiratory fitness and CHD events, CVD events, or all-cause 
mortality in healthy men and women showed that compared with participants 
with high cardiorespiratory fitness, those with low cardiorespiratory fitness had 
a relative risk (RR) for CHD/CVD events of 1.56 (95% CI, 1.39-1.75; p<0.001), 
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adjusting for heterogeneity of study design. Compared with participants with 
intermediate cardiorespiratory fitness, those with low cardiorespiratory fitness 
had a RR for CHD/CVD events of 1.47 (95% CI, 1.35-1.61; p<0.001), adjusting for 
heterogeneity of study design (84). Further a more recent study attempted to 
quantify the role of cardiorespiratory fitness in improving risk classification for 
CVD in previously healthy adults. Data from a study following up more than 
66,000 subjects for a median of 16 years showed that a single measurement of 
fitness significantly improves classification of both short-term (10-year) and 
long-term (25-year) risk for CVD mortality when added to traditional risk factors 
(85). 
 
 
1.5.2 Cardiorespiratory fitness in South Asians 
 
Limited data are available comparing cardiorespiratory fitness levels between 
men of South Asian and of European descent.  VO2max values in sedentary South 
Asians are typically around 10-15% lower than comparable sedentary European 
groups (45;86;87).  Interestingly, the relatives of patients withT2DM, who, like 
South Asians, have increased insulin resistance (88;89) and risk of T2DM (90;91), 
also have similarly lower values for VO2max (~10-15% lower) than age, BMI and 
body-fat matched controls (81;82).  However more recent data from a local 
study (n = 39, South Asians=20, Europeans =19) of young men indicated that the 
difference in VO2max values was far greater (in excess of 20%) between South 
Asians and White Europeans even after adjustment of fat mass (p<0.0005), (47). 
The study also showed that adjustment for VO2max attenuated the difference in 
insulin sensitivity between young South Asian and European men.  Thus it is 
important to determine if difference in cardiorespiratory fitness persists into 
later life when the risk of T2DM is greater and whether it is as influential in 
attenuating the unfavourable metabolic profile in South Asians. 
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1.6 Physical activity  
 
1.6.1 Definition and measurement of physical activity 
 
Physical activity can be defined as ‘any bodily movement produced by skeletal 
muscle that requires energy expenditure’ (92).  The American College of Sports 
Medicine recommends moderate-intensity aerobic (endurance) physical activity 
for a minimum of 30 minutes for five days every week or vigorous-intensity 
aerobic exercise for 20 minutes for three days each week (93). Similarly, 
guidelines relating to physical activity to avoid weight gain for adults are 30 
minutes of moderate intensity activity everyday (94).  Moderate intensity 
aerobic activity is equivalent to a brisk walk which accelerates the heart rate, 
whereas vigorous-intensity exercise is equivalent to jogging and causes rapid 
breathing and a substantial increase in heart rate (93). In UK the weekly physical 
activity recommendations are for adults to undertake a minimum of 150 minutes 
of moderate intensity activity in sessions lasting at least 10 minutes or more 
(95). Additionally, similar benefits can be achieved through 75 minutes of 
vigorous intensity activity spread over the week (95). Physical activity targets 
can be met by combining intensities and types of activity as well as performing 
daily activities including washing dishes, house chores and walking to and from 
the car (93).  
 
Physical activity can be measured subjectively by a physical activity diary or 
derived from validated questionnaire-based data which allow energy expenditure 
to be estimated. Such methods are cost effective and allow data collation from 
large study groups; however accuracy and validity of data are debatable in 
comparison to objective measurements of physical activity (96-98). Limitations 
include understanding of terminology e.g. ‘moderate’ and ‘vigorous’ exercise 
which can be interpreted differently by individuals completing the questionnaire 
(99). Accuracy in recall and honesty could lead to response bias in quantifying 
activity undertaken are other factors influencing validty of results. Finally 
repetition of the questionnaire by the same individual may not reproduce similar 
results especially if repeated after a period of time during which the individual 
has modified his/her physical activity. Further, it has been shown in one study 
that energy expenditure calculated from three of four frequently used physical 
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activity questionnaires (using data obtained on duration, intensity of each 
reported activity [in metabolic equivalents, METs] over the reporting period to 
measure the average activity level in METs/min), overestimated objective 
measurement of energy expenditure (100).  
 
Alternatives to written records of activity include objective measurement of 
physical activity such use of accelerometry, which is considered as a practical 
non-invasive and reliable way to measure physical activity (101;102). This 
method involves subjects wearing the accelerometer usually by attaching it to 
their waist - this has to be worn at all times while awake. Accelerometers 
measure body movements in terms of acceleration, which can then be used to 
estimate the intensity of physical activity over time (103).  Thus accelerometers 
provide information on the frequency, duration and intensity of physical activity 
(102).  An advantage is that data can be obtained any time of the day either 
during the day or night depending on individual’s activity patterns and activity 
intensity (including estimates of energy expenditure). Finally novel data 
comparing accelerometers to validated questionnaire-based data showed that 
the questionnaire-based data overestimated moderate-to vigorous physical 
activity (MVPA) activity by 250% compared to accelerometer data (397.8 
MET.min.day-1 v 155.9 MET.min.day-1) (104).  
 
 
1.6.2 Physical activity and cardiometabolic risk 
 
It is recognised that reduced physical activity is associated with increased insulin 
resistance and an increased risk of T2DM (105;106). Data from a longitudinal 
cohort study found that regular physical activity was associated with a reduced 
risk of T2DM (107). In the Nurses Health Study it was seen that vigorous exercise 
per week was associated with a 33% reduction in risk of T2DM in women in 
comparison to no exercise performed (108). Evidence from cohort studies 
suggests that those who are more active reduce the risk of T2DM even if they are 
at a high risk of T2DM e.g. in obese individuals (53). Finally the results from the 
Finnish Diabetes Prevention Programme demonstrated that those subjects that 
underwent lifestyle intervention (individualized counselling aimed at reducing 
weight, total intake of fat, and intake of saturated fat and increasing intake of 
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fibre and to undertake physical activity - 30 mins moderate activity daily), their 
cumulative incidence of diabetes after four years was 11% (95% CI, 6-15%) in the 
intervention group and 23% (95% CI, 17-29%) in the control group. During the 
trial, the risk of T2DM was reduced by 58% (p<0.001) in the intervention group - 
this reduction in the incidence of T2DM was directly associated with changes in 
lifestyle (109). 
 
Physical activity favourably influences CVD risk factors including reducing blood 
pressure, increasing HDL cholesterol and reducing body fat (94;110;111). 
However, even after controlling for these factors, physical activity has still been 
shown to be an independent risk factor for CVD (112), indicating that, as well as 
modifying the above risk factors, physical activity may influence CVD risk 
through other non-classical mechanisms (Figure 1.3). 
 
 
 
Figure 1.3 Mechanisms by which physical activity influence CVD risk  
Reproduced from  (113) with permission of Portland Press Ltd 
 
  
Despite the above studies showing the influence of physical activity on 
cardiometabolic risk, misclassification arising from the use of questionnaires to 
assess physical activity can substantially underestimate the true relationship 
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between activity and risk of cardiometabolic disease risk and should be borne in 
mind when interpreting such data (104;114).   
 
 
1.6.3 Physical activity in South Asians  
 
There is established evidence that physical activity levels are much lower in 
South Asians living in the UK than any other population (99;115-117). A detailed 
review on physical activity focused on studies that included the amount of time 
spent undertaking physical activity, or measured physical fitness or calculated 
energy expenditure of South Asians living in the UK (7 studies in adults, 5 in 
youths) (99).  The review consistently demonstrated that South Asians reported 
lower levels of physical activity in comparison to Europeans or the general 
population. Further, across three South Asian subgroups (Bangladeshis, Indians 
and Pakistanis) it was also found that women had low physical activity levels in 
comparison to men and older people also had a low physical activity level. 
 
Similar observations  have been found by Williams and colleagues who reviewed 
physical activity data in South Asians from The Health Survey for England 2004 
(118). The study reported adherence to physical activity recommendations, with 
only 11% of Bangladeshi and 14% Pakistani women achieving adequate physical 
activity levels. Also South Asians were ~33% less active than Europeans on a 
weekly basis- the total MET-min/week in South Asians being 973 MET-min 
compared to 1465 MET-min in Europeans, (p<0.001). The study also showed that 
South Asians were 60% less likely to comply with the current governmental 
guidelines on physical activity recommendations (OR 0.41, 95% CI, 0.38-0.45). 
Interestingly South Asians born in the UK reported higher levels of physical 
activity (by ~50%) than those born elsewhere (p<0.001).  Recent data from 
Leicester, UK, once again demonstrated that South Asians were more likely fall 
below the minimum physical activity recommendations for health compared to 
Europeans (age-adjusted odds ratio [OR] for South Asian men = 2.35, 95% CI, 
1.89–2.93, age adjusted OR for South Asian women = 2.25, 95% CI, 1.81–2.80) 
(117), indicating that little has changed over the past few years.  
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Several reasons have been suggested for reduced physical activity in South 
Asians compared to Europeans. One reason could be that South Asians engage in 
a restricted range of leisure activities in comparison to Europeans thus limiting 
options for expending energy (119). Another possibility could be that South Asian 
women could face barriers to participating in physical activity fitness, cultural 
norms and social expectations (120). Finally one cannot overlook any 
exacerbations of the above described limitations of questionnaire-based data in 
South Asians due to cultural interpretation of the terminology used (99). 
Ultimately there is a need for objective measurement of physical activity in 
South Asians to obtain a more accurate picture of how this compares to the 
indigenous European population and whether this may influence differences 
in cardiometabolic risk between the two ethnic groups. 
 
 
1.6.4 Sedentary time and cardiometabolic risk  
 
Whilst the terms ‘reduced physical activity’ and ‘physical inactivity’ are used 
interchangeably, the two terms are not synonymous. ‘Sedentary’ can be defined 
as time ‘spent sitting down’ (121); whereas ‘physical activity’ refers to body 
movement (99), which as described above can be of varying intensities. It has 
been suggested that sedentary time is associated with an increased risk of T2DM 
which influences vascular and metabolic risk factors independent of time spent 
undertaking any form of physical activity (122). A recent meta-analysis of cross-
sectional and prospective data of nearly 800,000 individuals showed that 
sedentary time is associated with an increased risk of DM, CVD and 
cardiovascular and all-cause mortality; with the strength of the association is 
most consistent for DM (123). 
 
Further analysis from the Health Survey for England 2004 data showed that 
physical inactivity explained >20% of the excess CHD mortality observed in the 
South Asians, even after adjustment for potential confounding variables 
(socioeconomic position, smoking, diabetes and existing CVD) (116). More 
recently, cross-sectional data from Gill and colleagues found that for South 
Asians living in UK, time spent sitting was significantly associated with increased 
2-h post glucose load plasma glucose concentrations (121). These data indicate 
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that sedentary time appears to influence cardiometabolic risk independently of 
less intensive physical activity, although once again one cannot overlook the 
subjective element of recording sedentary time. 
 
 
1.7 Liver fat  
 
1.7.1 Association of liver fat with obesity and pathogenesis of dysglycaemia  
 
Ectopic fat deposition in the liver is also a pathological process which 
contributes to insulin resistance, with on-going deposition exacerbating the 
insulin resistant state (124). It is not surprising therefore that liver fat has a 
strong association with obesity and T2DM. Obesity is a common feature of people 
with non-alcoholic fatty liver disease (NAFLD) – a condition when a person has 
more than 5% fat in their liver (125).  Up to 93% of people with NAFLD are 
thought to be obese (126). Likewise, 75 % of people with obesity have NAFLD, 
compared to a prevalence of 16% in people with a normal BMI (127).  
 
The most compelling data describing the associations between NAFLD, 
obesity/adiposity and T2DM comes from pilot data from bariatric surgery 
outcomes and reduced-energy diets in obese patients with T2DM. By applying the 
concept of ‘tracing the reverse route from cure to cause’ in T2DM pathogenesis 
(128), it can be alluded to that if a reduction in adiposity, (particularly liver fat 
content), is associated with a significant improvement in glycaemia in T2DM 
(129-131), then  the presence of liver fat in particular is likely to contribute to 
the development of T2DM. One study clearly demonstrated that in a group of 
obese subjects with T2DM, weight loss from a strict moderately hypocaloric 
very-low-fat diet followed by a period of weight stabilization, resulted in 8% 
weight loss over a mean of 7 weeks, which was associated with an 81% reduction 
in liver fat; with the reduction in overall body adiposity only falling 1.9% over 
the same period (132).  Mean fasting plasma glucose improved from 8.8 mmol/l 
to 6.4 mmol/l in these subjects. Therefore in an obese state, it appears that the 
relatively small quantity of fat deposited in the liver has a disproportionate role 
in glucose homeostasis. Thus given the current body of evidence, one can 
conclude that for many individuals, obesity drives insulin resistance, increases 
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the chances of ectopic fat deposition, chiefly in the liver which appears have a 
significant influence on the progression of insulin resistance which culminates in 
the onset of T2DM (Figure 1.4). 
 
 
 
Figure 1.4 Fat deposition in obese individuals  
VF: visceral fat; EF: ectopic fat 
 
 
1.7.2 Liver fat and cardiometabolic risk 
 
Plentiful data link liver enzymes (alanine aminotranferase [ALT] and γ-
glutamyltransferase [GGT]) to incident T2DM. A recent meta-analysis showed 
that one logged unit higher ALT was associated with a HR of 3.05 (95% CI, 2.59–
3.59, I2 = 26%) and one logged unit higher GGT with a HR of 2.56 (95% CI, 2.31–
2.84, I2 = 32%) in univariate age-adjusted analyses for the development of T2DM 
(133). In the model adjusted for major risk factors for DM, one unit higher 
logged ALT gave a HR for diabetes of 1.85 (95% CI, 1.57–2.18, I2 = 19%), and the 
HR per one unit higher logged GGT was 1.92 (95% CI 1.66–2.21, I2 = 55%). 
However whilst there was adjustment for common DM risk factors for all studies 
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(age, sex, BMI/waist circumference, smoking) included in the meta-analysis, 
other variables including physical activity, family history of DM, cholesterol, 
insulin sensitivity and fasting plasma glucose were not consistently adjusted for. 
In the same meta-analysis, data on ultrasound-diagnosed NAFLD as a 
determinant of incident T2DM were examined in 3 Asian studies. The pooled RRs 
comparing mild vs. no NAFLD for incident T2DM was 2.52 (95% CI, 1.07-5.96), but 
there was evidence of considerable heterogeneity between studies (I2=90%). 
 
Whilst the risk of T2DM in NAFLD is clearly elevated, data linking liver fat with 
risk of incident CVD are less convincing (134). There is a robust association 
between higher GGT levels (135), even within the normal range and incident 
CVD events (136); and this association is influenced by age, with the association 
being much stronger in younger adults (137). However, evidence to suggest that 
GGT can add incremental information in CVD risk prediction is limited (138). By 
contrast, current data suggest ALT levels are not significantly associated with 
CVD risk (139). With regard to image-reported NAFLD, the current evidence base 
is inconsistent and, due to study design, often unable to fully consider 
confounding or mediation by established cardiovascular risk factors (134). Even 
where adjustments have been made, they have often included weak variables 
such as metabolic syndrome, rather than the full range of continuous established 
CVD risk factors used in clinical practice. Thus currently, a diagnosis of NAFLD 
(or increases in liver enzymes) is in itself currently controversial with opinion 
divided on this matter (134;140). 
 
 
1.7.3 Liver fat in South Asians 
 
Limited comparative data on liver fat in South Asians exist in current medical 
literature. One comparative study (using magnetic resonance spectroscopy [MRS] 
to quantify liver fat between South Asians and Europeans indicate that South 
Asian men had nearly triple the hepatic triglyceride content) compared to 
Europeans after adjustment for age and BMI (1.94% v 0.75%, p<0.001) (141). 
Further, the increased hepatic triglyceride content was associated with the 
increased prevalence of insulin resistance in the South Asian group. However 
both groups were poorly matched for age and body composition.  
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A more recent study comparing MRS-quantified liver fat between South Asians 
and Europeans living in Canada showed that healthy South Asians had 
significantly more liver fat 9.9% v 2.2% p <0.05) (68). However on gender sub-
analysis, the 32 South Asian men (who were of similar BMI) who despite having 
double the liver fat content (10.8% v 4.7%) compared to the 21 European men, 
this difference was not statistically significant. This may be due to the small 
numbers in each group, as the study was not powered for this outcome measure. 
Further, both these studies did not accurately record or adjust results for 
alcohol consumption. Thus more research is needed in this area to determine 
whether South Asians indeed have more liver fat compared to Europeans, 
accounting for the confounding effect of alcohol and whether any observed 
difference influence cardiometabolic differences observed between these 
two ethnic groups. 
 
 
1.8 Carotid Ultrasound markers of CVD risk 
 
 
1.8.1 Screening for CVD 
 
In 1991 Dauz and Braunwald (142), introduced the concept of the CVD 
continuum, and highlighted the need for the identification and early detection 
of factors that predispose to the development and progression of coronary artery 
disease, shifting from the focus of managing overt disease. It is recognised that 
the pathogenesis of atherosclerosis involves the interaction between lipid and 
the inflammatory process, with the initiating step in atherosclerosis thought to 
be an inflammatory insult that precedes clinical manifestation by a number of 
years (143), rather than primary abnormalities in plasma lipid (144;145). Medium 
and large-sized arteries are affected first. The earliest visible lesion of 
atherosclerosis is the fatty streak, which is due to an accumulation of lipid-laden 
foam cells (lipid-rich macrophages) in the intimal layer of the artery (146). With 
time, the fatty streak can regress, but more often progresses into a fibrous 
plaque (atheroma), the defining lesion of established atherosclerosis. Figure 1.5 
summarises the macroscopic changes that occur in atherosclerosis over time. 
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Figure 1.5 Summary of the macroscopic changes in atherosclerosis over time 
(147)  
  
Over time the atherogenic lesions grow resulting in clinically silent disease 
manifesting either in a gradual process e.g. stable angina, or more acutely such 
as a fatal MI as a result of the lipid-rich plaque becoming unstable, fissuring or 
rupturing, resulting in the overlying artery thrombosing and occluding.  Rupture 
of the plaque can be due to direct physical damage as a result of endovascular 
procedures, hemodynamic stress due to traditional risk factors e.g. 
hypertension, use of tobacco products, high blood cholesterol levels, or enzymes 
released from platelets and leukocytes (Figure 1.6A and 1.6B) (148;149). 
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Figure 1.6A  Mature atherosclerotic plaque and intralesional components 
Reproduced from  (149) with permission of Elsevier Ltd 
 
SMC - smooth muscle cell;   HDL - high-density lipoprotein   ECM - extracellular 
matrix, IEL - internal elastic lamina; MFC - macrophage foam cell, ROS - reactive 
oxygen species 
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Figure 1.6B Thrombotic complications of atherosclerosis 
Reproduced from  (149) with permission of Elsevier Ltd 
EC - endothelial cell; PAI-1 - plasminogen activator inhibitor-1 
 
 
Despite the established knowledge of the pathophysiology underlying 
atherosclerotic vascular disease, the challenge of identifying asymptomatic 
individuals at moderate or higher risk of short-term future CVD events remains 
elusive. Numerous algorithms exist incorporating multiple risk factors in an 
attempt to improve risk prediction. Furthermore, despite the aetiological 
relevance of traditional risk factors in atherosclerosis, these CVD risk factors 
have a varied performance in predicting which asymptomatic subjects will go on 
to develop CVD (150;151). For example, one study showed the poor screening 
performance of blood pressure is reflected by the fact that individuals in the top 
10% of the distribution of systolic blood pressure experienced only 21% of all IHD 
events and 28% of all strokes at a given age (150). Using several cardiovascular 
risk factors in addition to blood pressure did not improve the screening 
performance of blood pressure. Among persons in a specified age group, the 5% 
at highest risk experienced 17% of all heart disease deaths with risk computation 
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based on blood pressure alone, 22% when based on blood pressure and 
cholesterol in combination, and only 28% using blood pressure, cholesterol, 
smoking and three other cardiovascular risk factors all in combination. Newer 
algorithms incorporating novel factors such as social deprivation and glycated 
haemoglobin A1c (HbA1c) continue to be developed with an attempt to better 
predict future vascular events in individuals (151). Proponents of those in favour 
of such tools indicate that their under-usage rather than their limitation may be 
one of the reasons why individuals miss out on primary prevention (151).  
 
 
1.8.2 Carotid intima-media thickness and prediction CVD 
 
As described, atherosclerosis reflects an interactive process between plasma 
lipid (predominantly LDL) and the inflammatory cascade, with the process 
predominantly affecting the intima, and tending to involve the media only once 
advanced stages are reached. Given that this process can be subclinical for a 
variable, substantial period of time, one might conceive that screening for 
asymptomatic vascular disease, particularly in high risk groups, such as South 
Asians would be beneficial.  
 
The general consensus historically is that noninvasive screening is only beneficial 
in patients without existing atherosclerotic disease who are classed as 
intermediate risk for having a primary cardiovascular event (e.g. one major risk 
factor, FRS 6-20%, family history of first degree relative with premature CVD) 
(152;153). This has been upheld in the most recent American Heart Association 
guidelines (154). Although subsequent to this one systematic review suggests the 
evidence remains inconclusive (155) and even more recently there has been 
further evidence and opinion suggesting that high risk patients (e.g. those with 3 
or more major risk factors) should only get screening if there is a possibility that 
it down classifies a patient (i.e. reclassifying a patient to a lower-risk category) 
and as a result a patient is not subjected to potentially unnecessary preventative 
medical therapy (153;156). 
 
With regard to screening modalities, much discussion has focussed on the role of 
carotid ultrasound scanning (152). A carotid ultrasound scan (USS) can be utilised 
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in one, two or three dimensions. One-dimensional (1D) carotid USS by using B-
mode ultrasound to quantify the degree of atherosclerosis started in the early 
1980s (157). This led to the measurement of IMT (intima-media thickness), with 
IMT becoming a validated measure in arteries in 1986 (158). The researchers 
were able to identify a ‘double line’ image which represented echoes from the 
intima and adventitial boundaries. The distance between these two lines 
represented the thickness of the intima and media combined – when the 
adventia was removed the outer echogenic line disappeared. They compared 
arteries with no plaque with those exhibiting plaque, and found that in order to 
maximise the accuracy and reduce variability in the measurement of carotid IMT 
(cIMT), IMT should be measured in the far wall of the common carotid artery 
(either maximum or mean cIMT), in a segment with no plaque. This has remained 
the approach in many protocols for measurement of cIMT, including prospective 
studies looking at cardiovascular outcomes in relation to cIMT (159-166), as well 
as an outcome measure in drug trials e.g. HMG CoA reductase inhibitors (statins) 
(167). 
 
Carotid IMT is recognised as a surrogate risk factor for CHD (159-164) and stroke 
(161;162;164-166). In a meta-analysis of 8 studies, Lorenz and colleagues 
calculated an age and sex adjusted RR for MI of 1.26 (95% CI, 1.21-1.30) per 1 
standard deviation (SD) difference in baseline cIMT and RR for stroke of 1.32 
(95% CI, 1.27-1.38) per 1 SD difference in baseline cIMT (164). Prior to the 
collation of this evidence, at The American Heart Association Prevention 
Conference V (2000) it was already suggested that the measurement of cIMT in 
clinical practice adds incremental information to traditional risk factor 
assessment in asymptomatic people, particularly those aged >45 years (168), 
with subsequent statements echoing this belief (152;169). An advantage of 
measuring cIMT is the availability of semi-automated software to read images 
and measure cIMT (170). A relatively recent small study (n= 43 women) showed 
that the use of automated software greatly reduced the time spent measuring 
segments (mean 57.5s for manual, 2.5s for automated); as well as showing 
better variation and reproducibility coefficients (171). However a very recent 
meta-analysis using general population cohort data has questioned the merit of 
the usage of progression of cIMT in clinical trials (172).  During a mean follow-up 
of 7 years (using 36,984 participants), whilst the mean cIMT of two ultrasounds 
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2-7 years apart was associated with an increased HR (1.16, 95% CI, 1.10-1.22) for 
combined CVD endpoints (MI, stroke or vascular death), the outcome for yearly 
cIMT progression was not increased (HR 0.97, 95% CI, 0.94-1.00) for the same 
endpoint. As a result the authors stated that no conclusion can be made on the 
use of cIMT progression as a surrogate in clinical trials. 
 
 
1.8.3 Carotid intima-media thickness in South Asians 
 
Currently there are no published prospective longitudinal data on cIMT and 
cardiovascular outcomes on South Asians. Furthermore, there is only one cross-
sectional study comparing cIMT between South Asians and Europeans from the 
same population (173). This study involved 342 South Asians, 326 Chinese and 
317 European men and women in Canada consisting of both asymptomatic 
individuals as well as those with known CVD (prevalence 8.6%, 1.9% and 4.9%, 
respectively).  Overall all three groups were of similar age but South Asians had 
the greatest prevalence of CVD (history of MI, angina, silent MI, PTCA, CABG, or 
stroke): South Asians 10.75, Chinese 5.4%, Europeans 2.4%, p<0.001.  However, 
when the three ethnic groups were compared for maximum cIMT (asymptomatic 
or diseased individuals, adjusted for age, sex and recruitment centre) South 
Asians did not have greater maximum cIMT compared to Europeans (0.72 mm v 
0.75 mm, p<0.001), with the European subgroup having highest maximum cIMT 
out of the 3 ethnic groups. 
 
However, when cardiovascular events were plotted against cIMT quartiles (Q1 
lowest cIMT), for combined groups (diseased and disease-free) for each ethnic 
group, South Asians had an excess of CVD prevalence compared with the other 
groups (Figure 1.7). For example, those within the highest quartile of cIMT, the 
prevalence of CVD was 26% among South Asians, 13% among Europeans, and 7% 
among the Chinese group and the differences were significant (p<0.001), 
however it was not clear whether these were ethnic-specific quartiles or not. 
Thus these data may suggest that absolute cIMT values are not a sensitive 
marker for CVD risk in South Asians, unless ethnic-specific risk-stratified values 
are proposed. 
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Figure 1.7 Prevalence of CVD in relation to cIMT in South Asians 
Reproduced from (173), with permission of Elsevier Ltd  
 
 
1.8.4 Carotid plaques and prediction of CVD 
 
 
It is argued that carotid plaques are pathologically more representative of 
atherosclerosis and that carotid plaque imaging is a potentially more predictive 
marker of vascular risk that cIMT. This is based on the rationale that  carotid 
plaque and cIMT represent different underlying pathophysiological entities (174).  
As described earlier, early atherosclerotic plaque is focal, involving the intima, 
localizing to branches and bends in arteries, probably relating to disturbances of 
flow. However cIMT also includes (and is largely dominated by) the thickness of 
the inner layer (media) of the carotid artery.  
 
As per early opinion and subsequent consensus statements, cIMT  is measured in 
areas without plaque (175;176), or when a number of measurements from 
normal segments of the artery are averaged (with only a couple of slices that 
unintentionally intersect plaque) - the methodology adopted in most of the 
studies included in the meta-analysis undertaken by Lorenz and colleagues 
described earlier (164).  Therefore what is measured is something different from 
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atherosclerosis, if atherosclerosis is defined as plaque. Furthermore, whilst 
atherosclerosis is chiefly an intimal process, it has been highlighted that IMT is 
approximately 80% media, and only 20% intima, therefore any measurements 
made, and any changes in cIMT are likely to be a reflection of changes in the 
media (177); thus a key determinant of cIMT is the effect of blood pressure 
which is known to cause medial wall hypertrophy (178). The researchers found 
that cIMT was only weakly associated with coronary artery disease; and others 
have found that the association of cIMT with coronary atherosclerosis is less 
strong than its association with left ventricular mass and less strong than the 
association between carotid plaque and coronary atherosclerosis (179;180).  
 
Carotid plaque disease can be recorded as plaque presence/absence, or by a 
scoring system, counting and grouping the number of carotid plaques present, or 
by subjectively measuring two dimensional plaque area. Evidence from 
prospective studies is compelling for carotid plaque and cardiovascular risk 
prediction.  Two-dimensional (2D) ultrasound detectable carotid plaque is 
currently defined as a focal structure encroaching into the arterial lumen of at 
least 0.5 mm or 50% of the surrounding IMT value, or demonstrating a thickness 
>1.5mm as measured from media-adventitia interface to intima-lumen interface 
(176).  
 
The majority of existing evidence suggests that at worst, presence of carotid 
plaque is non-inferior to cIMT for predicting future CVD events, with the 
presence of large plaques being a stronger predictor for future CVD events. For 
example, data from as early as 1991, from the Kuopio Ischaemic Heart Disease 
Risk Factor Study (181) found plaque presence to be more strongly predictive 
than carotid IMT of future cardiovascular events. This prospective longitudinal 
study involved 1,288 men asymptomatic from ischaemic heart disease followed 
up for up to 2.5 years. Data linking the association between acute coronary 
events and both cIMT and carotid plaques showed that the presence of mean 
intimal-medial thickening (cIMT >1 mm) was associated with a 2.17-fold (95% CI, 
0.70-6.74) HR, small carotid plaques with a 4.15-fold (95% CI, 1.51-11.47) HR, 
and large ("stenotic") plaques with a 6.71-fold (95% CI, 1.33-33.91) HR for MI. 
Data from a study of 10,000 low risk, healthy individuals in Italy supports this 
(182). Table 1.4 provides published data comparing cIMT and 2D carotid plaque 
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imaging and strength of prediction of cardiovascular outcomes from prospective 
longitudinal studies of subjects asymptomatic of CVD. 
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Table 1.4 Summary of studies comparing cIMT to 2D carotid plaque imaging in relation to CVD outcomes. 
 
AMI – Acute myocardial infarction; mm – millimetre; *Deﬁned as the development of cardiovascular signs and symptoms and/or complications related to arteriosclerosis requiring 
hospital admission and treatment (occurrence of ECG-documented angina, non-fatal, acute MI and coronary death, and requirement for revascularisation). Silent MI noted by ECGs 
obtained at annual follow-up examinations were not counted as clinical events. **cIMT >1.12 mm
Study Population size, 
breakdown and age 
(years) 
Follow-up  Primary outcome Risk associated with cIMT 
thickening  
Risk associated with carotid plaque (CP)  
KIHD (181) 1,288 men aged 42-60 1 month - 2.5 years AMI 2.17-fold (95% CI, 0.70-6.74; 
p>0.05) HR of AMI per mm 
increase in cIMT 
small carotid plaquess 4.15-fold (95% CI, 
1.51-11.47; p<0.01); large ("stenotic") 
plaques  6.71-fold (95% CI, 1.33-33.91; 
p<0.01) risk of AMI 
CAFES-CAVE(182) 10,000 subjects (6055 
men) aged 35-65 
10 years ‘Cardiovascular 
event’* 
Event incidence 8.6% in subjects 
with >1mm thickness in cIMT 
Event incidence 39.38% for nonstenosing 
plaques, 81.06% for stenosing plaques 
Tromso(183) 6,226 (3208 women) aged 
55-74 
mean  - 5.4 years 
median  - 5.8 years 
MI Adjusted RR for MI 1.73 in men, 
2.86 in women for highest v 
lowest quartile 
Adjusted RR for MI 1.56 in men, 3.95 in 
women for highest tertile compared to no 
plaque disease 
Rotterdam MI(184) 6,389 subjects (61.9% 
female) 
mean age 69.3  (SD 9.2) 
7-10 years MI HR 1.20 per SD increase in IMT 
thickness; 1.95 for ‘severe’** 
cIMT thickening 
HR 1.83 for ‘severe’ carotid plaque disease 
compared to no plaque disease 
Rotterdam CVA(185) 6,913 subjects (60.3% 
female) 
mean age 69.5  (SD 9.2) 
Mean 6.2 years Stroke Stroke RR 2.23 for highest tertile 
vs lowest tertile 
Adjusted RR for stroke rr 1.55 for highest 
tertile, v lowest tertile 
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In data from a recent local study (PsoBID study) (186), age and sex adjusted cIMT  
was significantly higher in participants from the most deprived (MD) areas than 
in those from the least deprived (LD) areas (0.70 mm (SD 0.16 mm) v 0.68 mm 
(SD 0.12 mm); p=0.015). On subgroup analysis, however, this difference was only 
apparent in the highest age tertile in men (56.3-66.5 years) (Figure 1.8). 
However, the difference in unadjusted mean plaque score between participants 
from the most deprived and those from the least deprived areas was more 
striking than the difference in intima-media thickness (least deprived 1.0 (SD 
1.5) v most deprived 1.7 (SD 2.0); P<0.0001). In addition, a significant difference 
in plaque score was apparent in the two highest age tertiles in men (46.8-56.2 
years and 56.3-66.5 years; P=0.0073 and P<0.001respectively) i.e ~10 years 
earlier in the life course than that needed to detect measurable differences in 
cIMT (Figure 1.9). Neither adjustment for traditional cardiovascular risk factors 
nor measured ‘novel’ risk factors, either alone or in combination, abolished the 
area-level deprivation-based difference in plaque presence.  
 
 
 
 
 
Figure 1.9  Differences in cIMT between socioeconomic groups stratified by 
age 
Reproduced from (186) with permission of BMJ Publishing Group Ltd 
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Figure 1.9  Differences in carotid plaque presence between socioeconomic 
groups stratified by age 
Reproduced from (186) with permission of BMJ Publishing Group Ltd 
 
Interestingly, two recent studies have incorporated both cIMT and carotid plaque 
presence to determine whether they enhance risk factor models for CVD 
prediction (156;187). The former showed that 23% of subjects would be 
reclassified by the addition of cIMT and carotid plaque to traditional risk factors 
(of which 80% receiving a downward reclassification), with plaque having a 
slightly better reclassification effect than cIMT when added to traditional risk 
factors (albeit statistically nonsignificant). The latter study which incorporated 
cIMT and carotid plaque (by virtue of elaborate composite measurements of 
cIMT) showed very modest improvements in risk reclassification. Finally a recent 
systematic review (studies up to September 2011) aimed to review the evidence 
which included studies that evaluated the added value of cIMT and/or carotid 
plaque scoring in the prediction of developing CVD (188). Once again a similar 
conclusion was made – when carotid ultrasound screening is undertaken, there is 
no noninferioty demonstrated for plaque over cIMT. 
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Finally, relatively novel validated three-dimensional (3D) ultrasound techniques 
exist and are demonstrated to possibly be more informative than existing 2D 
cIMT and plaque measures (189), which can detect earlier responses to 
intervention e.g. statin therapy over a six-month period(190) exist. However 
published long-term longitudinal data or indeed CVD outcome data based on 3D 
imaging of carotid arteries is lacking.  
 
Similarly, more descriptive and detailed contemporary imaging modalities of 
carotid plaque are being used (191). These include radiofrequency assessment of 
carotid plaque and intravenous ultrasound. The former can provide information 
on the content of plaque, by virtue of how echo lucent a plaque is and whether 
echogenicity/lucency is uniform or not (Echo-lucent carotid plaques are lipid-
rich and have a greater potential for clinical complications (192;193). 
Heterogeneous plaques have a hypoechoic component and are associated with 
the presence of intra-plaque haemorrhage, ulceration and lipids, more likely to 
result in adverse events (194). Further, some data suggest that in hospitalised 
cardiological patients, carotid plaque presence and morphology assessed by 
ultrasound are independent predictors of death (195). However, such analysis of 
plaque requires a trained individual as semi-automated software or simple 
criteria (e.g. plaque presence and score) are not currently available. Intravenous 
ultrasound can provide information on plaque type e.g. features indicative of 
vulnerability and thus more prone to rupture. The obvious drawback of this 
modality is that it is invasive and thus not an ideal screening option. Though this 
can be overcome by use of CT angiography, the access to and cost associated 
with this modality limits its practicality. 
 
 
1.8.5 Carotid plaques in South Asians 
 
The analyses of cIMT association suggest that left ventricular mass, blood 
pressure and age, are considered the main predictors of IMT is of major 
relevance in South Asians. Left ventricular mass is a reflection of high systemic 
arterial blood pressure (196) and a review of blood pressure levels in South 
Asians showed no significant difference in blood pressure levels between South 
Asians (as a combined entity) and Europeans (197).  Furthermore, the premature 
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cardiovascular morbidity and mortality seen in South Asians (9;12;13), may 
precede cIMT progression to reach sufficient thickness to classify a South Asian 
as high risk and worthy of primary prevention, i.e. the window of opportunity 
would already be missed. In light of all this evidence, it is unsurprising that 
cIMT has a low sensitivity as a measure of clinically important atherosclerotic 
plaques or as a predictor for vascular disease and suggests that carotid 
plaque may be a superior screening tool in South Asians. 
 
 
1.9 Endothelial function and arterial stiffness 
 
Endothelial dysfunction and changes in vasomotor tone are recognised 
preclinical stages in the pathogenesis of atherosclerosis (198). Endothelial 
function assessment includes measuring the response to an endothelium-
dependent, nitric oxide-mediated stimulus such as acetylcholine, or reactive 
hyperaemia, and a direct (endothelium independent) nitrovasodilator, like 
sodium nitroprusside or nitroglycerin (199). Endothelial function can also be 
assessed non-invasively by pulse wave analysis (200). Arterial ‘stiffness’ 
(sometimes referred to as compliance or ‘distensibility’) has been implicated as 
a feature of subclinical atherosclerosis (201). Several methods exist for the 
determination of arterial stiffness these include established as well as newer 
methods for non-invasively measuring arterial ‘stiffness’ and related 
intermediate cardiovascular phenotypes, and are listed in the Table 1.5 (201). 
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Table 1.5 – Methods for assessing arterial stiffness 
 
Pulse wave 
analysis 
Direct Assessment Other Methods 
Augmentation index PWV Pulse pressure 
Large artery 
compliance 
Local compliance measures AASI 
Small artery 
compliance 
  
PT/TT ratio   
 
PT/TT – peak time/total time, PWV – pulse wave velocity, AASI - Ambulatory 
arterial stiffness index 
  
Several of these methods used to identify asymptomatic cardiovascular 
phenotypes have been shown to predict cardiovascular risk.  One meta-analysis 
suggested that central augmentation index independently predicts future CV 
events and all-cause mortality (202). The same meta-analysis also suggested that 
pulse pressure may also have predictive value. PWV has also been found to be 
associated with cardiovascular events even after adjustment for cardiovascular 
risk factors (203). Recently, a non-invasive test for endothelial function has been 
developed which bases on the principle of reactive hyperaemia assessed by 
fingertip peripheral arterial tonometry without the need for ultrasound or 
plethysmographic assessment of brachial artery vasodilation. The Endo-PAT2000 
has been validated against conventional reactive hyperaemia-based assessment 
of endothelial function (204) and has been found to correlate with traditional 
and metabolic cardiovascular risk factors in the Framingham study (205).  
 
There are some published data on endothelial function and arterial stiffness in 
South Asians. One other study used flow-mediated dilation to assess responses to 
insulin in a clamp study in healthy non-diabetic South Asians compared to whites 
(206). This study showed the percent increase in resting brachial artery diameter 
from before the clamp to after the clamp, was significantly reduced in the Asian 
Indians compared with whites. However brachial artery diameter was similar and 
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the percent changes in brachial artery diameter in response to both reactive 
hyperaemia and nitroglycerin were not significantly different before the 
hyperinsulinaemic clamp between the 2 groups. Several small studies have found 
increased arterial stiffness in young South Asians aged in their 20s to early 30s 
compared to matched Europeans using flow-mediated brachial artery 
vasodilation (207), augmentation index (208) and maximum vasodilatory 
response to the beta-2 agonist isoproterenol (209).  Finally, noninvasive 
measurement of PWV has recently been found to be increased in healthy UK 
South Asian males compared to their European peers (210).  
 
However the duration and preparation required to undertake assessments of 
endothelial function and potential invasive component make the use of such 
modalities are not practical when studying larger groups of subjects particularly 
when attending for comprehensive phenotyping. Similarly these reasons make 
these forms of vascular assessment impractical for use as a screening modality. 
 
 
1.10 Summary and thesis aims 
 
The aim of the preceding literature review was to alert the reader to the 
seriousness and scale of the impact of cardiometabolic disease in South Asians 
living in the UK and further afield, and to highlight the research questions that 
this thesis is designed to aim to answer. Whilst there are emerging data on novel 
modifiable risk factors associated with cardiometabolic disease such as 
cardiorespiratory fitness and physical activity, data in studies of South Asians are 
either small scale (e.g. data relating to cardiorespiratory fitness), limited by 
quality (e.g. lack of objectively-measured physical activity) or inconclusive (e.g. 
role of liver fat in metabolic disease). Further, proposed methods for improved 
screening for CVD in South Asians (e.g. use of cIMT) lack sensitivity and this 
raises the question of whether alternative methods may be more sensitive in this 
high risk ethnic group. 
 
The aims of this thesis therefore are to try and address several of these areas 
which there are few or no published data on them, with the focus on South Asian 
men as the population to be studied. South Asian men were chosen for several 
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reasons, though as discussed in this introduction, South Asian women are also at 
increased risk of cardiometabolic disease. These include – South Asian men being 
at higher absolute risk of cardiometabolic disease compared to South Asian 
women; the components of the study design (anthropometric measurements, 
fitness tests) and the fact that the author and the technician undertaking these 
components were both male would make South Asian women highly unlikely to 
participate as cultural and religious sensitivities dictate that for women in 
particular same gender investigators/care providers are key to participation 
except in the case of necessity (211); and finally it is recognised that in addition 
to the previous point, South Asian women are generally a very challenging 
subpopulation to recruit from (212), thus increasing the risk of under-
recruitment and subsequent study underpowering. Thus using a study population 
of healthy age-matched South Asian and European men, I aimed to address the 
following areas: 
  
 Present comparative data on cardiorespiratory fitness, objectively-
measured physical activity and other metabolic phenotypical data in 
middle-aged South Asian and European men (Chapter 3).  
 
 To determine the extent to which differences in insulin resistance and 
glycaemia between these ethnic groups can be explained by differences in 
the factors mentioned above (Chapter 3). 
 
 To determine whether South Asians have increased liver fat compared to 
Europeans and the extent to which such differences contribute to the 
increased insulin resistance observed in South Asian men compared to 
European men. (Chapter 4) 
 
 Present comparative data on cIMT and carotid plaque presence between 
South Asian men and European men, whether any differences in carotid 
plaque presence between South Asian men and European men occur at an 
earlier age than differences in cIMT and finally to determine what risk 
factors (if any) could account for any such observed differences in cIMT 
and/or carotid plaque disease (Chapter 5). 
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Chapter 2 
General methods 
 
2.1 Introduction 
 
This chapter describes the methods of subject recruitment and subsequent tests 
undertaken by the selected participants. The study was named and publicly 
referred to as the Carotid Ultrasound and Risk of Vascular disease in Europeans 
and South Asians (CURVES) study. Ethical Approval for this study was granted by 
the West of Scotland Research Ethics Service Regional Ethics Committee 1 
(Reference – 09/S0703/118 and was conducted according to the principles 
expressed in the Declaration of Helsinki. The author was a registered medical 
practitioner with Advanced Life Support accreditation.  
 
 
2.1.1 Inclusion and exclusion criteria 
 
Individuals were considered suitable for participation in the study if they met 
the following inclusion criteria and did not meet any of the exclusion criteria 
listed below: 
 
Inclusion criteria 
 
 Male aged 40-70 
 South Asian (i.e. both parents from India, Pakistan, Bangladesh or Sri 
Lanka) or European (i.e. both parents of European origin). 
 Currently residing in the UK and registered with a UK general practitioner. 
 
Exclusion criteria 
 
 Known CHD (symptoms of angina, previously labelled IHD, previous MI, 
coronary artery bypass grafting, percutaneous revascularisation) 
 Previous stroke or TIA 
 Known DM (Type 1 or Type 2) 
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 Musculoskeletal or other disorder (e.g. significant respiratory or 
circulatory disorder), that prevents exercise testing on treadmill 
 Absolute contraindications to magnetic resonance imaging (MRI)  i.e. 
cardiac pacemaker, aneurysm clip, artificial heart valve, ear (cochlear) 
implant, metal fragments in eyes, head or body or any procedure to 
remove metal, metallic implant) 
 
If an individual had an underlying medical condition not listed in the exclusion 
criteria, but could confound results (e.g. ongoing treatment for malignancy), it 
was at the discretion of the author whether to enrol or exclude the individual in 
question. 
 
 
2.1.2 Recruitment, screening and selection 
 
Participants were recruited from the West of Scotland – the majority of 
participants living in NHS Greater Glasgow and Clyde catchment area with a 
minority recruited from NHS Lanarkshire, NHS Ayrshire and NHS Lothian.  
 
Participants were recruited via: (i) local advertising using posters displayed in 
prominent locations throughout the city of Glasgow, word of mouth, and (ii) by 
writing to potentially eligible participants identified from primary care 
databases - as agreed with the Scottish Primary Care Research Network, 
volunteering General Practitioner (GP) surgeries were visited to generate lists of 
potential participants from computerised data according to standard procedure. 
The relevant GPs vetted the lists. Practice-headed letters together with the 
Volunteer Information Leaflet (VIL) (Appendix A1) and an expression−of−interest 
return form (with prepaid envelope) were sent to suitable individuals. Interested 
respondents were then pursued for recruitment. 
 
The majority of participants (95 South Asians and 93 Europeans) were recruited 
by method (i).  For recruitment method (ii), 470 potential volunteers (220 South 
Asians and 250 Europeans) meeting the study inclusion criteria were identified 
from the databases of four primary care practices, and sent letters informing 
them of the study and inviting their participation.  Fifteen individuals (7 South 
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Asians, 8 Europeans) replied positively to these invitation letters.  Three of 
these individuals did not respond to further attempts at contact, and thus 12 
participants (7 Europeans, 5 South Asians) were recruited to the study by 
method (ii). During the Muslim holy month of Ramadan (in which Muslims are 
obliged not to eat from dawn to dusk), no volunteers who were Muslim were 
recruited to participate or indeed in the 2-3 week period after Ramadan (as 
many choose to keep 6 additional voluntary fasts in the subsequent month). 
There were two reasons for this – firstly the nature of what the visit entailed 
(overnight fast, exercise treadmill test to volitional fatigue) would make 
participation impractical and importantly inconvenient for participants. 
Secondly, it has been demonstrated that fasting can influence the metabolic 
profile in the short-term (213) and such physiological changes would confound 
the results of this study. 
 
Interested potential participants were communicated with in person, by email or 
by phone to discuss participation in more detail and confirm eligibility for 
participation. All interested individuals would receive an electronic or hard copy 
of the VIL. They were given the opportunity to ask questions and also meet in 
person if they wanted to discuss things further. Once eligibility was confirmed, 
participants were given an appointment to attend the British Heart Foundation 
(BHF) Glasgow Cardiovascular Research Centre (GCRC) for the main study visit.  
 
As all participants were chosen locally, and were required to read the VIL (which 
was printed in English), the method of recruitment excluded participants who 
could not understand written English. It was recognised that some older South 
Asian men may not be able to speak good English, but were considered for 
inclusion if able to speak Urdu or Hindi, as the author could verbally 
communicate fluently in these languages 
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2.2 Study protocol 
 
2.2.1 Overview of main study visit 
 
Eligible participants attended BHF GCRC at 9am after an overnight fast (≥10 
hours, allowed to drink water only). Participants were asked to bring trainers 
and shorts. Informed written consent was obtained in duplicate (last page of VIL, 
Appendix A1), and participants were given one copy to keep. Consent was 
obtained by the author, who had undertaken Good Clinical Practice training. If 
consent was given, a letter to the participant’s GP informing the GP of 
participation was either posted to the GP Practice or given to the subject to 
hand in to the GP surgery themselves. Figure 2.1 summarises the main visit 
which usually lasted 3-3.5 hours. All components of the visit up to and including 
the physical examination were undertaken in the BHF GCRC, with the remaining 
components undertaken at the purpose built exercise laboratory in the West 
Medical Building, University of Glasgow. Participants who completed the main 
visit received feedback on investigations undertaken (refer 2.6) and were 
offered £20 by the University of Glasgow towards travel/transport costs, but 
received no other incentive for participation. 
 
A health questionnaire (Appendix A2) and validated dietary intake questionnaire 
(Appendix A3) were completed (validated in European populations). The health 
questionnaire enabled comprehensive data to be collected on health history 
(including concurrent medication being taken), family health history smoking 
habits and alcohol consumption. Years of full-time education was also recorded 
as was socio-economic status (SES) and was determined by using the Scottish 
Index of Multiple Deprivation (SIMD) 2006 score (an area-based measure of 
deprivation based on residential postcode - 
http://www.scotland.gov.uk/Topics/Statistics/SIMD), and categorised in 
quintiles with quintile 1 representing the most affluent, and quintile 5 
representing the most deprived group.  Habitual diet was assessed using a 120-
item food-frequency questionnaire (214).  
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2.2.1.2 Questionnaires 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Overview of Main visit  
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2.2.2 Blood tests 
 
2.2.2.1 Routine blood tests 
 
Fasting venous blood samples were taken by the Glasgow Clinical Research 
Facility (GCRF) nursing and trained support staff by routine venepuncture. 
Samples were collected for urea, creatinine, electrolytes, total cholesterol, 
triglycerides, HDL-cholesterol, LDL-cholesterol, liver function tests (LFTs) – ALT, 
aspartate aminotransferase (AST), GGT glucose, HbA1C and CRP were collected. 
The samples were then analysed as routine samples on the day collected in the 
NHS Biochemistry Laboratory at Gartnavel General Hospital, Glasgow using 
standard automatic enzymatic (for glucose, lipids and  LFTs), 
immunoturidimetric (CRP) and HPLC (HbA1c methods). The laboratory 
participates in the U.K. National External Quality Assessment Service (UKNEQAS) 
scheme and all tests had inter-assay coefficients of variation (CVs) <5%. 
 
 
2.2.2.2 Non routine blood tests 
 
Additional venous blood samples were obtained for non-routine blood tests to be 
analysed in the University of Glasgow Biochemistry Laboratory facility in the BHF 
GCRC and for storage for future analysis including genetic analysis which all 
participants consented to. One 4 ml EDTA tube was collected for insulin and C 
peptide measurement. The sample was spun at 4 degrees Celsius at 3000 RPM for 
10 minutes the plasma split into 4 x 0.5 ml aliquots. If consent had been given, 
one further 9 ml EDTA tube was collected for potential future genetic analysis. 
The sample was spun at 4°C at 3000 RPM for 10 minutes and one 0.5 ml aliquot 
consisting of the aspirated buffy coat was prepared. All sample preparation was 
undertaken by the GCRF nursing and trained support staff. All samples were 
stored in the freezers in BHF at -80 °C until the time of analysis. Measurement 
of insulin, proinsulin and C-peptide were undertaken using commercially 
available enzyme-linked immunoassays (ELISA) (Mercodia AB, Uppsala, Sweden), 
in a single batch at the end of the study.   
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2.2.3 Carotid Ultrasound 
 
2.2.3.1 Training 
 
Prior to commencing recruitment for the study, a period of training in carotid 
ultrasound under the tutelage of Dr Kevin Deans (KD), Consultant Chemical 
Pathology and Metabolic Medicine, Aberdeen Royal Infirmary, UK, was 
undertaken by the author. KD was trained in cIMT scan analysis by the 
Department of Vascular Medicine, Academic Medical Centre, Amsterdam who 
met the American Society of Echocardiography (ASE) standards for USS scanning 
and cIMT analysis (169). Training was undertaken on a Siemans Acuson Sequoia 
512 scanner with an L8 5-12 MHz linear array broadband transducer (Siemens 
Medical Solutions, Erlangen, Germany), in the GRCF, in the Western Infirmary, 
Glasgow. Scans would be saved as a Digital Imaging and Communications in 
Medicine (DICOM) files to enable offline analysis. An identical model was used in 
the BHF GCRC for scanning the participants for the study.  
 
 
2.2.3.2 Scanning Protocol 
 
All participants underwent carotid ultrasound scans in the BHF GCRC, during 
which both left and right carotid arteries were assessed. All participants were 
scanned by the author, using the same machine which was used for his training. 
A protocol for scanning was created (Appendix A4) and followed for all scans. 
This protocol was adapted from the protocol used in the PsoBid study, which 
included  the same carotid ultrasound outcomes of interest that were measured 
and analysed (186). In summary, with the subject supine, the right carotid artery 
was scanned and then the left. B mode still images and dynamic clips were 
recorded from three sites in the following order: distal 2 cm of the common 
carotid artery, the carotid bulb, and the proximal internal carotid artery. 
Finally, an M mode image of wall movement in the distal 1 cm of the common 
carotid artery was recorded over at least two cardiac cycles to enable potential 
assessment of carotid artery stiffness. Doppler images of each internal carotid 
artery were obtained prior to the B mode still images and clips to exclude pre-
existing significant stenosis. If velocity was above 1.25m/s, the participant 
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would not be included in the study, and appropriate clinical advice was sought 
from the Stroke Team at the Western Infirmary, Glasgow regarding further 
management. The typical position of the participant’s neck is depicted in Figure 
2.2. On occasion, to enhance or indeed obtain images, participants had to turn 
their head more to the contralateral side and thus the 45 degree angle to the 
horizontal was reduced slightly. The mean IMT of the right common carotid 
artery (RCCA ) and left common carotid artery (LCCA) was calculated to give the 
mean cIMT for each participant. 
 
 
 
Figure 2.2 Participant position for carotid USS  
Image obtained with patient supine, neck turned from midline towards opposite 
side (i.e. arteries scanned from ear to ear) 
 
 
2.2.3.3 Carotid intima-media thickness image reproducibility data 
 
To ensure that images of adequate quality were being obtained, 9 healthy male 
volunteers aged 21-33 each had two carotid USSs 6-8 days apart. Images were 
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saved, with KD undertaking the cIMT measurements offline using validated semi-
automated software by Siemens - Syngo US Workplace release 3.5, which 
includes the Arterial Health Package (AHP) (215). For each visit the mean IMT of 
the right common carotid artery and left common carotid artery was calculated. 
The software measured the mean cIMT for the 1 cm region immediately proximal 
to the carotid bulb for each side and the mean of these to values was 
subsequently calculated.  
 
The difference between the means of each visit was then calculated, and the 
mean of this difference was calculated to give the mean absolute difference - a 
marker of quality of image reproducibility. The mean absolute difference for the 
9 volunteers was 0.0357mm, falling within the ASE cut-off of 0.055mm – thus 
meeting the ASE standards of repeatability (169) (Table 2.1). 
 
 
Table 2.1 Carotid intima-media thickness image reproducibility 
 
Volunteer RCCA1* LCCA1* Mean 1* RCCA2* LCCA2* Mean 2* Difference* 
1 0.604 0.691 0.6475 0.55 0.558 0.554 0.0935 
2 0.566 0.408 0.487 0.514 0.425 0.4695 0.0175 
3 0.631 0.717 0.674 0.649 0.665 0.657 0.017 
4 0.406 0.424 0.415 0.375 0.3 0.3375 0.0775 
5 0.442 0.552 0.497 0.505 0.496 0.5005 0.0035 
6 0.409 0.398 0.4035 0.426 0.431 0.4285 0.025 
7 0.588 0.522 0.555 0.503 0.552 0.5275 0.0275 
8 0.473 0.465 0.469 0.421 0.469 0.445 0.024 
9 0.614 0.397 0.5055 0.488 0.452 0.47 0.0355 
      MAD 0.0357 
*All values are in mm 
 
 
RCCA – right common carotid artery; LCCA – left common carotid artery; MAD – 
mean absolute difference  
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2.2.3.4 Carotid intima-media thickness intra-reader and inter-reader 
reproducibility 
 
All scans were read by Greig Logan (GL), a then BSc Honours student at the 
University of Glasgow. GL was trained by KD in cIMT analysis using the AHP 
software. To ensure GL met the ASE intra-reader reproducibility measurements, 
10 scans from the 18 volunteer scans (9 volunteers each having 2 scans on 
separate days, as described above) were randomly selected for inter-
reproducibility assessment. The cIMT was measured for the LCCA and RCCA for 
each of the 10 scans and the mean of these two measurements was then taken. 
The process was repeated 10 times, with the order of subject measurement 
taken at random (lists generated by the author) to ensure the examiner did not 
gain familiarization with the scans. Thus a total of 200 measurements were 
taken (100 LCCA, 100 RCCA), giving 100 means. Each subject’s mean absolute 
difference of IMT had to be <0.055mm with a CV of <6% in order to comply with 
the ASE intra-reader reproducibility standards (169) and was met by GL 
(Appendix A5, Table 1). 
 
For inter-reader reproducibility, the same scans were sent to an external 
examiner with whom the author was trained by (KD) who read the scans in the 
same manner as GL as described above. As per ASE standards (169), Inter-reader 
reproducibility was achieved if the overall means for each of the 10 scans all 
were had a difference of < 0.11mm. Data in Appendix A5, Table 2 confirms this 
criterion was met. 
 
 
2.2.3.5 Carotid ultrasound data analysis – cIMT measurements 
 
Scans were analysed using the AHP software.  All scans were analysed by the 
same reader (GL). GL was blinded to the identities of the participants. All scans 
were analysed after study recruitment had been completed. The mean cIMT for 
each participant was calculated from their respective LCCA and RCCA cIMT 
measurements using the same method described in 2.2.3.3. 
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2.2.3.6 Carotid ultrasound data analysis – carotid plaque scoring 
 
As detailed in the scanning protocol, images were burned to CD to enable offline 
analysis. Carotid plaque score was determined by KD, who was blinded to the 
identities of the study participants and used the AHP software to view the 6 
video corresponding to the respective sites from which images and video clips 
were taken. All scans were analysed after study recruitment had been 
completed. A plaque was defined as a ‘focal structure encroaching into the 
arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value, or 
demonstrating a thickness >1.5 mm as measured from the media-adventitia 
interface to the intima-lumen interface’ (176). To adjust for any unreadable 
video clips, the plaque count was then converted into a plaque score by dividing 
this value by the number of readable images present and multiplying the 
outcome by six (the maximum possible number of images per participant) (184).  
 
 
2.2.4 Blood pressure 
 
Blood pressure was measured on the left arm after at least 15 minutes of seated 
rest using an automated blood pressure monitor (Omron HEM705 CP, Omron 
Healthcare UK Limited, Milton Keynes, UK) which has been validated according 
to the European Society of Hypertension International Protocol (216). The four 
blood pressure measurements that were taken during the carotid ultrasound scan 
were used to calculate the mean systolic and diastolic blood pressure used for 
analysis in the study. The same sphygmomanometer was used throughout the 
study. 
 
 
2.2.5 Physical examination 
 
All participants underwent a basic physical examination performed by the 
author. Examination included assessment of the cardiovascular and respiratory 
systems and any other relevant system at the author’s discretion.  
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2.2.6 Anthropometric measurements 
 
2.2.6.1 Height 
 
Participants had their vertical height measured barefoot using a stadiometer 
(Invicta Plastics Ltd, Leicester, UK). The stretch stature was adopted for all 
height measurements (217), to negate circadian variation in height (218). 
 
The stretch stature is the maximum distance from the floor to the vertex of the 
head. The vertex is the highest point on the skull when the head is held in the 
Frankfort plane. To achieve the Frankfort plane, the head is orientated position 
in which the head when the orbitale and tragion form an invisible horizontal line 
with each other and this line is made perpendicular to the long axis of the body 
(Figure 2.3). 
 
 
Figure 2.3 Position of the head in the Frankfort Plane  
(modified from (217)) 
O- Orbitale; T – Tragion; V - Vertex  
 
The method of adopting the stretch stature involved the subject standing with 
his back, buttocks and heels against a stadiometer, with the participant’s feet 
together and flat on the floor. Either the research fellow or senior exercise 
laboratory technician would stand in front of the subject and orientate the head 
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to the Frankfort plane. His hands were far enough along the line of the 
participants jaw to ensure that upward pressure is transferred through the 
mastoid processes. 
 
The participant was asked to take and hold a deep breath. Whilst the head was 
kept in the Frankfort plane, a gentle upward lift through the mastoid processes 
was applied. At the same time the headboard was brought firmly down on the 
vertex, flattening the hair as much as possible by an assistant who also ensure 
that the feet did not come off the ground. Measurement was made at the end of 
the participant’s deep inward breath, recorded to the nearest 0.001 m. 
 
 
2.2.6.2 Body mass 
 
Body mass was measured with the participant wearing light clothing (e.g. shorts 
and t-shirt), minimal jewellery and their footwear removed.  Body mass was 
measured using a manual balance weighing scale (Avery, Birmingham UK), with 
the same scale used for all participants in the study. Participants would stand 
with their feet flat on the balance in the anatomical position. Mass was 
measured to the nearest 0.05 Kg. 
 
 
2.2.6.3 Skinfold thickness 
 
Skinfold measurements for all participants were performed by the same trained 
individual (John Wilson, JW).  The between-day CV for all skinfold 
measurements was <5%. Measurements were done in private. Measurements 
were made using Harpenden skinfold callipers (Cranlea & Company, Birmingham 
UK). The between-day CV for all skinfold measurements was <5%.  The same 
callipers were used on all participants, and measurements were made to the 
nearest 0.1 mm. All measurements were measured on the participant’s right 
side, and skinfold measurements were taken from the following sites: 
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Upper Body 
 
 Biceps 
 Triceps 
 Subscapualar 
 Iliac Crest 
 Supraspinale 
 
Lower Body 
 
 Front Thigh 
 Medial Calf 
 
All measurements were undertaken with the participant standing up with the 
arms hanging loosely by his side unless stated otherwise. The landmarks for each 
skinfold (including nomenclature) and position for measurement are described 
below and based on international guidelines (217). 
 
Biceps: The elbow was flexed to 90° and the midpoint between the most lateral 
point of the acromion and inferior border of the olecranon was marked. The arm 
was then left to hang loosely with the arm supinated. The measurement was 
made in the midline of the biceps muscle at the level of the mark. 
 
Triceps: This was measured on the posterior aspect of the arm in the midline at 
the same level of the biceps skinfold measurement. 
 
Subscapular:  The subscapulare was first identified (the undermost tip of the 
inferior angle of the scapula). To facilitate the identification of the inferior edge 
of the scapula, the participant would slowly reach behind his back with his right 
arm. If the inferior angle was palpated with the arm moved, then the inferior 
angle would remain palpated as the hand returned back to the resting position. 
The skinfold was measured 2 cm at a 45° angle inferiolaterally from the 
subscapulare. 
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Iliac crest: The participant folded his right arm across his chest AND the skinfold 
was measured above the iliocristale with the callipers held over a diagonal fold 
beginning at the anterior axillary line. 
 
Supraspinale: A straight line from the anterior axillary border to the undermost 
part of the tip of the anterior superior iliac spine was marked. The participant 
then folded his right arm across his chest to allow a horizontal line to be marked 
from the most lateral aspect of the iliac tubercle on the iliac crest (iliocristale) 
towards the front of the abdomen. The point where these two lines intersected 
was the site of skinfold measurement with the participant’s right arm hanging by 
his side and the callipers held at 45° to the vertical. 
 
Medial Calf: The participant stood with his right foot on an anthropometric box. 
The skinfold was measured on the medial aspect of the calf at the level of 
maximum girth which was prior determined when measuring the maximum calf 
circumference (see later). The most medial point was located by the technician 
viewing the site from the front of the participant. The skinfold was measured by 
holding the callipers held vertically. 
 
Front thigh: The participant was seated with his back upright and the knee is 
flexed to 90 degrees. The skinfold was measured parallel to the long axis of the 
thigh and marked at the midpoint between the middle of the inguinal fold 
(crease at the angle of the trunk and thigh) and the superior margin of the 
anterior surface of the patella (determined while the knee was flexed). The 
measurement was made in the midline of the thigh at level of the mark. On 
occasion if the skin of the thigh was taught, the author would hold and lift the 
skin a few centimetres either side of the marked point to facilitate the use of 
the callipers. 
 
All skinfolds were held between the technician’s thumb and index finger. The 
callipers were applied and the measurement was made after pressure had been 
applied for between two and five seconds. For all sites measured, two 
measurements were taken, and the mean of the two measurements was to be 
used for analysis. If the second measurement was not within 5% of the first 
measurement, a third measurement was taken. If the third measurement was 
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within 5% of either the first or second measurement, then the mean of the 
closest two measurements would be used for analysis; if this third measurement 
did not fall within 5% of either of the previous two measurements, then the 
mean of all three measurements would be used for analysis.  
 
 
2.2.6.4 Body circumferences 
 
Body circumferences were measured at five sites - mid upper arm, waist, hips, 
mid-thigh and maximal calf. Measurements were done in private with the 
participant wearing shorts only. A non-elastic tape was used and all 
measurements were performed by the same technician throughout the study. All 
measurements were undertaken with the participant standing up with the arms 
hanging loosely by his side unless stated otherwise. Limb girths were measured 
on the participant’s right side. The landmarks for each skinfold and position for 
measurement are described below and based on international guidelines (217). 
All measurements were done in duplicate, and the mean was used for analysis. 
All measurements were taken horizontally the tape was parallel to the floor. The 
waist hip ratio was calculated by dividing the mean waist circumference by the 
mean hip circumference. 
 
Mid-upper arm (arm relaxed): The girth of the arm was measured at the level 
of the mark used for the biceps skinfold. 
 
Waist: The participant would stand in with his feet close together and his arms 
folded in front of his chest and hands place on the contralateral shoulder. The 
technician kneeled in front of the participant and the circumference was 
circumference was measured at the level of the narrowest point between the 
superior border of the iliac crest and the inferior costal margin (10th rib) at the 
end of a normal expiration. If there was no obvious narrowing, measurement was 
made at the midpoint between the above bony landmarks.   
 
Hips: The participant kept his hands in the same position as for the waist 
measurement, and kept his feet close together. The technician kneeled by the 
right side of the participant. The circumference was measured at the greatest 
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posterior protuberance of the buttocks, at approximately the level of the pubic 
symphysis. 
 
Mid-thigh: The participant kept his hands in the same position as for the waist 
measurement with his feet separated. This circumference was measured at the 
midpoint between the most superior point of the greater trochanter (not the 
most lateral) and the upper most part on the lateral border of the head of the 
tibia.  
 
Calf: The participant stood on the anthropometric box with the technician 
kneeling by the right side of the participant. The maximum girth was determined 
by wrapping the tape round the participant’s calf and measuring the girth at 
what appeared to be the area of maximum girth. The tape was moved up and 
down slightly in a series of up and down measurements to determine the position 
of maximum girth. 
 
 
2.2.7 Body fat measurements using air displacement plythesmography  
 
2.2.7.1 Principles and technique 
 
Total body fat content (expressed as mass in kg and percentage of total body 
mass) and lean body mass (expressed as mass in kg and percentage of total body 
mass) were measured using air displacement plythesmography (ADP). ADP was 
performed using the BOD POD body composition system (Life Measurement 
Instruments, California, USA) according to the manufacturer's instructions and 
recommendations. This system comprises of the BOD POD chamber, digital Scale 
(accommodating body mass measurements up to 250 kg), Calibration Standards 
and Specially configured computer system and Windows®-based BOD POD 
software (219).  
 
ADP for all participants was measured by the author. Participants would wear 
shorts only and be asked to remove all jewellery (including wedding 
bands/rings). All participants would then be asked to wear a swimming cap to 
trap any air pockets present in the hair (regardless of degree of scalp hair) 
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(220). As per product software instruction, the system would be calibrated for 
mass and volume measurements. This involved a volume calibration with and 
without a 50 litre metal cylinder. Mass calibration was done using a 20 kg 
weight. Required participants data was then entered onto the computer, 
including gender, age and height (using the height obtained from the 
anthropometric measurements). The participant then entered the BOD POD and 
sat still inside the anterior (test) chamber (450 litres), with their hands resting 
on their lap. The test chamber was connected to a rear measuring chamber (300 
litres) via oscillating diaphragms (used to induce pressure changes in the anterior 
chamber (Figure 2.4). The participant would be instructed to breathe normally. 
The recommended procedure, consisting of two measurements of body volume 
(50 seconds each), was adopted and when, occasionally, body volumes differed 
in excess of 150 ml, the system required that a third measurement be performed 
(221). The final result reported by the BOD POD instrumentation was the mean 
of the two (or the two closest) measurements. Air conditioning was switched off 
for the duration of the calibration and measurement process to avoid potential 
changes in air pressure. 
 
 
Figure 2.4  Body volume measurement using BOD POD (219) 
 
Calculations of body volume:  The instrumentation measures the volume of air 
in the anterior chamber, using pressure changes induced by the oscillating 
diaphragm according to Boyle's laws (inverse relationship between pressure and 
volume at constant pressure and temperature (222), and provides raw body 
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volume (raw BV; litres) for each participant, simply by calculating the difference 
between the volumes of air in this chamber, with and without the participant 
being present. Raw BV measurements are adversely influenced by adiabatic 
conditions created by the participant's presence (this warmer air, approximately 
37°C, is more compressible than the ambient air), therefore the manufacturer's 
software applies certain corrections to the thoracic gas volume (TGV; litres) and 
the air in close proximity to the skin (using the surface area artefact, SAA; litres) 
to adjust to isothermal conditions.  All calculations were performed 
automatically by the system software. Actual body volume (ABV) was calculated 
using Equation 2.1 (220;221).  TGV (Equation 2.2) was predicted from functional 
residual capacity (FRC; litres) and tidal volume (TV; litres) (223). The system 
predicts FRC using a series of equations (224) with TV assumed to be constant at 
1.2 litres for men (age range 15-91 years). Calculation of SAA has been described 
in detail by Dewit and Colleagues (220). 
 
ABV (litres)  = raw BV  +  0.4TGV − SAA. 
Equation 2.1 Actual body volume (ABV) 
 
 
TGV  =  FRC  +  0.5TV 
Equation 2.2 Thoracic gas volume (TGV) 
 
 
Body density was calculated as body mass/volume (kg/litre). Percentage body 
fat  was calculated according to Equation 2.3 (225). Fat mass was calculated 
from percentage body fat and body mass 
 
% body fat  =  (495 / body density)  −  450 
Equation 2.3 Percentage body fat 
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2.2.7.2 Reproducibility Data 
 
To validate the BOD POD for reliability, 16 volunteers (2 South Asian, 1 East 
African and 13 European) each underwent body composition measurements by 
the BOD POD on two separate occasions 6-8 days apart. A Bland-Altman plot was 
created, by assigning the mean percentage body fat measurement for each 
participant as the x-axis value, and the difference between the two 
measurements as the ordinate (y-axis) value (Figure 2.5). 95% confidence limits 
were created using 1.96 standard deviations (SDs) either side of the mean 
difference in % body fat between visit 2 and visit 1 for the 16 participants. In 
addition, the within-participant CV i.e. the difference between measurements, 
or difference in test-retest values for the same participant expressed as a 
percentage was calculated as an index of reproducibility using online software 
(226). The CV for this sample was 8.2% i.e. a participant who had a body fat 
value of 30% would expect to have a retest body fat value between 27.5% and 
32.5%. The within-participant SD (calculated as the SD of the difference between 
the 2 visits divided by √2) was calculated prior to calculating the within-
participant CV (227). This test-retest reliability being similar to previously 
published data for the BOD POD (228). 
 
 
 81 
 
 
 
Figure 2.5 Bland-Altman plot for reproducibility of BOD POD 
Difference is visit 2- visit 1. CL- confidence limits 
 
 
2.2.8 Exercise testing 
 
2.2.8.1 Protocols and selection 
 
Hybrid continuous incremental uphill walking protocols based on the Balke (229) 
and Taylor (230) protocols were created to be used in the study. A total of 9 
protocols were created. All protocols had a starting speed of 4.5, 5.0, or 5.5 
Km.h-1 respectively and the gradient would increment by a fixed value (2, 2.5 or 
3%), starting at 0% at 2 minute intervals. Additional increments in work-rate 
(increments resulting in similar increments in predicted oxygen uptake, VO2pred) 
were calculated to be used once the maximum gradient had been exceeded 
(25%) in each of the protocols by increasing the speed of the treadmill. The 
appropriate increase in walking speed was determined using Equation 2.5 (231). 
VO2pred determined by adding VO2pred for the previous stage to the incremental 
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change in VO2pred (ΔVO2pred), and speeds converted from Km.h
-1 to m.min-1 
(Appendix A6).  Appendix A7 details the 9 protocols used. 
 
VO2pred = 3.5 + 0.1 x speed (m.min
-1) + (gradient % x speed (m.min-1) x 1.8) 
 
Equation 2.5 
 
 
The ideal protocol is one that would result in the exercise test duration to 
exceed 8 minutes, but not substantially exceed 12 minutes (232). The 
appropriate protocol would be determined by JW for all participants, who would 
enquire from the participant directly about the frequency, duration, intensity 
and nature of regular physical activity undertaken. JW is experienced in this 
regard; having been in charge of a number of previous exercise test-based 
studies at the University of Glasgow. 
 
The rationale behind using variations of the Balke protocol was to allow for a 
more gradual warm-up, with smaller increments compared to the standard Bruce 
protocol (233). It was considered safer and easier for unfit and older participants 
and also for participants not accustomed to running, given the upper age limit of 
the study group, with older South Asians even more likely to be unaccustomed to 
undertaking regular physical activity (118). Finally, by having a choice of nine 
different protocols, it would enable each participant to have a tailored exercise 
test. 
 
The main three disadvantages of this type of protocol were: 1) the time factor 
for fit individuals – being an easier test, it takes much longer for fitter 
individuals to reach a maximum effort; and 2) with this type of test 
incriminating by gradient initially, it can be technically challenging for 
individuals who have reached the maximum gradient of the treadmill to start 
running at such a gradient; and 3) a participant may lose motivation to exercise 
to maximal effort if the test is taking too long. If factor (1) was an issue, the 
option to attend for an incremental running-based treadmill test was offered, 
using a protocol that JW has devised and used in previous studies undertaken in 
the exercise laboratory. If factor (2) was an issue, the participant could re-
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attend for a repeat test using the same protocol or selecting a more appropriate 
protocol from the remaining 8 options. Factor (3) was addressed by having music 
and verbal engagement with the participant during the exercise test including 
encouragement when volitional fatigue was being reached (as described in 
section 2.2.8.2). 
 
 
2.2.8.2 Preparation and initiation 
 
In preparation for the test, the technician would go through the exercise test in 
detail with the participant. This included 1) technique of optimal walking style 
on the treadmill (with demonstration, and an opportunity for familiarisation on 
the treadmill including walking at the initial test speed); 2) safety issues, 
including how to terminate the test in the case of an emergency or unexpected 
reason to stop; 3) an explanation of how expired air would be measured (expired 
air from the mouth) and reassurance that despite the nose being clipped-off, the 
participant would not be deprived of room air; 4) explanation of the equipment 
being worn (headset to hold mouth piece for tubing to allow expired air 
collection and nose clips; and 5) how the participant should communicate with 
the team during the test using gesticulations as verbal communication would not 
be possible (3 gestures were used – one to indicate that the participant was 
progressing satisfactorily, the second to indicate that the participant was 
starting to tire, and the final gesture to indicate that the participant could only 
perform for a further minute or so). 
 
JW oversaw all the exercise tests for the study and the same treadmill 
(Woodway PPS 5Med-1, Woodway GmbH, Weil am Rhein, Germany) was used for 
all the exercise tests. The author was also present for all the exercise tests and 
would be responsible for treadmill operation as well as ECG and heart rate 
monitoring (as described in section 2.2.8.3). On occasion a third person would 
form part of the team conducting the test and would assume responsibility for 
treadmill operation in such an instance. 
 
The participant would wear the necessary equipment – headset (which held the 
mouth piece), nose clips (to ensure that all inspired and expired air would be 
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orally), ECG pads/leads and heart rate monitor ( as described in section 2.2.8.3). 
Prior to commencing the test, the participant would be given the opportunity to 
walk wearing the headset and nose clips to confirm comfort and for 
familiarisation. Once the participant was satisfied the test would commence 
after the participant had reached the initial walking speed for the test.  Each 
team member started a stopwatch in synchronisation when the test started. 
 
 
2.2.8.3 ECG, heart rate and participant monitoring 
 
Continuous ECG monitoring was performed for the duration of the test, using 
multiple lead monitoring (234). 12-lead ECGs were recorded at every minute 
throughout the test and be reviewed in real time by the author. A resting test 
prior test commencement was also performed and reviewed by the author to 
exclude any underlying pathology he deemed unsafe for the participant to 
undertake the exercise test. Heart rate was monitored continuously throughout 
the test using a short-range telemetry system. This consisted of a chest wall 
sensor with built-in transmitter and a watch that would receive the signal and 
display the heart rate (Polar s610i Heart Rate Monitor, Polar electro Oy, 
Kempele, Finland). The heart rate was recorded 45 seconds into every minute of 
the test by the treadmill operator. If the signal was lost from this monitor, the 
heart rate being recorded on the ECG machine would be used instead. 
 
 
2.2.8.4 Termination of exercise test and recovery 
 
The exercise test would terminate once the participant had given a maximum 
effort, which usually coincided with the participant completing the last minute 
of expired air collection. The participant would subsequently straddle the 
running surface of the treadmill to enable the operator to reduce the speed and 
gradient of the treadmill to allow the participant to go back on the running 
surface of the treadmill and actively recover from the test. If the participant 
was unable to complete this last minute, they would straddle the treadmill when 
they wanted to terminate the test. The participant would be given verbal 
encouragement throughout the test, to minimise premature indication of ‘one 
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minute left’ gesture. The test could also be terminated by the participant (by 
straddling the treadmill) even if maximal effort was not achieved, but was 
experiencing chest pain, troublesome breathlessness, or pain or discomfort 
elsewhere that was affecting the participant’s ability to continue on the 
treadmill. 
 
Premature termination of the test could also occur at the request of the author 
if the participant indicated any of the following ECG changes were identified: 1) 
horizontal or downsloping ST depression or ST elevation in excess of 0.2 mV (test 
terminated before this in the presence of concomitant chest pain, typical of 
angina, associated with horizontal or downsloping ST depression >0.1 millivolts); 
3) sustained ventricular tachycardia or frequent runs of non-sustained ventricular 
tachycardia (235). The participant would be asked to straddle the treadmill if 
premature termination was indicated. 
 
The stopwatches would be stopped as soon as the participant had straddled the 
treadmill and the time displayed would be considered as the duration of the test 
for that participant (to the nearest second). The time recorded by the author 
would be used. If it was felt that the author’s time was inaccurate the time 
recorded by the technician was used as a back-up. 
 
After the speed and gradient of the treadmill had been reduced, the participant 
returned back onto the running/walking surface of the treadmill, the participant 
would walk at a reduced pace on the flat until the heart rate had fallen to 
around 120/beats per minute and the participant was no longer feeling 
exhausted. 
 
 
2.2.8.5 Expired air collection and analysis 
 
JW would start the collection of expired air when it was felt that the participant 
was reaching maximal effort during the exercise test. JW was experienced in 
recognising when a participant would be approaching maximal effort, paying 
particular attention to pattern of respiration and heart. Expired air was 
collected in 1 minute intervals until termination of the exercise test in Douglas 
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Bags, using the standard technique (236). This would enable minute by minute 
values of oxygen uptake (VO2), and carbon dioxide production (VCO2) to be 
calculated.  
 
Expired air analysis for each bag of collected air was two-stage: 
 
Stage 1: A flow meter extracted 500 ml of air through the sampling port of the 
Douglas bag at a constant flow rate. This air passed through a gas analyser 
(Servomex 4000 series, Servomex Group Ltd, East Sussex, UK) which measured 
the percentage fraction of expired oxygen (FEO2) and the percentage fraction of 
expired carbon dioxide (FECO2). 
 
Stage 2: The remaining air was extracted by a vacuum at a constant flow rate 
through a dry gas meter (Harvard Apparatus Ltd, Kent, UK), which measured the 
volume of expired air. The dry gas meter’s theromometer measured the 
temperature of the expired air. 
 
Before each exercise test, the gas analyzer was calibrated using known 
reference gases (BOC Gases, BOC Ltd, Surrey, UK) and barometric pressure was 
recorded from the barometer in the exercise laboratory. All the gas 
measurements were corrected to standard room temperature and pressure 
(STPD) for a dry gas. Values of VO2 and VCO2 were calculated from expired air 
using the Haldane transformation of the Fick equation as shown in equations 2.6-
2.8) (237). 
 
 
VI = VESTPD x (100- FEO2 - FECO2) / 79.04  
Equation 2.6 Volume of Inspired air 
VI – volume of inspired air; VESTPD – volume of expired air corrected to standard 
temperature and pressure. 
 
 
VO2 (l/min) = VI x 0.2093 - (VESTPD x FEO2 / 100)   
Equation 2.7 Oxygen consumption 
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VCO2 (l/min) = (VESTPD x FEO2 / 100)  - VI x 0.0003   
Equation 2.8 Carbon dioxide production 
 
 
Achievement of VO2max was assessed by confirming a minimum of two of the 
three following criteria: (i) respiratory exchange ratio (RER) ≥1.15; (ii) 
achievement of heart rate ≥90% of age predicted maximum; and (ii) plateau of 
VO2 (238). Respiratory exchange ratio (RER was calculated) by the formula in 
equation 2.9. The age predicted maximum heart rate (HtRmax) was determined 
by the formula in equation 2.10 (239). Plateau of VO2 was determined by  having 
a difference of < 2.l ml/kg/min in VO2 between the last 2 bags of collected 
expired air (230). If the criteria were fulfilled, then highest calculated value of 
VO2 (which may not necessarily be from the last Douglas Bag of collected expired 
air) would then be considered to be the participant’s VO2 max 
 
 
RER= VCO2 / VO2 
Equation 2.9 Respiratory exchange ratio (RER) 
 
 
HtRmax= 220 - Age 
Equation 2.10 Predicted maximum heart rate 
 
 
2.2.9 Habitual physical activity measurements using accelerometry 
 
Objective measurement of habitual physical activity was assessed by seven-day 
accelerometry (Actigraph 3TX+ or ActiTrainer, Actigraph, Florida, USA). 
Participants would wear the device by attaching it to their waistband of their 
outermost lower garment using a belt clip on their right or left side. The 
accelerometer display was switched off. Participants were encouraged to wear 
the accelerometer for all the time spent awake, only removing the 
accelerometer if the participant was indulging in an activity which could result 
in it becoming damaged (e.g. showering contact sports) or falling off (e.g. 
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football). Where possible, if the accelerometer had to be removed, the 
participant was asked to keep it in their trouser pocket for the duration of 
removal where possible.   
 
Accelerometers were programmed to collect data on activity only. Vertical axis 
accelerometer readings were summarized in 60-second epochs. Actilife software 
(version 5 and subsequent updates, ActiGraph, Florida, USA) was used to 
programme accelerometers and download data after the accelerometer had 
been worn. Freedson cut-offs were used for the demarcation of intensity 
domains of activity (240).  A template spreadsheet was created for data to be 
transferred on to, to enable Freedson cut-offs to be determined. A minimum of 
4 valid days’ data was required for analysis. A valid day was defined as having 10 
or more hours of accelerometer wear. A day would commence with the first time 
the accelerometer was put on after waking up from overnight/daily sleep for the 
very first time. ‘Wear’ time was determined by subtracting ‘nonwear’ time for 
each subsequent 24 h thereafter. ‘Nonwear’ was defined by ‘an interval of at 
least 60 consecutive minutes of zero activity intensity counts, with allowance for 
1–2 min of counts between 0 and 100’ (241). However to prevent over estimation 
of ‘nonwear’, participants were asked to complete a booklet detailing the daily 
times the accelerometer was put on and taken off, and further opportunity to 
detail additional times when the accelerometer was taken off and put back on. 
If it appeared that an interval of >60 minutes inactivity as defined above 
occurred whilst the participant was awake, and it was not documented that the 
accelerometer had been removed, then this period of time was included as 
‘wear’ time. 
 
 
2.2.10 Magnetic resonance spectroscopy for quantification of liver fat 
 
52 participants (28 South Asians, 24 Europeans) were recruited from the CURVES 
study to undergo MRS and were chosen at random (but matched for age) within 4 
months of their original main study visit. It was intended to recruit equal 
numbers of participants from each ethnic group. All participants had no known 
parenchymal liver disease. 
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MRS was performed with a 1.5T HDxt GE Signa magnetic resonance scanner (GE 
Healthcare, Milwaukee) using an 8-channel cardiac coil at The Beatson West of 
Scotland Cancer Centre, Glasgow, UK.  Scott Hanvey (SH), Medical Physicist, was 
responsible for contacting volunteers and performing the scans under the 
supervision of Dr John Foster (JF) Consultant Clinical Scientist and Deputy Head 
of MR Physics for NHS Greater Glasgow and Clyde. Consent was undertaken by 
trained MRI staff working in the centre and clinical supervision and review of 
scans was provided by Dr Stuart Ballantyne, Consultant Radiologist, Gartnavel 
General Hospital. 
 
In accordance with previously published data (242), a 30 x 30 x 30mm MRS single 
voxel was acquired near the base of the liver (to minimise effects of respiratory 
motion) avoiding large vessels and at least one centimetre from the liver’s edge.  
Two consecutive spectra were acquired – with echo times (TE) of 144 ms and 35 
ms, respectively (both with repetition times (TR) of 1500 ms) – in the same 
location for each volunteer using the point-resolved spectroscopy (PRESS) 
sequence. The manufacturer’s software (SAGE, GE Healthcare, Milwaukee) was 
used to obtain liver fat and liver water ratios, which was converted into a liver 
fat fraction percentage (FF) using the equation FF = 100  FA / (FA + WA) where 
FA is the area under the fat peak and WA is the area under the water peak 
(243). The two values obtained with the different TE were averaged to give a 
liver fat fraction percentage for each volunteer. Anonymised data were stored 
on the Computers connected to the MR scanner. All analysis was performed 
offline by SH under the Supervision of JF. 
 
 
2.3 Power calculations 
 
2.3.1 Carotid plaque, insulin resistance, VO2max and body fat analysis 
 
Based on observation of carotid plaques in 40% of European men aged 40-70 
(186) and assuming a 1.5 relative risk (i.e. plaques in 60% of SA men aged 40-
70), then 97 men per ethnic group would be needed for 80% power to detect 
differences between plaques between the South Asian and European groups at a 
significance of p=0.05. The power calculation was checked by Professor Ian 
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Ford, Professor of Biostatistics, University of Glasgow, UK. Based on previously 
published local data (47), this number of participants would enable detection of 
differences ~0.4 units, ~3 ml kg1 min1 and ~2 kg in HOMAIR, VO2max and fat 
mass, respectively, with the same power, between the South Asian and 
European groups. The aim was to therefore recruit 100 men from each ethnic 
group for the main study visit. 
 
 
2.3.2 Differences in liver fat 
 
There is a relative lack of data on hepatic fat in SAs but one prior study reported 
a near tripling in hepatic fat (by determination of liver triglyceride levels 
comparing 23 SAs with 73 European men (1.94% v 0.75%, p<0.001) (244). Based 
on these data, as determined by David Purves (DP) and overseen by Dr Alex 
McConnachie (AM) of the Robertson Centre for Biostatics, University of Glasgow, 
it was estimated that a sample size of 22 in each group would be required to 
show, with 90% power, a difference of 0.53 and 0.95 in the log means of insulin 
resistance and liver fat respectively (equivalent to a percentage difference of 
68%  and 158% in the means of insulin resistance and liver fat respectively), at 
the 5% significance level, between Asian and European men. 
 
 
2.4 Statistical analysis 
 
Unless stated otherwise, all statistical analysis was performed using Minitab 
(version 15.1.30.0, Minitab Inc., State College, Pennsylvania) and undertaken by 
the author and overseen by his supervisors - where necessary, more complex 
analyses were have been undertaken by DP and overseen by AM with appropriate 
acknowledgement.  The specific methods of analysis and presentation of data 
are described accordingly in the respective ‘Data analysis’ sections in chapters 3, 
4 and 5. 
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2.5 Insulin resistance calculation 
 
Insulin resistance was assessed using fasting insulin and glucose levels in the 
Homeostasis Assessment Model of Insulin Resistance (HOMAIR) (245). It is the 
most widely used method and is considered presently as the best surrogate 
method for insulin resistance using fasting glucose and insulin measurement 
(246).  Insulin resistance was calculated using equation 2.7. As the laboratory 
assay measured in insulin in mIU/l, each result was multiplied by 6 to obtain the 
corresponding value in pmol/l. 
 
HOMA IR = (fasting glucose [mmol/l] x fasting insulin [mIU/l])/22.5 
Equation 2.11 HOMAIR 
 
 
2.6 Participant notification of results of tests 
 
All participants were conveyed the results of their routine blood tests, blood 
pressure and useful anthropometric results. General lifestyle advice was given by 
the author relevant to the participant’s results. If a participant had blood test 
results that were abnormal, this was discussed with the participant, and if 
appropriate, and consent had been given, the participant’s GP was written to 
informing them of the participant’s results with any appropriate advice or 
follow-up suggestions. It was left to individual GPs to take things forward with 
the participant in question. Those who expressed an interest to know the results 
of the exercise test were provided with also provided their VO2max results. 
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Chapter 3  
Contribution of cardiorespiratory fitness and objectively measured physical 
activity to the increased insulin resistance and fasting glycaemia observed in 
middle-aged South Asian compared to European men living in the United 
Kingdom 
 
 
3.1 Introduction 
 
South Asians living in the United Kingdom have a 3-5 fold increased prevalence 
of T2DM, and develop the disease around a decade earlier and at a lower BMI, 
compared to Europeans (25;28).  In addition, non-diabetic South Asians exhibit 
higher glucose levels than Europeans (14;67).  While the mechanisms for their 
higher risk are not fully understood, greater insulin resistance is a strong 
candidate (14;44;47).  
 
Adiposity (46;80;247), cardiorespiratory fitness (80;83) and physical activity 
(105;113) are key factors influencing insulin resistance, glycaemia and diabetes 
risk.  South Asians carry more body fat than Europeans and this may be 
distributed more centrally (24;44;248).  However, it appears that South Asians 
remain more insulin resistant than Europeans after matching or adjustment for a 
range of adiposity markers (46;47).  Furthermore, limited data from small 
studies suggests that cardiorespiratory fitness, as assessed by VO2max, is ~10-20% 
lower in South Asians than matched Europeans (45;47;87), with previous local 
data (47) showing that adjustment for VO2max attenuated the difference in 
insulin sensitivity between young South Asian and European men.  In addition, 
habitual levels of physical activity amongst South Asians living in the UK appear 
lower than in Europeans (99;116-118).  Low physical activity has been shown to 
explain part of the excess CVD risk observed in South Asians (118), and could 
conceivably contribute to their increased diabetes risk.  However, available data 
on physical activity in South Asians have all been obtained from self-report 
questionnaires: these have limited validity compared to objective measures 
(96;98), which is potentially exacerbated in South Asians due cultural 
interpretation of the terminology used in the questionnaires (99). 
Misclassification arising from the use of questionnaires to assess physical activity 
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can substantially underestimate the true relationship between activity and risk 
of vascular and metabolic disease (104;114).   
 
Thus, from the available data, the extent to which lower cardiorespiratory 
fitness and lower physical activity contributes to increased insulin resistance and 
glycaemia in South Asians is not established.  Thus it was hypothesised that 
these factors would explain a substantial proportion of the increased insulin 
resistance and glycaemia observed in South Asian men living in the UK.    
 
 
3.2 Methods 
 
3.2.1 Participants and recruitment 
 
All participants were recruited and screened as detailed in section 2.1. Specific 
inclusion and exclusion criteria are defined in section 2.1.1. All participants 
received payment for towards transport and received feedback as detailed in 
sections 2.2.1 and 2.6 respectively. 
 
Participants’ health history, including smoking status and family health history, 
education history, SES information and dietary information were obtained as 
described in section 2.2.1 
 
 
3.2.2 Blood biochemistry and blood pressure measurements 
 
Venous blood samples were obtained after an overnight fast of 10-12 hours as 
described in section 2.2.2.1. Samples were sent for routine tests outlined in 
section 2.2.2.1.  Plasma was stored for the subsequent measurement of insulin 
as described in section 2.2.2.2.  Insulin resistance was assessed by HOMAIR and 
was calculated as outlined in section 2.5. 
 
Blood pressure was measured as described in section 2.2.4. 
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3.2.3 Anthropometry 
 
Anthrompometric measurements were performed on all participants as detailed 
in section 2.2.6. Total body lean and fat mass was measured using ADP as 
described in section 2.2.7.  
 
 
3.2.4 Determination of cardiorespiratory fitness 
 
All participants had a clinical assessment and resting ECG performed prior to 
undertaking the exercise test to ensure no contraindications to maximal 
exercise.  Exercise testing was undertaken as described in section 2.2.8. 
Cardiorespiratory fitness was determined by measuring VO2max as described in 
sections 2.2.8.5 and 2.2.8.6. A valid measure of VO2max was achieved in 199 of 
the 200 participants. 
 
 
3.2.5 Measurement of physical activity 
 
Objective measurement of physical activity was obtained through accelerometry 
as described in section 2.2.9. Valid data were obtained for 85 South Asians and 
84 Europeans. 
 
 
3.2.6 Data analysis 
 
The sample size for the CURVES study was determined as calculated in section 
2.3.1.  
 
Summary statistics are presented for all variables for both South Asians and 
Europeans. Continuous variables were compared between the ethnic groups by t-
tests (or Wilcoxon rank sum test for non-normally distributed variables) and 
Fisher’s Exact test for categorical variables. 
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Factor analysis was used to reduce the number of anthropometric variables into 
underlying latent factors.  Three factors emerged relating to ‘total adiposity’ 
(identified by biceps, triceps, subscapular, supraspinale, suprailiac, thigh, and 
calf skinfolds, and fat mass), ‘body size’ (height, lean mass, and hip, mid-thigh 
and mid-calf circumferences), and ‘central adiposity’ (waist circumference and 
WHR).  A summary measure was calculated to describe each factor.  Each 
variable was standardised (by subtracting the mean and dividing by the standard 
deviation), summed according to the factor analysis groups and then 
standardised again.  Initially, linear regression models, adjusted for ethnicity 
(i.e. nullifying the ethnicity effect), were used to assess associations between 
total adiposity, body size, central adiposity, physical activity, sedentary 
behaviour and fitness (expressed as standardised measures) on HOMAIR and 
fasting glucose concentration.  Effects of potential confounding covariates (age, 
education, SES, smoking, alcohol, diabetes family history) on HOMAIR and fasting 
glucose concentration were also assessed.   Both outcome variables were log 
transformed for analysis. Then,  relative effects of ethnicity on HOMAIR and 
glucose was calculated: when it was the only predictor in the model;  after 
separate adjustment for total adiposity, body size, central adiposity, physical 
activity, sedentary behaviour and fitness; and in the final model including 
adjustment for all of the above variables which significantly influenced the 
ethnicity effect.  Thus, this analysis enabled determination of the extent to 
which differences in HOMAIR and fasting glucose concentration between South 
Asians and Europeans could be explained by body composition, fitness, and 
physical activity variables.  The absolute differences in geometric means for 
HOMAIR and fasting glucose concentration between the groups were calculated 
for each model, using the mean value for continuous predictors and the 
reference level for any categorical variables, and 95% CIs for the difference were 
derived by bootstrapping. The percentage change in the relative percentile 
difference between South Asians and Europeans in HOMAIR and fasting glucose 
concentration were calculated with 95% CIs and p-values derived by 
bootstrapping (reductions greater than 100% describe a change in direction of 
the effect). 
 
All the above analysis was undertaken by DP and AM and in consultation with the 
author and his supervisors. 
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The statistical software package R for Windows v2.14 was used for all analysis. 
Statistical significance was accepted at p < 0.05. 
 
 
3.3 Results 
 
3.3.1 Demographic, metabolic and dietary variables 
 
Thirteen South Asian men and one European man who completed the full study 
protocol were subsequently noted to have HbA1c concentrations >6.5% (>48 
mmol/mol) and/or fasting glucose concentrations >7 mmol/l, indicating possible 
undiagnosed diabetes.  Their data were excluded from the analyses.  The final 
data set therefore included 87 South Asian and 99 European men.  Demographic 
and metabolic variables for the final South Asian and European cohorts are 
presented in Table 3.1.  Baseline data for all 200 participants are presented in 
Table 5.1. There were no differences between groups in age or BMI, but South 
Asians were shorter than the Europeans.  South Asians also had completed more 
years in education, were less likely to smoke or consume alcohol, and were more 
likely to have a parent or sibling withT2DM.  There were no differences in SES.  
South Asians had significantly higher glucose, HbA1c, insulin, HOMAIR, CRP and 
diastolic blood pressure, and lower HDL-cholesterol, than the Europeans.  Mean 
± SD reported energy intake (expressed per kg body mass) did not differ between 
Europeans and South Asians (19.9 ± 6.0 vs 18.7 ± 6.5 kcal.kg-1.day-1, p = 0.21).  
There were also no differences in reported protein, carbohydrate or fat intakes 
between the two groups (data not shown), but reported alcohol intake was 
higher in the Europeans than South Asians (22.1 ± 18.3 vs 1.2 ± 6.0 g.day-1, p < 
0.001).  
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Table 3.1 Demographic and metabolic variables for South Asian and European 
men.  
 
  
South Asian 
(N = 87) 
European 
(N = 99) 
p-value 
Demographic and lifestyle variables 
    
Age (years) 
 
48.3 (6.8) 49.7 (6.8) 0.162 
Body mass (kg) 
 
82.0 (12.1) 85.7 (13.9) 0.056 
Height (m) 
 
1.74 (0.07) 1.79 (0.06) <0.001 
BMI (kg/m2) 
 
27.1 (3.8) 26.9 (4.3) 0.700 
Years in Education 
 
15.4 (3.4) 14.4 (3.2) 0.042 
SIMD Quintile 1 6 ( 6.9%) 7 ( 7.1%)  
 
2 10 (11.5%) 13 (13.1%) 
 
 
3 16 (18.4%) 19 (19.2%) 0.751 
 
4 23 (26.4%) 18 (18.2%) 
 
 
5 32 (36.8%) 42 (42.4%) 
 
Smoking Status 
never-
smoker 
71 (81.6%) 54 (54.5%) 
 
 
ex-smoker 5 (5.7%) 35 (35.4%) <0.001 
 
current 11 (12.6%) 10 (10.1%) 
 
Alcohol Consumptionb none 81 (93.1%) 10 (10.2%)  
(units per week) ≤ 20 4 (4.6%) 69 (70.4%) <0.001 
 
≥ 21 2 (2.3%) 19 (19.4%) 
 
Parental Diabetes Statusb yes 50 (57.5%) 12 (12.2%) <0.001 
Sibling Diabetes Statusb yes 13 (14.9%) 2 (2.0%) 0.002 
Metabolic variables 
 
   
Glucose (mmol/l)  5.3 (4.9, 5.7) 5.1 (4.8, 5.4) 0.018 
HbA1c (mmol/mol)c  39.0 (37.0, 41.0) 36.0 (33.0, 38.0) <0.001a 
HbA1c (%)c  5.7 (5.5, 5.9) 5.4 (5.2, 5.6) <0.001a 
Insulin (pmol/l)c  88.9 (69.5, 119.5) 54.2 (36.8, 79.9) <0.001a 
HOMAIR
c  3.0 (2.4, 4.2) 1.8 (1.1, 2.6) <0.001a 
Total Cholesterol (mmol/l)  5.4 (1.0) 5.6 (1.0) 0.107 
HDL-Cholesterol (mmol/l)  1.1 (1.0, 1.3) 1.3 (1.1, 1.6) <0.001a 
LDL-cholesterol (mmol/l)  3.5 (0.9) 3.6 (0.8) 0.458 
Triacylglycerol (mmol/l)  1.4 (1.0, 2.2) 1.3 (0.9, 1.8) 0.135a 
AST (U/l)  23.3 (6.8) 25.1 (8.6) 0.100 
ALT (U/l)  26.0 (21.0, 35.5) 26.0 (20.0, 35.5) 0.857a 
GGT (U/l)  30.0 (22.0, 42.5) 28.0 (20.5, 43.5) 0.572a 
CRP (nmol/l)b  17.1 (10.5, 38.1) 10.5 (5.7, 23.8) 0.003a 
Systolic blood pressure (mm Hg)  126.3 (15.4) 127.5 (12.9) 0.568 
Diastolic blood pressure (mm Hg)  77.8 (9.1) 74.9 (7.2) 0.018 
Values are mean (SD) for normally distributed variables with p values calculated by t-tests and median 
(inter-quartile range, IQR) for non-normally distributed variables with p-values calculated by Wilcoxon 
testa. Categorical variable p-values are calculated by Fisher's Exact test. bn = 98 for Europeans; cn = 86 for 
South Asians.
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3.3.2 Body composition, fitness and physical activity variables 
 
Body composition, fitness and physical activity variables are presented in Table 
3.2. There were no differences in waist or hip circumferences between the 
South Asian and European groups, but WHR was higher in the South Asians.  
South Asians also had a smaller mid-thigh circumference, and higher values for 
all skinfold thicknesses than the Europeans.  Lean mass was lower and fat mass 
and percentage body fat were higher in the South Asians.  Total adiposity and 
central adiposity factors were higher and body size units lower in South Asians 
than Europeans.  Cardiorespiratory fitness (as assessed by VO2max) was lower in 
South Asians than Europeans, irrespective of whether this was expressed in 
absolute terms (i.e. l/min) (lower on average by 24%),  per kg body mass (by 
21%) or per kg lean mass (by 16%).  
 
South Asians also engaged in less moderate and vigorous physical activity than 
Europeans: the proportion of time spent in moderate-to-vigorous physical 
activity was ~32% lower in South Asians than Europeans.  This equated to South 
Asians engaging in ~23 minutes of moderate-to-vigorous physical activity (MVPA) 
per day compared to ~34 minutes per day for the Europeans.  There were 
significant correlations between VO2max (in ml.kg
-1.min-1) and (log) MVPA in both 
South Asians (r = 0.326, p = 0.004) and Europeans (r = 0.326, p = 0.003). 
However, the lower VO2max values in South Asians could not be explained by their 
lower levels of physical activity: South Asians’ VO2max values were lower than 
Europeans’ across the range of MVPA levels, and their VO2max values remained 
significantly lower than Europeans after adjustment for MVPA (Figure 3.1).   
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Table 3.2 Body composition, fitness, and physical activity variables for South 
Asian and European men.  
 
 
South Asian 
(N = 87) 
European 
(N = 99) 
p-value 
Anthropometric variables 
   
(a) Body circumferences 
   
Waist (cm) 97.3 (10.9) 95.6 (11.2) 0.315 
Hips (cm) 99.5 (6.6) 100.5 (7.1) 0.336 
Waist-to-hip ratio 0.98 (0.07) 0.95 (0.06) 0.009 
Mid-upper arm (cm) 34.5 (8.2) 33.4 (3.3) 0.238 
Mid-thigh (cm) 52.6 (4.3) 54.0 (4.0) 0.030 
Mid-calf (cm) 37.7 (3.4) 38.6 (4.1) 0.101 
(b) Skinfold thicknesses 
   
Biceps (mm)e 8.0 (3.6) 6.8 (2.9) 0.015 
Triceps (mm) 16.4 (5.8) 12.6 (4.3) <0.001 
Subscapular (mm) e, k 25.7 (7.3) 18.3 (7.1) <0.001 
Suprailiac (mm)g, j 23.4 (6.2) 18.2 (6.2) <0.001 
Supraspinale (mm) 18.0 (6.6) 12.6 (5.4) <0.001 
Thigh (mm) e 19.1 (7.9) 14.6 (5.7) <0.001 
Calf (mm)i 13.0 (5.4) 10.4 (4.2) <0.001 
(c) Fat and lean mass    
Lean mass (kg) e 57.2 (6.4) 63.3 (7.1) <0.001 
Fat mass (kg) e 24.4 (9.0) 21.8 (9.7) 0.058 
Percentage body fat e 29.2 (7.4) 24.8 (7.4) <0.001 
(d)     Summary anthropometric factors     
Total adiposityb (standardised units) 0.4 (1.0) -0.3 (0.9) <0.001 
Body sizec (standardised units) -0.3 (0.9) 0.3 (1.0) <0.001 
Central adiposityd (standardised units) 0.1 (1.0) -0.1 (1.0) 0.058 
Fitness variables    
VO2 max (l.min
-1) e 2.6 (0.4) 3.4 (0.6) <0.001 
VO2 max (ml.kg
-1.min-1) e 31.5 (5.8) 39.6 (7.5) <0.001 
VO2 max  (ml.kg lean mass
-1.min-1)f 44.7 (6.4) 53.0 (7.8) <0.001 
Physical activity variables    
Sedentary (% of wear time)h, l 66.5 (9.5) 64.2 (9.1) 0.136 
Light physical activity (% of wear time) h, l 30.4 (9.2) 30.8 (8.1) 0.789 
Moderate-to-vigorous physical activity (% of wear 
time) h, l 
2.8 (1.7, 4.1) 4.1 (3.0, 6.8) <0.001a 
Total accelerometer wear time (min.day-1) h, l 824.5 (85.1) 863.0 (74.2) 0.003 
 
Values are mean (SD) for normally distributed variables with p-values calculated by t-tests and median 
(IQR) for non-normally distributed variables with p-values calculated by Wilcoxon testa. Categorical variable 
p values are calculated by Fisher's Exact test. bDerived from biceps, triceps, subscapular, supraspinale, 
suprailiac, thigh, and calf skinfolds, and fat mass; cderived from height, lean mass, and hip, mid-thigh and 
mid-calf circumferences; dderived from waist circumference and waist-to-hip ratio. en = 98, fn = 97, gn = 95 
and hn = 83 for Europeans; in = 86, jn = 84, kn = 82, ln = 75  for South Asian
 100 
 
 
 
 
Figure 3.1 Relationship between VO2max and moderate-to-vigorous physical 
activity in South Asian and European men.   
Solid circles and the solid line represent South Asian men with open circles and the dotted line 
representing European men. Solid and dotted vertical bars indicate mean MVPA levels in South 
Asian and European men, respectively; the horizontal arrow shows the mean difference in MVPA 
between ethnic groups.  Solid and dotted horizontal bars, with corresponding vertical arrows 
indicate mean VO2max values in South Asian and European men and the mean ethnic difference, 
both unadjusted and adjusted for MVPA. 
 
 
3.3.3 Associations between anthropometric, physical activity and fitness 
variables with HOMAIR and fasting glucose concentration  
 
Table 3.3 shows ethnicity-adjusted relative effects of anthropometric, physical 
activity and fitness variables on HOMAIR and fasting glucose concentration.  
HOMAIR increased with increasing total adiposity, body size, central adiposity 
 101 
 
and time spent sedentary and decreased with increasing MVPA and VO2max.  
Fasting glucose concentration increased with increasing total adiposity and 
decreased with increasing VO2max.  For these analyses VO2max was expressed in 
ml.kg-1.min-1, but results were similar when VO2max was expressed in l.min
-1 or in 
ml.kg lean mass-1.min-1. Effects of potential confounding covariates (smoking 
status, alcohol consumption, years in education and SES) on HOMAIR and fasting 
glucose concentration are shown in Appendix A8.  HOMAIR was higher in ex-
smokers (but not current smokers) than non-smokers (by 26%, 95% CI: 2%, 56%, 
p=0.03).  Other than this, none of measured covariates were significantly 
associated with HOMAIR or fasting glucose concentration. 
 
 
 
Table 3.3 Associations between HOMAIR and fasting glucose concentration 
with standardised anthropometric, physical activity and fitness variables.   
 
Predictor 
HOMAIR Fasting glucose concentration 
Relative effect estimate  
(95% CI), p-value 
Relative effect estimate  
(95% CI), p-value 
Anthropometric variables  
  
Total adipositya  
1.40 (1.30, 1.50) 
p<0.001 
1.02 (1.00, 1.03) 
p=0.013 
Body sizeb  
1.21 (1.12, 1.31) 
p<0.001 
1.00 (0.99, 1.02) 
p=0.666 
Central adiposityc 
1.40 (1.31, 1.49) 
p<0.001 
1.01 (1.00, 1.03) 
p=0.075 
Physical activity variables  
  
Moderate-to-vigorous physical activity 
0.86 (0.79, 0.94) 
p=0.001 
0.99 (0.97, 1.01) 
p=0.263 
Sedentary  
1.10 (1.01, 1.20) 
p=0.024 
1.01 (0.99, 1.02) 
p=0.299 
Fitness variables   
VO2 max
d 
0.74 (0.68, 0.80) 
p<0.001 
0.98 (0.97, 1.00) 
p=0.020 
 
Relative effects are for a 1 SD change in the predictor variable, adjusted for ethnicity. Values 
are presented with 95% CIs and p values. aDerived from biceps, triceps, subscapular, 
supraspinale, suprailiac, thigh, and calf skinfolds, and fat mass; bderived from height, lean mass, 
and hip, mid-thigh and mid-calf circumferences; cderived from waist circumference and waist-to-
hip ratio. dexpressed in ml.kg-1.min-1. 
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3.3.4 Contribution of anthropometric, physical activity and fitness variables 
to the difference in HOMAIR between Europeans and South Asians   
 
Table 3.4 shows the relative effect of ethnicity, in relative and absolute terms, 
on HOMAIR, unadjusted and in models adjusted for anthropometric, physical 
activity and fitness variables. In unadjusted analysis, HOMAIR values in South 
Asians were 67% (95% CI, 42-96%, p<0.001), higher than the values observed in 
Europeans. Ethnicity contributed 18% of the total variance in HOMAIR.  Adjusting 
for total adiposity attenuated the difference in HOMAIR between ethnic groups 
by 51.7% (95% CI, 29.5-80.3%), whereas adjusting for body size increased the 
difference by 28.5% (95% CI, 11.5-48.3%).  Adjusting for MVPA reduced the 
difference in HOMAIR between South Asians and Europeans by 27.5% (95% CI, 
10.7-45.9%).  However, the difference in VO2max between South Asians and 
Europeans explained more of the difference in HOMAIR than any other variable: 
adjustment for VO2max attenuated the difference in HOMAIR between ethnic 
groups by 67.5% (95% CI, 45.1-90.9%).  This is further illustrated in Figure 3.2.  
Adjustment for central adiposity or sedentary time did not significantly alter the 
ethnicity effect on HOMAIR.  Simultaneously adjusting for the four variables 
which significantly changed the ethnicity effect (total adiposity, body size, MVPA 
and VO2max) attenuated the difference in HOMAIR between South Asians and 
Europeans by 83.4% (95% CI, 50.1-118.9%).  Repeating the analyses after 
adjustment for smoking, alcohol consumption, education and SES produced 
similar findings. In these confounder-adjusted analyses, the difference in VO2max 
between South Asians and Europeans explained 77.8% (95% CI, 38.4-132.2%) of 
the ethnic difference in HOMAIR, and the contribution of total adiposity to the 
difference in HOMAIR between the ethnic groups was attenuated slightly to 41.3% 
(95% CI, 0.5-95.7%).   
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Table 3.4 relative effects of ethnicity on HOMAIR, unadjusted and adjusted by anthropometric, physical activity and fitness 
variables.   
 
 Ethnicity effect estimate for HOMAIR 
 N Unadjusteda  Adjustedb  Percentage changec 
  
Relative effect 
estimate (95% CI) 
p-value R2adj  
Relative effect 
estimate (95% CI) 
p-value R2adj  
Percentage 
change estimate 
(95% CI) 
p-value 
Anthropometric variables            
Total adiposityd  185 1.67 (1.42, 1.96) <0.001 0.17  1.32 (1.15, 1.53) <0.001 0.43  
-51.7 (-72.1, -
34.3) 
<0.001 
Body sizee  185 1.67 (1.42, 1.96) <0.001 0.17  1.86 (1.59, 2.18) <0.001 0.26  28.5 (10.4, 52.3) <0.001 
Central adiposityf  185 1.67 (1.42, 1.96) <0.001 0.17  1.53 (1.34, 1.74) <0.001 0.46  -21.2 (-38.1, 3.4) 0.080 
Physical activity variables             
Moderate-to-vigorous physical activity 157 1.57 (1.32, 1.86) <0.001 0.14  1.41 (1.18, 1.68) <0.001 0.19  
-27.5 (-49.9, -
10.0) 
<0.001 
Sedentary  157 1.57 (1.32, 1.86) <0.001 0.14  1.53 (1.29, 1.82) <0.001 0.16  -6.0 (-17.9, 2.5) 0.162 
Fitness variables            
VO2 max
g 184 1.66 (1.41, 1.95) <0.001 0.17  1.22 (1.03, 1.44) 0.022 0.35  
-67.5 (-94.8, -
45.0) 
<0.001 
All Statistically Significant Factors            
Total adiposity + Body size +  
Moderate-to-vigorous physical activity  
+ VO2 max 
 
156 1.56 (1.31, 1.85) <0.001 0.14  1.09 (0.91, 1.31) 0.332 0.45  
-83.4 (-120.7, -
55.3) 
<0.001 
Estimates for the relative effect (ratios of geometric means) of ethnicity on HOMAIR and the percentage change between these effects are presented with 95% CIs and p 
values. Adjusted R
2
 (R
2
adj) for unadjusted and adjusted models also displayed.  
a
unadjusted relative ethnicity effect (for South Asians compared to white Europeans); 
b
ethnicity effect adjusted for predictor variables; 
c
percentage change in unadjusted race effect estimate to adjusted model effect. 
d
Derived from biceps, triceps, 
subscapular, supraspinale, suprailiac, thigh, and calf skinfolds, and fat mass; 
e
derived from height, lean mass, and hip, mid-thigh and mid-calf circumferences; 
f
derived 
from waist circumference and WHR. 
g
expressed in ml.kg
-1
.min
-1
. 
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Figure 3.2 Relationship between HOMAIR and VO2max in South Asian and 
European men  
Solid circles and the solid line represent South Asian men with open circles and the dotted line 
representing European men. Solid and dotted vertical bars indicate mean VO2max values in South 
Asian and European men, respectively; the horizontal arrow shows the mean difference in VO2max 
between ethnic groups.  Solid and dotted horizontal bars, with corresponding vertical arrows 
indicate mean HOMAIR values in South Asian and European men and the mean ethnic difference, 
both unadjusted and adjusted for VO2max. 
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3.3.5 Contribution of anthropometric, physical activity and fitness variables 
to the difference in fasting glucose concentration between Europeans and 
South Asians  
 
Table 3.5 presents similar data for the fasting glucose concentration. In 
unadjusted analysis, fasting glucose concentrations in South Asians were 3% (95% 
CI, 1-6%, p<0.017) higher than in Europeans.  Ethnicity contributed to 3% of the 
variance in fasting glucose. Adjusting for total adiposity attenuated the ethnic 
difference in fasting glucose by 39.1% (95% CI, 9.4-76.1%).  Similar to effects on 
HOMAIR, VO2max explained more of the difference in fasting glucose concentration 
between South Asians and Europeans than any other variables, with adjustment 
for VO2max attenuating the ethnic difference by 60.7% (95% CI, 9.2-111.0%).  The 
ethnicity effect for fasting glucose concentration was not significantly 
influenced by body size, central adiposity, MVPA or sedentary time. 
Simultaneously adjusting for total adiposity and VO2max attenuated the ethnic 
difference in fasting glucose by 63.4% (95% CI, 8.2%-114.6%).  Repeating the 
analyses after adjustment for smoking, alcohol consumption, education and SES 
produced essentially similar findings, with VO2max still explaining more of the 
difference in fasting glucose concentration between the ethnic groups than 
other any variable, attenuating the difference by 41.6% (95% CI, 1.7-232.0%)).  In 
these confounder-adjusted analyses no other variables significantly contributed 
to the ethnicity difference.  
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Table 3.5: Relative and absolute effects of ethnicity on fasting glucose concentration, unadjusted and adjusted by anthropometric, 
physical activity and fitness variables.  
  
 N 
Relative ethnicity effect estimate for fasting glucose 
concentration  
 
Absolute difference in fasting 
glucose concentration between 
Europeans and South Asians 
(mmol/l) 
 
Percentage change in 
ethnicity difference with 
adjustment
c
 
  Unadjusted
a
 p-value 
Adjusted for 
predictor 
variable 
p-value  Unadjusted
b
 
Adjusted for 
predictor 
variable 
 
Percentage 
change estimate  
p-value 
Anthropometric variables            
Total adiposity
d
  186 
1.03 (1.01, 
1.06) 
0.017 
1.02 (0.99, 
1.05) 
0.163  
0.18 (0.03, 
0.33) 
0.11 (-0.05, 
0.27) 
 -39.1 (-76.1, -9.4) 0.008 
Body size
e
  186 
1.03 (1.01, 
1.06) 
0.017 
1.04 (1.01, 
1.07) 
0.016  
0.18 (0.03, 
0.33) 
0.19 (0.03, 
0.33) 
 5.4 (-15.9, 26.4) 0.600 
Central adiposity
f
  186 
1.03 (1.01, 
1.06) 
0.017 
1.03 (1.00, 
1.06) 
0.033  
0.18 (0.03, 
0.33) 
0.16 (0.01, 
0.30) 
 -10.6 (-31.7, 1.8) 0.128 
Physical activity variables             
Moderate-to-vigorous physical activity 158 
1.04 (1.01, 
1.07) 
0.016 
1.03 (1.00, 
1.07) 
0.063  
0.20 (0.04, 
0.36) 
0.16 (0.00, 0.33)  -18.0 (-48.6, 10.6) 0.220 
Sedentary  158 
1.04 (1.01, 
1.07) 
0.016 
1.04 (1.01, 
1.07) 
0.023  
0.20 (0.04, 
0.36) 
0.19 (0.03, 
0.34) 
 -5.2 (-19.2, 5.5) 0.406 
Fitness variables            
VO2 max
g
 185 
1.03 (1.00, 
1.06) 
0.023 
1.01 (0.98, 
1.05) 
0.430  
0.17 (0.02, 
0.30) 
0.07 (-0.09, 
0.22) 
 
-60.7 (-111.0, -
9.2) 
0.028 
All Statistically Significant Factors            
Total adiposity + VO2 max 185 
1.03 (1.00, 
1.06) 
0.023 
1.01 (0.98, 
1.04) 
0.460  
0.17 (0.02, 
0.30) 
0.06 (-0.09, 
0.22) 
 
-63.4 (-114.6, -
8.2) 
0.030 
 
Estimates for the effect of ethnicity on fasting glucose concentration, expressed as a relative effect (ratios of geometric means); in terms of absolute difference in 
the geometric mean (in mmol/l); and the percentage change between these effects after adjustment are presented with 95% CIs and p values.  aunadjusted 
relative ethnicity effect (for South Asians compared to Europeans); bunadjusted ethnicity effect in mmol/l; cpercentage change in unadjusted ethnicity effect 
estimate to adjusted model effect. dDerived from biceps, triceps, subscapular, supraspinale, suprailiac, thigh, and calf skinfolds, and fat mass; ederived from 
height, lean mass, and hip, mid-thigh and mid-calf circumferences; fderived from waist circumference and waist-to-hip ratio. gexpressed in ml.kg-1.min-1. 
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3.4 Discussion 
 
The main novel finding of this chapter was that low cardiovascular fitness, as 
measured by gold-standard maximal incremental treadmill test, was the single 
most important factor associated with the increased insulin resistance and 
fasting glycaemia observed in middle-aged South Asian compared to European 
men living in the UK. Ethnicity explained 18% of the variance in HOMAIR, with 
HOMAIR values being 67% higher (1.2 HOMAIR units) in South Asians than 
Europeans. South Asians’ lower VO2max levels (statistically) explained more than 
two-thirds of this ethnic difference (0.8 HOMAIR units).  The ethnic difference in 
fasting glucose concentration was less pronounced. Ethnicity explained 3% of the 
variance in fasting glucose, and values were 3% higher (~0.2 mmol/l) in South 
Asians than Europeans: nevertheless over 60% of the ethnic difference in fasting 
glucose (~0.1 mmol/l) could be explained by VO2max.  Higher total adiposity and 
lower MVPA in South Asians also associated with their greater HOMAIR; their 
increased total adiposity also associated with their higher fasting glucose values.  
Fitness, anthropometric and physical activity variables together explained over 
four-fifths of the increased insulin resistance and three-fifths of the increased 
glycaemia observed in South Asians. 
 
The finding that greater total adiposity explained about half of South Asians 
increased insulin resistance and two-fifths of their increased fasting glycaemia 
compared to Europeans, is consistent with other reports (24;44;248),  although 
interestingly South Asians smaller body size acted in the opposite direction, 
appearing to attenuate the difference in HOMAIR between the groups.  
Furthermore, these findings demonstrate, using robust objective measures, that 
levels of physical activity were significantly lower in South Asians than 
Europeans in our sample, which is consistent with the suggestions from previous 
self-reported data (99;116-118), and reveals for the first time that this 
contributes to their greater insulin resistance.  However, the most striking 
finding from this study is the extent to which lower cardiorespiratory fitness was 
associated with South Asians insulin resistant phenotype.  This is consistent with 
data from animal models which have demonstrated a causal link between low 
fitness and insulin resistance (249) and with epidemiological data reporting 2.6-
fold increased risk of incident T2DM, independent of BMI, in men with low 
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compared high cardiorespiratory fitness levels (83).   Importantly, the present 
data demonstrate that although fitness increases with increasing physical 
activity, South Asians’ lower VO2max values could not be simply explained by their 
lower physical activity levels.  South Asians had lower fitness levels than 
Europeans at all levels of physical activity, and adjusting for MVPA only modestly 
attenuated the ethnic difference in VO2max (see Figure 3.1). Interestingly, recent 
data from the NHANES study support the suggestion of innate differences in 
fitness between ethnic groups, with Ceaser and colleagues reporting systematic 
differences in VO2max between Mexican Americans (highest), non-Hispanic whites 
and non-Hispanic blacks (lowest), which were independent of time spent in (self-
reported) physical activity and demographic factors (250). There is a strong 
heritable component to VO2max, with heritability estimates in this trait of up to 
50% (251;252) thus, it seems likely that there will be a genetic (and/or early 
origins) contribution to the lower VO2max values in South Asians.  Our group have 
recently reported that South Asians have a reduced ability to oxidise fat during 
exercise than Europeans (47), suggesting that there may be innate differences in 
the physiology of South Asians compared to Europeans which may contribute to 
this effect.  The fact that South Asians increased insulin resistance and 
glycaemia is strongly associated with their lower fitness levels, and that 
increasing physical activity is the only way to increase cardiorespiratory fitness, 
suggests that South Asians need to engage in greater levels of physical activity 
than Europeans to achieve the same levels of cardiorespiratory fitness and 
minimise their metabolic risk. This has potential implications for physical 
activity guidance, which, at present, do not take ethnicity into account.  Recent 
consensus statements have recommended that the BMI threshold for obesity in 
South Asian populations should be lowered from 30 kg/m2 to BMI 25 kg/m2 
(73;75), in recognition of the fact that substantially lower BMIs are needed in 
South Asians to confer equivalent cardiometabolic risk factor profiles to those 
observed in populations of white European origin (66;67).  The present data 
suggest that differential physical activity guidance for South Asians may also be 
needed. Larger epidemiological studies, and intervention trials, comparing the 
dose-response relationship between (objectively measured) physical activity and 
cardio-metabolic disease risk in South Asians and Europeans are urgently needed 
to enable appropriate levels of physical activity to minimise risk in South Asian 
populations to be robustly quantified.   
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This study has a number of strengths.  We were initially rigorous to exclude 
those with known diabetes and those with potential undiagnosed diabetes 
(remarkably 13% of South Asian men (vs. 1% of European men)) were excluded 
from further analysis, to prevent potential confounding.  This is the largest study 
to compare objectively measured physical activity and cardiorespiratory fitness 
between South Asian and European men.  Thus, differences in fitness and 
activity between these groups and the contribution of these factors to insulin 
resistance and glycaemia can be robustly assessed from the present data.  
Furthermore, we measured a wide range of adiposity variables and used factor 
analysis to derive robust summary measures of body size and composition to 
enable us to determine which specific features of South Asians greater adiposity 
contributed to their increased insulin resistance and glycaemia.  The groups 
were well-matched for age, BMI and socioeconomic status, and although the 
South Asians spent more years in education, smoked less and drank less alcohol 
than the Europeans, adjusting for these factors did not change the key study 
outcomes: difference in VO2max remained the most important factor associated 
with South Asians greater insulin resistance after adjustment for these potential 
confounders.  However, the study does have limitations.  By nature of the 
recruitment methods, the study cohort represents a self-selected group, and 
thus, a degree of caution is warranted in extrapolating the findings to the 
general UK South Asian population.  However, as the findings with respect to 
fitness, physical activity, adiposity and metabolic variables in South Asians are 
fully consistent with the body of previously published data on this topic, this 
seems unlikely to have introduced substantial bias into the findings. Insulin 
resistance was assessed using HOMAIR, as the size of this single centre study 
made use of the gold-standard euglycaemic hyperinsulinaemic clamp unfeasible.  
Similarly, glycaemia was assessed from fasting glucose concentrations: HbA1c 
was not chosen as a marker of long-term glycaemia in this analyses because of 
potential confounding from known ethnic differences in glycation rates 
independent of glycaemia (253).  Data were not collected on the specific 
country of origin for South Asian (i.e. whether from India, Pakistan, Bangladesh 
or Sri Lanka) participants, due to questionnaire design and it is recognised that 
whilst collectively South Asians are at increased risk of cardiometabolic disease, 
the degree of increased risk factor burden may not be equivalent between the 
contributory backgrounds (254). Finally, the cross-sectional nature of the study, 
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with simultaneous assessment of exposure and outcome variables, means that it 
is not possible to definitively exclude reverse causality as a potential influence 
of the findings.   
 
In conclusion, the present findings show that low cardiorespiratory fitness is 
the single most important factor associated with the increased insulin 
resistance and fasting glycaemia in middle-aged South Asian, compared to 
European, men living in the UK.  Although they were less physically active than 
their European counterparts, South Asians’ lower fitness levels could not be 
explained by their lower physical activity levels, suggesting that low fitness is an 
innate feature of the South Asian phenotype.    Though the observational nature 
of this study means that conclusions cannot be drawn about causality, present 
data suggest that South Asians may need to engage in higher levels of physical 
activity than Europeans to overcome their lower innate fitness and the 
associated metabolic consequences.  This raises the possibility that ethnicity-
specific recommendations for physical activity, and thus prevention of T2DM, 
may be needed. 
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Chapter 4 
Does liver fat contribute to the increased insulin resistance in middle-aged 
South Asian compared to European men living in the United Kingdom? 
 
 
Introduction 
 
South Asians  living in the United Kingdom have a 3-5 fold increased prevalence 
of T2DM, developing the disease around a decade earlier and at a (BMI) 
compared to white Europeans (25).  Furthermore, non-diabetic South Asians 
have higher fasting glycaemia and are more insulin resistant than Europeans 
(47).  
 
Liver fat is associated with insulin resistance and T2DM risk and is considered to 
play a causal role in diabetes (128). Limited data suggest that South Asians have 
higher liver fat content than age- and BMI-matched Europeans (68;141), but it is 
not currently clear whether this contributes to the observed ethnic difference in 
insulin resistance.  The purpose of this chapter was (a) to determine whether 
South Asian men have increased liver fat percentage compared to white 
European men living in the UK and (b) to determine the extent to which such 
differences could explain the increased insulin resistance observed in South 
Asian compared to European men. 
 
 
4.2 Methods 
 
4.2.1 Participants and recruitment 
 
All participants (28 South Asians, 24 Europeans) were recruited from the wider 
CURVES study and screened as detailed in section 2.1 and were chosen at 
random (but matched for age) within 4 months of their original main study visit. 
It was intended to recruit equal numbers of participants from each ethnic group. 
Specific inclusion and exclusion criteria are defined in section 2.1.1. All 
participants received payment for towards transport and received feedback as 
detailed in sections 2.2.1 and 2.6 respectively. 
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Participants’ health history, including smoking status and family health history, 
education history SES information and dietary information were obtained as 
described in section 2.2.1 
 
 
4.2.2 Blood biochemistry and blood pressure measurements 
 
Venous blood samples were obtained after an overnight fast of 10-12 hours as 
described in section 2.2.2.1. Samples were sent for routine tests outlined in 
section 2.2.2.1.  Plasma was stored for the subsequent measurement of insulin 
as described in section 2.2.2.2. Insulin resistance was assessed by HOMAIR and 
was calculated as outlined in section 2.5. 
 
Blood pressure was measured as described in section 2.2.4. 
 
 
4.2.3 Anthropometry 
 
Anthropometric measurements were performed on all participants as detailed in 
section 2.2.6. Total body lean and fat mass was measured using ADP as described 
in section 2.2.7.  
 
 
4.2.4   Magnetic resonance spectroscopy for quantification of liver fat 
 
MR spectroscopy technique and subsequent quantification of liver fat were 
undertaken as detailed in section 2.2.10. 
 
 
4.2.5 Data analysis 
 
The sample size for this study was determined as calculated in section 2.3.2.  
Statistical analysis was performed using R for Windows v2.14. Values are 
presented as mean (SD) for normally distributed and log transformed variables 
with p-values calculated by t-tests and median (IQR) for non-normally distributed 
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variables with p-values calculated by Wilcoxon test.  Linear regression modelling 
was undertaken to determine the extent to which differences in insulin 
resistance (calculated by Homeostasis Model Assessment estimated insulin 
resistance, HOMAIR (245)) between ethnic groups could be explained by 
differences in liver fat content.  Outcome variables were log transformed for 
analysis to better meet the assumption of normally-distributed model residuals. 
 
 
4.3 Results 
 
Baseline demographic, metabolic and anthropometric variables for the two 
ethnic groups are presented in Table 4.1. The two groups were well-matched for 
age and BMI.  Waist circumference was numerically, but not significantly, higher 
in South Asians than Europeans. South Asians had higher HbA1c, fasting insulin 
and HOMAIR than Europeans, although fasting glucose concentrations were 
similar.  South Asians also had a lipoprotein profile consistent with greater 
insulin resistance with lower HDL cholesterol concentrations, but similar LDL 
cholesterol concentrations.  However, liver fat levels did not differ significantly 
between South Asians and Europeans.  As reported, alcohol consumption differed 
markedly between South Asians than Europeans: only one Asian in the sample 
consumed alcohol and, in contrast, only two Europeans did not. After adjusting 
for alcohol consumption, to correct for potential confounding effects, the liver 
fat percentage in South Asians was 41% (10% to 62%; p=0.016) lower than in 
Europeans.  Liver enzyme concentrations were similar in South Asians and 
Europeans.  
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Table 4.1 Demographic, metabolic and anthropometric variables for South 
Asian and European men  
 
 
  
South Asian 
(N=28) 
European 
(N=24) 
p-value 
Demographic, anthropometric and 
lifestyle variables 
    
Age (years)  49.8 (8.2) 50.3 (5.9) 0.799 
BMI (kg.m-2)  28.5 (4.8) 27.4 (3.2) 0.314 
Waist (cm)  101.1 (12.5) 96.8 (7.3) 0.148 
Waist-to-hip ratio  0.99 (0.07) 0.97 (0.05) 0.233 
Percentage body fat  29.3 (8.2) 25.7 (6.7) 0.010 
Alcohol Consumption (grams per day)  0.16 (0.85) 21.19 (13.25) <0.001 
Metabolic variables     
Glucose (mmol.l-1)  5.25 (4.90, 5.70) 5.00 (4.80, 5.55) 0.333a 
HbA1c (%)  5.60 (5.50, 5.83) 5.40 (5.28, 5.60) 0.010a 
HbA1c (mmol/mol)  38.0 (37.0, 40.3) 36.0 (33.8 38.0) 0.010a 
Insulin (mU.l-1)  15.1 (9.7, 19.6) 10.1 (6.7, 12.3) 0.016a 
HOMAIR  3.36 (2.41, 4.44) 2.27 (1.39, 2.99) 0.027
a 
Total Cholesterol (mmol.l-1)  5.33 (0.83) 5.39 (0.98) 0.80 
HDL-Cholesterol (mmol.l-1)  1.11 (0.17) 1.27 (0.24) 0.010 
LDL-cholesterol (mmol.l-1)  3.49 (0.71) 3.44 (0.84) 0.806 
Triglycerides (mmol.l-1)  1.35 (0.98, 2.00) 1.20 (0.93, 1.68) 0.473a 
AST (U.l-1)  22.0 (19.0, 26.3) 23.5 (20.0, 28.5) 0.265a 
ALT (U.l-1)  25.5 (20.5, 36.0) 26.5 (21.8, 44.0) 0.538a 
GGT (U.l-1)  27.0 (19.0, 35.5) 28.0 (20.8, 45.3)  0.441a 
Systolic blood pressure (mm Hg)  123.9 (11.9) 129.3 (12.4) 0.111 
Diastolic blood pressure (mm Hg)  76.5 (7.0) 76.8 (6.9) 0.490 
Liver fat     
Unadjusted liver fat (%)b  5.28 (2.11) 5.41 (2.35) 0.913 
Alcohol adjusted liver Fat (%)b  5.30 (2.10) 9.03 (2.22) 0.017 
 
Values are mean (SD) for normally distributed variables with p-values calculated by t-tests and 
median (IQR) for non-normally distributed variables with p-values calculated by Wilcoxon testa. 
Geometric means presented (p-values calculated using t-tests on log means)b. 
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Figure 4.1 shows the relationship between alcohol-adjusted liver fat content and 
HOMAIR in South Asians and Europeans.  There was a positive association 
between adjusted liver fat percentage and HOMAIR with both ethnic groups, with 
no significant ethnicity-liver fat interaction.  Adjusted liver fat and ethnicity 
together explained 31% of the variance in HOMAIR (ethnicity alone explained 5.6% 
of the variance in HOMAIR). There was a significant offset in the regression lines: 
for any given alcohol-adjusted liver fat percentage HOMAIR was 80% (31% to 
149%; p<0.001) higher in Asian men compared to Europeans. Adjustment for 
alcohol-adjusted liver fat percentage did not attenuate, and in fact slightly 
increased, the difference in HOMAIR between ethnic groups (see Figure 1).  
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Figure 4.1 Relationship between HOMAIR and alcohol-adjusted liver fat in 
South Asian and European men   
 
Solid circles and the solid line represent South Asian men with open circles and the dotted line 
representing European men. Solid and dotted vertical bars indicate mean liver fat percentages 
(adjusted to zero alcohol consumption) in SA and European men, respectively; the horizontal 
arrow shows the mean difference in liver fat percentage between ethnic groups.  Solid and 
dotted horizontal bars, with corresponding vertical arrows indicate mean log HOMAIR values in 
South Asian and European men and the mean ethnic difference, both unadjusted and adjusted 
for liver fat. 
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4.4 Discussion 
 
The main finding of this chapter is that, despite having a phenotype consistent 
with greater insulin resistance, middle-aged South Asian men did not have 
greater percentage liver fat than Europeans of similar age and BMI.  These 
results indicate that while increasing levels of liver fat were associated with 
increasing insulin resistance in both South Asians and Europeans – consistent with 
the body of evidence showing clear associations and a potential mechanistic link 
between liver fat and insulin resistance (128) – South Asians were markedly more 
insulin resistant than Europeans for any given level of liver fat.  No previous 
study has directly investigated whether increased liver fat levels can explain the 
greater insulin resistance, but previous studies have reported that South Asians 
have higher levels of liver fat compared to Europeans (68;141). The present data 
suggest that, while some South Asians may have greater levels of liver fat than 
Europeans, increased percentage liver fat is not a consistent feature of the 
South Asian phenotype.  Because of clear differences in alcohol consumption 
between the European and South Asian groups, we adjusted our data for the 
potential confounding effects of alcohol on liver fat levels. However, our 
findings were robust to this effect: adjusting for alcohol consumption acted to 
reduce, rather than increase, liver fat levels in South Asians, relative to 
Europeans.  Thus, factors other than increased liver fat per se must be 
responsible for South Asians’ greater insulin resistance.    Data from the previous 
chapter suggest that differences in cardiorespiratory fitness as well as previous 
local data suggesting that the capacity of skeletal muscle to oxidase fat are also 
likely to play a key role (47).  It is also possible that differences in ectopic fat in 
the pancreas may contribute to greater dysglycaemia– novel data indicate that 
pancreatic fat is more influential than liver fat in the dysglycaemic process 
(255). Finally, it remains possible that a given level of liver fat may be more 
metabolically toxic in South Asians than Europeans, a suggestion which requires 
further study.  
 
In conclusion, these data indicate that although clear associations between liver 
fat percentage and insulin resistance were observed in South Asians and in 
Europeans, increased insulin resistance in South Asians cannot be explained by a 
greater liver fat percentage. 
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Chapter 5  
Differences in ultrasound-based measures of carotid atherosclerosis between 
middle-aged South Asian compared to European men living in the United 
Kingdom 
 
 
5.1 Introduction 
 
Migrant South Asian populations in Europe, North America the Westernised 
countries have a greater CVD risk than their respective indigenous populations 
(8).  Several studies have shown that both overall and premature (i.e. 10 years 
earlier and age <40) CHD morbidity and mortality is significantly higher in 
migrant South Asians than in white populations in the UK and globally (9;12;13), 
with there being little change over a 30-year period (11). Similarly, deaths from 
cerebrovascular disease remain in excess compared to White Europeans for 
migrant South Asian populations (11).   
 
The increased CHD burden in migrant South Asians is not fully explained by 
traditional CVD risk factors, such as total cholesterol, blood pressure, smoking 
and diabetes (14-18), though South Asians have a more atherogenic lipoprotein 
profile (22;23). Prospective data from one study showed that the age-adjusted 
HR for male CHD mortality in South Asians to be 1.64 (95% CI, 1.24–2.16), 
compared with white Europeans, increasing to 2.14 (2.14 (95% CI, 1.56–2.94) 
after adjustment for smoking and cholesterol (14). Further analysis using 
multivariable models adjusting for conventional risk factors and T2DM and/or 
impaired glucose regulation, features of insulin resistance, or the metabolic 
syndrome showed that CHD mortality remained significantly higher in South 
Asian men (HR 1.6–1.9).  In other words, current risk models do not account for 
the excess CVD risk in South Asians. Thus identification of other markers to 
identify the increased CVD risk in South Asians is a pressing clinical concern. 
Indeed, in recognition of the increased ethnicity-associated CVD risk, one of the 
latest risk scores that has been developed to estimate a patient’s 10 year risk of 
CVD based on certain key known risk factors in England and Wales, incorporates 
ethnicity into the equation (256). 
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Carotid intima media thickness is recognised as a surrogate risk factor for 
coronary heart disease (159-164) and stroke (161;162;164-166).  A key strength 
of this method is the availability of semi-automated software to read images and 
measure cIMT (170), making it a rapid, accurate and potentially reproducible 
screening modality. Currently there are no published prospective longitudinal 
data on cIMT and CVD outcomes on South Asians and only one cross-sectional 
study comparing cIMT between South Asians and Europeans from the same 
population (173).  This study indicated that cIMT was not higher in South Asians 
compared with Europeans, despite South Asians having a higher number CVD 
events, suggesting that absolute cIMT values may not be a sensitive marker of 
excess CVD risk in South Asians. 
 
Two-dimensional assessment of carotid plaque has also been used as a modality 
to facilitate CVD risk stratification and is also associated with future risk of MI 
and stroke (183-185;257)  Furthermore, when incorporated into risk 
stratification models - as is the case for cIMT - carotid plaque presence/absence 
appears to provide enhanced risk classification (156;187).  Thus, both cIMT and 
carotid plaque assessment may have a role when considering patients for 
preventative medical therapy (156). 
 
In addition, one cross-sectional study which compared age-related cIMT 
differences, with differences in carotid plaque disease between population 
groups of two socioeconomic extremes, demonstrated that differences between 
affluent and deprived populations in plaque score were apparent earlier in the 
life-course (~10 years) than differences in cIMT  (186).   This suggests that 
plaque score may be a more sensitive marker of deprivation associated CVD risk 
than cIMT. Neither adjustment for traditional cardiovascular risk factors nor 
measured ‘novel’ risk factors, either alone or in combination, abolished the 
area-level deprivation-based difference in plaque presence.   These intriguing 
data suggest the possibility that plaque score be a more sensitive measure of 
CVD risk than cIMT and therefore may reveal a difference in CVD risk between 
South Asians and Europeans not evident from cIMT measures. 
 
There are no published data comparing carotid plaque presence between 
Europeans and South Asians from the same population.  Thus the aims of this 
 120 
 
chapter are to determine: (i) whether South Asians have a difference in cIMT or 
carotid plaque presence compared to Europeans; and if so, (ii) whether 
differences carotid plaque presence between South Asians and Europeans occur 
at an earlier age than differences in cIMT and (iii) to determine whether any 
measured risk factors (if any) could account for any such observed differences in 
cIMT and/or carotid plaque presence. 
 
 
5.2 Methods 
 
5.2.1 Participants and recruitment 
 
All participants were recruited and screened as detailed in section 2.1. Specific 
inclusion and exclusion criteria are defined in section 2.1.1. All participants 
received payment for towards transport and received feedback as detailed in 
sections 2.2.1 and 2.6 respectively. 
 
Participants’ health history, including smoking status and family health history, 
education history, SES information and dietary information were obtained as 
described in section 2.2.1. 
 
 
5.2.2 Carotid ultrasound scanning and analysis 
 
The scanning protocol used was as described in section 2.2.3.2. The author 
performed all the scans and met predefined reproducibility criteria for scan 
quality as described in section 2.2.3.3. All scans for cIMT measurements were 
analysed as described in sections 2.2.3.5 using software as described in section 
2.2.3.3 by a trained reader (GL) as described in section 2.2.3.4 
 
All scans for plaque scoring were analysed by KD, a trained individual (as 
described in section 2.2.3.1), who was blinded to the participant group, using 
the software described in section 2.2.3.3 to view data and was blinded to the 
identities of the participants. The criteria applied for plaque identification and 
scoring was as described in section 2.2.3.6. 
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5.2.3 Anthropometry 
 
Anthropometric measurements were performed on all participants as detailed in 
section 2.2.6. Total body lean and fat mass was measured using ADP as described 
in section 2.2.7.  
 
 
5.2.4 Blood biochemistry and blood pressure measurements 
 
Venous blood samples were obtained after an overnight fast as described in 
section 2.2.2.1. Samples were sent for routine tests as detailed in section 
2.2.2.1.  Plasma was stored for the subsequent measurement of insulin as 
described in section 2.2.2.2.  HOMAIR was calculated as outlined in section 2.5. 
 
Blood pressure was measured as described in section 2.2.4. 
 
 
5.2.5 Determination of cardiorespiratory fitness 
 
All participants had a clinical assessment and resting ECG performed prior to 
undertaking the exercise test to ensure no contraindications to maximal 
exercise.  Exercise testing was undertaken as described in section 2.2.8. 
Cardiorespiratory fitness was determined by measuring VO2max as described in 
sections 2.2.8.5 and 2.2.8.6. A valid measure of VO2max was achieved in 199 of 
the 200 participants. 
 
 
5.2.6 Measurement of physical activity 
 
Objective measurement of physical activity was obtained through accelerometry 
as described in section 2.2.9. Valid data were obtained for 85 South Asians and 
84 Europeans. 
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5.2.7 Data analysis 
 
The sample size for the CURVES study was determined as calculated in section 
2.3.1.  
 
Summary statistics are presented for all variables for both South Asians and 
Europeans. The dataset for this chapter include the full cohort (100 South Asians 
and 100 Europeans) recruited into the CURVES study. Continuous variables were 
compared between the ethnic groups by t-tests (or Wilcoxon rank sum test for 
non-normally distributed variables) and Chi Square test for categorical variables. 
 
Factor analysis was used to reduce the number of anthropometric variables into 
underlying latent factors as described in section 3.2.6.  Linear regression was 
used to model cIMT and logistic regression for modelling the predictors of plaque 
presence. Missing values were removed from the relevant analyses. The 
difference in the predicted probability of plaques between South Asians and 
Europeans was calculated across the age range with a 95% CI derived by 
bootstrapping. The odds of a South Asian having carotid plaque compared to 
Europeans are presented, with 95% CI and p-value, when ethnicity was the only 
predictor in the model and when adjusted for participant age together with 
select demographic, lifestyle and CHD risk factor variables. Logistic regression 
modelling and ORs are presented for adjusted and unadjusted models. A 
composite group of predictors was selected using backwards elimination on each 
subgroup, to select variables significant at the 10% level for the final model.  
 
Statistical analyses were undertaken by DP and AM in consultation with the 
author and his supervisors. The statistical software package R for Windows v2.14 
was used for all analysis. Statistical significance was accepted at p < 0.05. 
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5.3 Results 
 
5.3.1 Demographic, metabolic and dietary variables 
 
Baseline data for all 200 volunteers are presented in Table 5.1. There were no 
differences between groups in age or BMI, but South Asians were shorter than 
the Europeans.  South Asians also had completed more years in education, were 
less likely to smoke or consume alcohol, and were more likely to have a parent 
or sibling with T2DM.  There were no differences in SES.  South Asians had 
significantly higher glucose, HbA1c, insulin, HOMAIR, CRP and diastolic blood 
pressure, and lower HDL-cholesterol, than the Europeans.  Mean ± SD reported 
energy intake (expressed per kg body mass) did not differ between the 
Europeans and SA (19.8±6.0 vs 18.7±6.4 kcal.kg-1.day-1, p=0.21).  There were 
also no differences in reported protein, carbohydrate or fat intakes between the 
two groups (data not shown), but reported alcohol intake was higher in the 
Europeans than SA (21.9±18.3 vs 1.1±5.6 g.day-1, p<0.0001). 
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Table 5.1 Demographic and metabolic variables for all South Asian and 
European men. 
  
South Asian 
(N=100) 
European 
(N=100) 
p-value 
Demographic and lifestyle variables 
    
Age (years) 
 
49.4 (7.2) 49.7 (6.8) 0.755 
Body mass (kg) 
 
82.0 (12.1) 85.7 (13.9) 0.049 
Height (m) 
 
1.74 (0.06) 1.78 (0.06) <0.0001 
BMI (kg.m-2) 
 
27.1 (3.9) 26.9 (4.2) 0.692 
Years in Education 
 
15.6 (3.5) 14.4 (3.2) 0.010 
SIMD Quintile 1 9 (9.0%) 7 (7.0%) 
 
 
2 10 (10.0%) 14 (14.0%) 
 
 
3 17 (17.0%) 19 (19.0%) 0.620 
 
4 26 (26.0%) 18 (18.0%) 
 
 
5 38 (38.0%) 42 (42.0%) 
 
Smoking Status never-smoker 81 (81.0%) 54 (54.0%) 
 
 
ex-smoker 6 (6.0%) 36 (36.0%) <0.0001 
 
current 13 (13.0%) 10 (10.0%) 
 
Alcohol Consumptionb none 93 (93.0%) 10 (10.1%) 
 
(units per week) ≤ 20 5 (5.0%) 70 (70.7%) <0.0001 
 
≥ 21 2 (2.0%) 19 (19.2%) 
 
Parental Diabetes Statusb yes 54 (54.0%) 13 (13.1%) <0.0001 
Sibling Diabetes Statusb yes 17 (17.0%) 2 (2.0%) 0.0004 
Metabolic variables  
   
Glucose (mmol.l-1)  5.4 (5.0, 5.8) 5.1 (4.8, 5.4) 0.0005a 
HbA1c (%)c  5.7 (5.5, 6.1) 5.4 (5.2, 5.6) <0.0001a 
HbA1c (mmol.mol-1)b  39.0 (37.0, 43.0) 36.0 (33.0, 38.0) <0.0001a 
Insulin (mcU.l-1)b  14.9 (7.4) 9.2 (5.3) <0.0001 
HOMAIR
b  3.3 (2.4, 4.6) 1.8 (1.1, 2.7) <0.0001a 
Total Cholesterol (mmol.l-1)  5.3 (0.9) 5.6 (1.0) 0.053 
HDL-Cholesterol (mmol.l-1)  1.1 (1.0, 1.3) 1.3 (1.0, 1.3) <0.0001a 
LDL-cholesterol (mmol.l-1)  3.4 (0.9) 3.6 (0.8) 0.457 
Triglycerides (mmol.l-1)  1.7 (1.1) 1.5 (0.9) 0.0423a 
AST (U.l-1)  23.8 (7.6) 25.1 (8.5) 0.242 
ALT (U.l-1)  27.0 (22.0, 36.2) 26.0 (20.0, 35.2) 0.758a 
GGT (U.l-1)  32.5 (22.0, 47.0) 28.0 (20.8, 42.8) 0.261a 
CRP (mg.l-1)c  1.8 (1.1, 3.8) 1.2 (0.6, 2.5) 0.0028a 
Systolic blood pressure (mm Hg)  126.8 (15.0) 127.6 (12.8) 0.686 
Diastolic blood pressure (mm Hg)  78.2 (8.9) 74.9 (7.2) 0.004 
Values are mean (SD) for normally distributed variables with p values calculated by t-tests and 
median (IQR) for non-normally distributed variables with -values calculated by Wilcoxon testa. 
Categorical variable p values are calculated by Fisher's Exact test. bn = 99 for South Asians and 
Europeans respectively. 
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5.3.2 Body composition, fitness and physical activity variables 
 
Body composition, fitness and physical activity variables for all 200 volunteers 
are presented in Table 5.2. There were no differences in waist or hip 
circumferences between the South Asian and European groups, but WHR was 
higher in the South Asians.  South Asians also had a smaller mid-thigh 
circumference, and higher values for all skinfold thicknesses than the Europeans.  
Lean mass was lower and fat mass and percentage body fat were higher in the 
South Asians.  Total adiposity and central adiposity factors were higher and body 
size units lower in South Asians than Europeans.  Cardiorespiratory fitness (as 
assessed by VO2max) was lower in South Asians than Europeans.  
 
South Asians also engaged in less moderate and vigorous physical activity than 
Europeans: the proportion of time spent in moderate-to-vigorous physical 
activity was ~29% lower in South Asians than Europeans.  This equated to South 
Asians engaging in ~22 minutes of MVPA per day compared to ~31 minutes per 
day for the Europeans.    
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Table 5.2 Body composition, fitness, and physical activity variables for all 
South Asian and European men.  
 
South Asian 
(N=100) 
European 
(N=100) 
p-value 
Body composition variables 
   
(a) Body circumferences 
   
Waist (cm) 97.8 (10.9) 95.7 (11.2) 0.183 
Hips (cm) 99.4 (6.6) 100.5 (7.1) 0.240 
Waist-to-hip ratio 0.98 (0.07) 0.95 (0.07) 0.0009 
Mid-upper arm (cm) 34.3 (7.7) 33.4 (3.3) 0.289 
Mid-thigh (cm) 52.4 (4.2) 53.9 (4.0) 0.011 
Mid-calf (cm) 37.6 (3.3) 38.6 (4.0) 0.063 
(b) Skinfold thicknesses 
   
Biceps (mm)i 8.0 (3.7) 6.8 (2.9) 0.0120 
Triceps (mm) 16.0 (5.7) 12.6 (4.2) <0.0001 
Subscapular (mm)g,i 25.5 (7.0) 18.3 (7.1) <0.0001 
Suprailiac (mm)f,l 23.2 (6.1) 18.3 (6.3) <0.0001 
Supraspinale (mm) 17.8 (6.4) 12.6 (5.4) <0.0001 
Thigh (mm)i 18.6 (7.8) 14.7 (5.7) 0.0001 
Calf (mm)e 12.6 (5.2) 10.4 (4.2) 0.0011 
(c) Fat and lean massi    
Lean mass (kg) 57.1 (6.2) 63.1 (7.2) <0.0001 
Fat mass (kg) 24.5 (9.0) 21.8 (9.7) 0.044 
Percentage body fat 29.3 (7.4) 24.9 (7.4) <0.0001 
(d)   Summary anthropometric factors    
Sum of arm (mm)b 23.9 (8.8) 19.2 (6.5) <0.0001 
Sum of central area (mm)c 65.0 (16.9) 48.8 (16.6) <0.0001 
Sum of leg (mm)d 31.2 (11.8) 25.0 (8.9) <0.0001 
Fitness variables    
VO2 max (l.min
-1)i 2.52 (0.43) 3.33 (0.63) <0.0001 
VO2 max (ml.kg
-1.min-1)i 31.2 (5.8) 39.4 (7.8) <0.0001 
VO2 max  (ml.kg lean mass
-1.min-1)j 44.2 (6.3) 52.8 (8.0) <0.0001 
Physical activity variablesh,l    
Sedentary (% of wear time) 66.3 (10.0) 64.3 (9.0) 0.185 
Light physical activity (% of wear time) 30.6 (9.6) 30.8 (8.0) 0.901 
Moderate-to-vigorous physical activity (% of wear 
time) 
2.8 (1.6, 4.2) 4.1 (3.0, 6.8) <0.0001a 
Total accelerometer wear time (min.day-1) 813.4 (90.6) 864.0 (74.4) 0.0001 
Values are mean (SD) for normally distributed variables with p-values calculated by t-tests and 
median (IQR) for non-normally distributed variables with p-values calculated by Wilcoxon testa. 
Categorical variable p-values are calculated by Fisher's Exact test. bDerived from biceps, triceps, 
subscapular, supraspinale, suprailiac, thigh, and calf skinfolds, and fat mass; cderived from 
height, lean mass, and hip, mid-thigh and mid-calf circumferences; dderived from waist 
circumference and waist-to-hip ratio. en = 99, fn = 97, gn = 94, hn = 85  for South Asians; in = 99, 
jn = 98, kn = 97 and ln = 84 for Europeans; 
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5.3.3 Carotid ultrasound analysis 
 
Differences in ultrasound markers of atherosclerosis for are presented in Table 
5.3.  There were no significant differences in unadjusted or age-adjusted 
differences in mean cIMT between South Asians and Europeans.  Numerically 
there was increased odds ratio for the presence of plaque disease in South Asians 
compared to Europeans, however this was not statistically significant (OR 1.57, 
95% CI 0.89-2.77, p=0.13). 
 
 
Table 5.3 Differences in cIMT and plaque scores between South Asian and 
European men. 
 
 
South Asian 
N=100 
European 
N=100 
South Asian - 
European  
(adjusted for age) 
p-value 
cIMT analysis 
Mean (SD) of cIMT 
0.64 (0.16) 0.65 (0.12) -0.01 (-0.05, 0.03)* 0.638 
Plaque Analysis 
Median (IQR) of plaque score 
 
0.00 (0.00, 1.00) 
 
0.00 (0.00, 1.00)  
0.194**a 
0 plaques 
1 to 2 plaques 
>2 plaques 
52 (52.0%) 
38 (38.0%) 
10 (10.0%) 
63 (63.0%) 
29 (29.0%) 
8 ( 8.0%) 
 
0.161**b 
 
*95% CI; **not adjusted for age; aWilcoxon test, bChi-squared test for trend 
 
 
Figure 5.1 shows the differences in cIMT for each ethnic group, separately split 
by three consecutive age decades. The expected trend of increasing mean cIMT 
with age was present for each ethnic group; however, there were no differences 
in mean cIMT between the ethnic groups in any age group. In regression analysis 
cIMT increased by 0.08 mm (95% CI: 0.06, 0.11; p<0.001) for a ten year 
increment in age, with a similar increase observed for each ethnic group (p-
value for ethnicity by age interaction = 0.177). Figure 5.2 shows the carotid 
plaque distribution by age. There was a significant linear age-association for 
plaque presence in Europeans only (p=0.006). 
 
 128 
 
As expected, with both ethnic groups combined, cIMT was strongly correlated 
with plaque presence (odds ratio (OR) 1.35 per 0.1mm increase, 95% CI, 1.01-
1.67, p=0.005), and this association remained after adjustment for age (OR 1.27 
per 0.1mm increase, 95% CI, 1.01-1.60, p=0.042); and there was no significant 
ethnicity interaction (p=0.755). Both systolic and diastolic blood pressure were 
significantly associated (per 10mm Hg increase) with cIMT even after adjustment 
for age and BMI and antihypertensive treatment for the cohort as a whole 
(systolic blood pressure 0.03 mm increase in cIMT, 95% CI, 0.02-0.05,  p<0.001; 
diastolic blood pressure 0.05 increase in cIMT 95% CI, 0.03,-0.08 p<0.001) and 
there was no significant ethnicity interaction (systolic blood pressure p=0.642, 
diastolic blood pressure p=0.087). 
 
 
Figure 5.1 Carotid intima-media thickness by age tertile and ethnicity 
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Figure 5.2 Presence of carotid plaque by ethnicity and age*  
*Percentage of participants within each category  
 
 
5.3.4 Univariate and multivariate analyses for plaque presence 
 
Table 5.4 presents univariate and multivariable regression analyses showing the 
effects of groups of variables on the odds of plaque presence between South 
Asians compared to Europeans. All models are adjusted for age (quadratic, at 
age 50), ethnicity and their interaction. Plaque presence rather than plaque 
score was used as the dependent variable in these analyses because plaque score 
did not fit conventional distributions that might be used for regression analyses 
and it was decided that the binary approach to transformation would encompass 
most of the information in the data. The unadjusted odds for plaque presence 
was 57% (95% CI: -11% to 177%) higher in South Asians compared to Europeans. 
Further adjustment for age and ethnicity and their interaction increased the OR 
to 1.88 (95% CI: -17% to 327%), but this was not significant (p=0.130). Addition of 
traditional CVD risk factors to the age- and ethnicity-adjusted model did not 
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attenuate the OR, and this remained the case even after further adjustment for 
fasting glucose and/or insulin resistance. The final model (which consisted of 
significant predictors selected from variable subgroups by backward selection) 
included ethnicity and age (quadratic) interaction and HDL cholesterol and 
attenuated the OR to 1.30 (95% CI: -33% to 327%) but this was not significant 
(p=0.097) 
 
 
Table 5.4 Adjusted ORs for plaque presence between South Asians and 
Europeans 
 
 
Odds Ratio(95% CI) p-value 
Unadjusted 1.57 (0.89, 2.77) 0.116 
Age+ (quadratic) at 50 years 1.88 (0.83, 4.27) 0.130 
BMI 1.89 (0.83, 4.30) 0.129 
Skinfold Measuresa  1.88 (0.81, 4.36) 0.138 
Body sizeb  1.96 (0.83, 4.60) 0.120 
Central fatsc  1.83 (0.80, 4.19) 0.150 
Combined adiposity measuresd  2.09 (0.82, 5.37) 0.122 
Smoking 1.95 (0.83, 4.58) 0.125 
Smoking + Systolic blood pressure + cholesterol / HDL ratio 1.77 (0.74, 4.24) 0.200 
Classic risk factorse  1.90 (0.76, 4.73) 0.167 
Insulin resistance  1.67 (0.70, 3.96) 0.246 
Classic risk factors + insulin resistance  1.77 (0.69, 4.54) 0.232 
Classic risk factors + fasting glucose  1.83 (0.71, 4.71) 0.208 
Classic risk factors + insulin resistance + glucose  1.76 (0.68, 4.56) 0.243 
Metabolic risk factorsf 1.60 (0.67, 3.80) 0.288 
Novel risk factorsg  1.89 (0.82, 4.35) 0.131 
Moderate to vigorous physical activity  1.89 (0.75, 4.76) 0.176 
VO2max*  1.83 (0.74, 4.56) 0.190 
Final Modelh**  1.30 (0.67, 2.53) 0.097 
 
Table shows the relative effect of ethnicity, adjusted for age (quadratic) and their interaction, on the odds 
of plaques and further adjusted by the stated variables. 
aSkinfold measures: Suprailiac, supraspinale, triceps, subscapular, thigh, calf, biceps and fat mass. 
bBody Size: Lean mass, height, mid-thigh, mid-calf and hip circumference. 
cCentral Fats: Waist circumference and waist-to-hip ratio. 
dCombined effect of a, b and c 
eTraditional risk factors: Total cholesterol, HDL cholesterol, smoking status, systolic blood pressure and 
diastolic blood pressure 
fMetabolic risk factors: HDL cholesterol, triglycerides and insulin 
gNovel risk factors: CRP, AST, ALT and GGT 
hFinal model: Ethnicity and age (quadratic) interaction and HDL. 
+: at age 50 years 
* ml.kg-1.min-1 
** Significant predictors selected from variable subgroups by backward selection.  
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5.4 Discussion 
 
The main finding from this chapter confirmed that there was no difference in 
cIMT despite their being the expected differences in the usual cardiometabolic 
risk factors observed in middle-aged South Asian compared to European men 
living in the UK. The other finding from this study was that there was no 
significant difference in carotid plaque presence, though pre-defined subgroup 
analysis suggests South Asians may have more plaques at younger ages with 
apparently no obvious increase in prevalence in older South Asians. That noted, 
it could be that the results were inadvertently biased against seeing higher 
plaque load in older South Asians given that none of the participants could have 
demonstrable CVD; more South Asian men are known to have premature CVD (9), 
and thus proportionally more older South Asians would have been ineligible for 
the study.  Clearly, these latter observations are speculative and hypothesis 
generating and larger studies are needed to examine this issue. 
 
The finding that cIMT is not increased in South Asians is consistent with the one 
previous published study comparing South Asian men with those of European 
ancestry (173).  However unlike data presented in this analysis, the earlier data 
combines healthy subjects with those who have CVD. Furthermore novel 
published data on cIMT measurements in children living in the UK showed that 
cIMT levels in South Asian children were similar to those of European children 
(258). These data in combination with this present analysis indicate that cIMT 
between South Asians and Europeans remains similar throughout life and hence 
may suggest that absolute cIMT values are not a sensitive marker for CVD risk in 
South Asians. Of interest, South Asians have narrower carotid artery diameter 
compared to Europeans, thus relative to vessel diameter, South Asians have a 
greater cIMT compared to Europeans (259) but the relevance of this finding is 
uncertain.  
 
One possible explanation for the lack of difference in cIMT is that whilst 
atherosclerosis is chiefly an intimal process, It has been highlighted that IMT is 
approximately 80% media, and only 20% intima, therefore any measurements 
made, and any changes in cIMT are likely to be a reflection of changes in the 
media (177) thus a key determinant of cIMT is the effect of blood pressure which 
 132 
 
is known to cause medial wall hypertrophy (178). Data from this present analysis 
show that South Asians have similar systolic blood pressure compared to 
Europeans and whilst South Asians have higher diastolic blood pressure, the 
mean values fall well within the normal range for healthy adults. Further, a 
systematic review of blood pressure in South Asians showed no significant 
difference in blood pressure between South Asians and Europeans (197). 
 
The aim of this study was to investigate plaque presence/quantity and not 
carotid plaque morphology. Atherosclerotic plaque morphology/size  has been 
indicated to be different between South Asians and Europeans, with South Asians 
having more aggressive morphology in coronary arteries for example (260;261). 
Thus the negative finding in this analysis should not be interpreted to indicate 
that South Asians are not more susceptible to atherosclerotic plaque or 
subsequent pathological manifestations from them.  
 
This analysis has a number of specific strengths.  To the author’s knowledge, it is 
the first study measuring and comparing carotid plaque and cIMT between South 
Asian with European adults in the UK. The groups were well-matched for age, 
BMI and SES, and although the South Asians spent more years in education, 
smoked less and drank less alcohol than the Europeans, these factors were found 
not to significantly confound the key study outcomes.  Furthermore, compared 
to the previous published data from Canada (which had a study population 
spanning a similar age-range), participants in this analysis were better matched 
for age and present clearer comparative data on individuals without CVD (173) 
 
However, this study does have limitations. A degree of caution is warranted in 
extrapolating the findings to the general UK South Asian population. By nature of 
the recruitment methods, the study cohorts represented a self-selected groups 
owing to the exclusion criteria as mentioned earlier. This healthier South Asian 
cohort, may have resulted in an underpowering of the study if CVD risk was 
lower than in the average South Asian cohort.  However, as the findings with 
respect to ethnic cIMT differences, fitness, physical activity, adiposity and 
metabolic variables in South Asians are fully consistent with the body of 
previously published data in this area, this suggests substantial bias is unlikely.  
That said, if the same exclusion criteria were to be applied, based on the data in 
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this study population in which South Asians had an unadjusted OR of 1.57 for 
plaque presence compared to Europeans, a sample size of 317 per group would 
be required to show a difference at 80% power at the 5% significance or 423 per 
group at 90% power. A more pragmatic approach if the study were to be 
repeated, would be to relax the inclusion criteria to include participants with 
known diabetes in subjects over the age of 50 given the premature onset and 
increased prevalence of diabetes of South Asians (25;28). An alternative to this  
could recruitment of the original sample size, but limit the age range from age 
40-50 years, given the suggestive findings of increased plaque in this age group, 
the relative increased premature CVD burden in South Asian males and the 
clinical importance of identifying such individuals at increased. Further, the 
major weakness of cIMT measurement and 2 dimensional plaque scoring is that 
change over time is limited because plaque propagates longitudinally along the 
artery wall ~2.4 times quicker than it extends into the arterial lumen (262) and 
data suggest that South Asians may have longer atherosclerotic lesions 
(260;261). Validated three-dimensional (3D) ultrasound techniques exist and are 
demonstrated to possibly be more informative than existing 2D cIMT and plaque 
measures (189), which can detect earlier responses to intervention e.g. statin 
therapy over a six-month period(190) exist. However published long-term 
longitudinal data or indeed CVD outcome data based on 3D imaging of carotid 
arteries is lacking.  Finally, the cross-sectional nature of the study, with 
simultaneous assessment of exposure and outcome variables, means that 
conclusions on causality cannot be definitively made or refuted. 
 
In conclusion, this present study strongly reaffirms that cIMT is similar between 
South Asian and European men despite greater risk factors in the former group.  
They also suggest no overall difference in plaques in South Asians although there 
is a strong suggestion for greater plaques at younger ages, an observation which 
requires further investigation and extension to women.  Of course, ideally, 
prospective studies linking plaques to outcomes in South Asians (particularly in 
younger South Asians) are need to investigate whether these measures help 
improve CVD risk prediction.  
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Chapter 6  
General Discussion  
 
6.1 Experimental chapter summaries  
 
The broad aim of this thesis was to further the understanding of the high risk 
cardiometabolic phenotype associated with South Asian men living in the UK. By 
undertaking this cross-sectional phenotyping study between middle-aged South 
Asian and European men, three interlinked aims were addressed n Chapters 3, 4 
and 5 respectively. 
 
The aims of Chapter 3 were to present comparative data on cardiorespiratory 
fitness, objectively-measured physical activity and other metabolic phenotypical 
data between South Asian and European men and to determine the extent of 
which differences in insulin resistance (as assessed by HOMAIR) and glycaemia 
between these ethnic groups can be explained by such factors. South Asians 
were 67% more insulin resistant than Europeans.  Lower VO2max, lower physical 
activity and greater total adiposity in South Asian individually explained 68%, 
28% and 52%, respectively, and together explained 83% (all p<0.001), of the 
ethnic difference in HOMAIR. Thus lower cardiorespiratory fitness is the single 
most important factor explaining increased insulin resistance in middle-aged 
South Asian, compared to European, men living in the UK. Although they were 
less physically active than their European counterparts, South Asians’ lower 
fitness levels could not be explained by their lower physical activity levels, 
suggesting that low fitness is an innate feature of the South Asian phenotype. 
 
The aims of chapter 4 were to determine whether South Asian men had 
increased liver fat compared to white European men and the extent to which 
such differences can explain the increased insulin resistance observed in South 
Asian men. Unadjusted liver fat content did not differ significantly between both 
groups, but following adjustment for alcohol consumption was significantly lower 
in South Asians than Europeans. Adjustment for alcohol-adjusted liver fat did not 
attenuate the difference in HOMAIR between ethnic groups. Thus whilst clear 
associations between liver fat and insulin resistance were observed in South 
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Asians and Europeans, these results challenge the notion that excess liver fat per 
se explains the greater insulin resistance observed in South Asians. 
 
 
The aims of chapter 5 were to present comparative data on cIMT and carotid 
plaque presence between South Asians and Europeans and to determine whether 
any age-related changes in differences in carotid plaque disease precede any 
age-related changes in differences in cIMT between ethnic groups and finally to 
determine what risk factors (if any) would account for any such observed 
differences in cIMT and/or carotid plaque presence. The analysis showed that  
mean cIMT was similar between South Asians and European men and there was a 
tendency for increased odds for the presence of plaque disease in South Asians 
compared to Europeans, particularly in younger South Asians. 
 
6.2 Strengths of data 
 
The published data from this thesis represent the largest cohort of South Asians 
living in Scotland with this degree of cardiometabolic phenotyping for which 
there is a well-matched European comparator group.  This study demonstrates 
the feasibility and potential success from recruiting from this sizeable minority 
ethnic population living in Scotland and moreover that good quality matching 
with European controls is also achievable. Further, as mentioned in Chapter 1, 
the published data represent the largest published study on measurements of 
fitness as well as the first published data on objectively measured physical 
activity in South Asian adult males. These large and novel data coupled with the 
storage of blood samples (for which ethical approval has been granted) allows 
for potential further metabolic and genetic analysis and phenotyping (as 
described later). 
 
The results on liver fat comparisons between these two ethnic groups are 
important in contextualising the role of liver fat as a pathophysiological 
influence on the increased metabolic risk seen in South Asians. The findings in 
this thesis highlight that previous conclusions and hypotheses require further 
examination and thus should be interpreted more cautiously. 
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Finally the non-dissimilarity in markers of carotid artery atherosclerosis is an 
important negative finding as it indicates that such methods cannot be used with 
any degree of confidence in stratifying cardiac risk in South Asians. These finding 
highlight the need for further research in alternative screening methods for CVD 
which are more sensitive in identifying subclinical CVD. 
 
 
6.3 Public health and clinical implications from current findings 
 
The demonstration that reduced cardiorespiratory fitness in South Asians 
compared to their European peers which simply cannot be explained by their 
reduced physical activity levels has important public health implications. As 
mentioned in section 3.4, the current physical activity guidelines are not ethnic-
specific and thus may be inadequate to reduce risk of cardiometabolic disease in 
South Asians. Consequently increased prescribed physical activity levels may be 
necessary in South Asians to derive equivalent cardiometabolic benefit. 
 
The results described in chapter 3 emphasise the importance to engaging with 
South Asians with lifestyle interventions even in preclinical cardiometabolic 
disease even from childhood as their inherent risk is excessive. Published data 
comparing South Asian and European Children living in the London area 
demonstrate that South Asian children have a higher-risk cardiometabolic 
phenotype (including behavioural patterns) (263-265). Thus if such behaviour is 
left unchanged, this may yet exacerbate cardiometabolic risk longer-term. 
Indeed very recent qualitative data from Scotland itself indicate that in order to 
get South Asian adults to undertake physical activity, then external motivators 
for doing so are important (266). These include undertaking physical activity as a 
means to an end, which included the opportunities that physical activity 
provided for social activity and enjoyment. The goals of weight reduction and 
improving mental and physical health and were also mentioned. Hence such 
motivational reasons need to be conveyed from a young age to maximise 
sustained positive lifestyle change. 
 
The final reason as to why it is important to engage with South Asians with 
preclinical metabolic derangement are because when South Asians do develop 
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T2DM, they appear to experience suboptimal processes of care and this may 
explain the persisting differences in glycaemic control intermediate outcomes 
(20;28;267-269). Further, South Asians appear to be more sensitive to the macro 
and microvascular complications of T2DM (14;270), hence metabolic disease 
prevention is vital.  
 
 
6.4 Implications for future research 
 
Whilst the results presented in this thesis have a number of strengths as 
previously mentioned, the cross-sectional nature of this study means that 
conclusions cannot be drawn about causality. Thus to strengthen the conclusions 
made in Chapter 3, it would be beneficial to perform intervention trials using 
structured exercise programmes or measures to improve fitness and measure 
change in metabolic risk factors – for example prospective data in healthy and 
high risk European population groups for T2DM has shown that an improvement 
in cardiorespiratory fitness is associated with improvement in insulin resistance 
(80;271).  Such trials are potentially achievable in South Asians living in Scotland 
as reflected by the recent conclusion of the Prevention of Type 2 Diabetes and 
Obesity in South Asians (PODOSA) trial (http://www.podosa.org/), which is a 
cluster randomized controlled trial investigating whether family-based lifestyle 
intervention (dietary modification and increased physical activity) can induce 
long-term weight loss and prevent diabetes in individuals with impaired glucose 
tolerance and/or impaired fasting glycaemia of Indian and Pakistani origin (121). 
The study screened over 1300 individuals, recruiting over 170 subjects and is the 
first interventional trial undertaken in South Asians in Scotland. Further, the 
limitations highlighted in Chapter 5 including suggestions for future study design 
if the study were to be repeated are potentially worth pursuing. 
 
Another area of future research is to replicate some of the outcomes from this 
present study in South Asian women. South Asian women living in the UK, just 
like their male counterparts are at increased risk of cardiometabolic disease 
Table 6.1 (11). However it is recognised and discussed in published literature 
they are less-well studied (including those born in the UK) compared to their 
male counterparts (211;212). Further subtle cardiometabolic differences exist 
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between South Asian women and European women compared to South Asian men 
and European men such as the role of adiposity on interleukin-6 and differences 
in liver fat content (68;272). Presently a local study is on-going to investigate 
the association between adiposity, nutritional habits and physical activity with 
metabolic risk in South Asian women compared to European women. The 
investigator has contributed to its design as well as facilitating current 
recruitment of South Asian women into the study. 
 
 
Table 6.1 Deaths from IHD in the UK for women 2001-2003  
 
Country Number of IHD 
Deaths 
SMR (95% CI) 
England and Wales 125 289 97  (96-97) 
Scotland 2767 108 (105-112) 
India 1672 149 (142-157) 
Pakistan 454 174 (159-192) 
Bangladesh 97 167 (136-204) 
 
 
Of key importance is to pursue the investigation of ethnic-specific physical 
activity guidelines for those ethnic groups such as South Asians who are at 
increased risk of cardiometabolic disease. Given the recent published qualitative 
data from fieldwork in Scotland, engaging in physical activity for its own sake is 
of limited importance in South Asians (266). Thus if an evidence-base is created 
to demonstrate the value of increased physical activity in relation to reducing 
cardiometabolic disease risk, then this may act as an important goal which will 
change attitude and behaviour in South Asians – as tangible goals are important 
positive factors for this high risk ethnic group (266). 
 
In an attempt to address this area, the author with his supervisors and 
colleagues have utilised this existing thesis data to determine the level of 
moderate physical activity required in South Asians to confer a similar 
cardiometabolic risk profile to that observed in Europeans undertaking the 
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current UK weekly recommended moderate physical activity level of 150 minutes 
a week (95). The results from this analysis indicate that the equivalent moderate 
physical activity value for the overall cardiometabolic risk factor was 266 (95% CI 
185-347) min/week (273). Thus South Asian men need to engage in at least two-
thirds more the amount of physical activity that is presently recommended in 
the UK for adults (95). 
 
Whilst this present study’s findings suggest that liver fat is not increased in 
South Asians compared to Europeans, all studies to date have had relatively 
small sample sizes. The cost of MR scanning make larger scale studies financially 
more challenging, but at least one such study in well-matched, well phenotyped 
South Asians would be beneficial in addressing this growing area of interest. 
Indeed coupling such imaging with an intervention-based study as described 
above would be an efficient method of further investigation. Further, novel data 
suggests that pancreatic fat rather than liver fat is more influential in the 
dysglycaemic process (255), and is a potential area for future research. Our 
team attempted to image the pancreas using MRI/MRS on the study subjects, but 
given the current resources, were not convinced that image quality would 
permit for accurate analysis. 
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6.5 Final conclusions  
 
In conclusion, this thesis describes studies which have attempted to increase 
understanding of the cardiometabolic phenotype of South Asians. Novel findings 
from the studies suggest that increased insulin resistance in South Asians, which 
has a significant pathophysiological association with T2DM risk, is most strongly 
adversely influenced by their reduced cardiorespiratory fitness compared to 
their white European counterparts, with differences in physical activity not 
explaining the differences in cardiorespiratory fitness observed between the two 
groups. Similarly, data from this thesis data suggest that South Asians are likely 
to need to engage in higher levels of physical activity than Europeans to 
overcome their lower innate fitness and the associated metabolic consequences.  
This raises the possibility that ethnic-specific recommendations for physical 
activity levels to promote healthy living and reduce cardiometabolic disease are 
needed. Further, the strong association of increased liver fat on increased 
insulin resistance and subsequent onset of T2DM has been questioned by this 
thesis. Finally this thesis suggests that existing carotid ultrasound screening 
modalities for subclinical CVD may lack sensitivity in South Asians. This highlights 
the need for further study in existing (e.g. focussing on younger South Asians, 
aged 40-50) and novel screening methods for CVD which may be  more sensitive 
and thus could be utilised in this high risk ethnic group for CVD.  
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Appendix A1 - VOLUNTEER INFORMATION LEAFLET 
(Version 2.1 12/5/10) 
 
A novel assessment of vascular disease and its association with insulin 
resistance, fitness and adiposity in South Asians 
 
Short Title: Carotid plaques, insulin resistance, fat and fitness in South Asians 
 
Lay title: Fatty deposits in the arteries in the necks of South Asians and their 
relation to blood sugar control, fitness and body fat  
 
Study Doctor: Dr Nazim Ghouri 
 
Other investigators: Prof Naveed Sattar (Principal Investigator, University of Glasgow), 
Dr Jason Gill, Dr Stuart Ballantyne, Prof Ian Ford  
 
You are being invited to take part in a research study.  Before you decide whether or not 
to take part, it is important for you to understand why the research is being done and what 
it will involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would like 
more information.  Take time to decide whether or not you wish to take part. 
 
 
What is the purpose of the study? 
Individuals of South Asian ancestry have higher heart disease risk but why this is so is not 
known. One theory suggests South Asians carry more fat but have less muscle size and 
this has never been explored.  We also do not know how best to assess heart disease risk 
in South Asians. This proposed study will measure thickening of arteries in the necks of 
South Asians by two different methods, good measures of heart disease risk, and relate 
this to a detailed look at their fat and muscle levels. If we are correct, this information will 
help reduce heart disease risk in South Asians.  
  
  
Why have I been chosen? 
You have been chosen because you are a healthy adult male aged between 40 and 70, 
with both parents of either European or South Asian (i.e. Indian, Pakistani, Bangladeshi or 
Sri Lankan) origin.  The study will compare the two different groups to establish whether 
there are differences in the thickness in the arteries if the neck and if there is any 
connection with the body’s ability to control sugar and the amount and location of body fat. 
We are excluding men who have angina or diabetes, or have had a previous heart attack, 
stroke, or mini-stroke (TIA), or have problems with their joints, muscles, limbs and 
breathing that would prevent them from going on a treadmill and exercising. We are also 
excluding anyone who is not allowed to have an MRI scan (cardiac pacemaker, aneurysm 
clip, artificial heart valve, ear (cochlear) implant, metal fragments in eyes, head or body or 
any procedure to remove metal, metallic Implant) 
 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. 
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What is my part in the study? 
If you agree to take part in the study and meet entry requirements then your participation 
will consist of 1 visit lasting around 3 hours and 1 further short visit for a an MRI scan of 
your abdomen. You will be paid £20 as a token of gratitude for your participation and we 
will arrange taxi journeys to and/or from the University if you require transport. 
 
 
What do I have to do? 
If you are happy with the information provided and agree to participate, you can attend 
directly for the main visit. If you have any questions or wish to discuss things before 
agreeing, we can discuss things via telephone, email or in person before attending for the 
main visit. 
 
You will be asked to report to the BHF Cardiovascular Research Centre to attend for the 
main visit (address at bottom of first page, map on last page). The fist part of the visit will 
take place here. The rest of the main visit will take place in the University’s purpose built 
exercise-testing facility in the neighbouring West Medical Building 
 
You will be asked to attend for the main visit after an overnight fast (not having had 
anything to eat or drink, except water, for at least 10 hours). It may, therefore be more 
convenient for you to arrange visits in the morning. We ask that you wear/bring a pair of 
shorts and other clothes and footwear you will find comfortable exercising in. 
 
 We will re-discuss with you the study and your involvement, and then help you 
complete confidential questionnaires regarding your health, family history, and 
diet.  We will also measure your blood pressure.  There will be an opportunity for 
you to ask questions. You will also complete a questionnaire to see if you are 
allowed to have an MRI scan. We will then take bloods from a vein in your 
forearm. We will take samples to check the function of your kidneys and liver, and 
measure glucose, insulin and fat levels and other markers related to 
cardiovascular disease. If you are agreeable, we will also store a sample of blood 
for any future analysis, including looking for genes associated with vascular 
disease and diabetes. We will take approximately 20-30 mls of blood (4-6 
teaspoons) for this. This will last around 45 minutes. You will then be offered 
breakfast. 
 
 The next part of this visit will involve you have an ultrasound scan of the arteries in 
your neck. This will take up to 45 minutes. This is a non-invasive pain-free scan 
and will involve some water-based jelly being put on your neck and a small probe 
will be placed over this area and images of your arteries will be taken and stored. 
These images will then be analysed later on to measure the thickness of the 
arteries and count any fatty deposits that may be seen.    
 
You will then be taken over to the West Medical building to complete the last parts of the 
main visit. Here you will have some simple body fat distribution measurements taken, sit 
in a special device (BodPod) to measure your body fat levels, and will then be put on a 
treadmill and made to exercise (walk/run) to your capacity. 
 
 The distribution of your body fat will be determined by measuring body girths and by 
using callipers to measure skin fold thickness at seven different sites on your arms, 
upper body and legs (a sophisticated version of "pinch an inch"). Your height, weight 
and waist and hip circumferences will also be recorded. You will need to wear only 
underclothing for these measurements which will be made in private.  These 
measurements only take a few minutes. 
 
 The BodPod is a computerized, egg-shaped chamber, in which the individual sits. 
The measurement will be done with you wearing a pair of shorts or surgical scrub 
trousers only (privacy provided). The measurement will take around 5 minutes, and 
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you will be expected to sit still for the measurement. This measurement will be able 
to tell us what proportion of your body is made up of fat and how much is ‘fat-free’.  
 
 The exercise treadmill test will be done to determine your fitness level i.e. how fit 
you are. You will have quick medical examination and a heart tracing (ECG) will be 
done to ensure your safe to have the test. The test will involve you initially walking 
on the treadmill at a fixed speed on the flat, and you will have self-adhesive 
electrodes attached to your chest to monitor how hard your heart is working 
(continuous ECGs).  The speed and slope will be gradually increased at fixed time 
intervals. You will have to walk faster and possibly run to keep up with the speed of 
the treadmill, and this will get progressively harder. The test will stop if you indicate 
that you can no longer keep up with the treadmill, or if your ECG shows changes 
that require the test to be stopped. You will also be wearing a mouth piece that will 
have a tube, to measure the amount of oxygen and carbon dioxide you are 
breathing in and out. As this test involves you exercising to maximal effort, you 
should wearing clothing and footwear you will feel comfortable exercising in. 
 
 You will then be asked to wear an accelometer (pager-like machine to sit on the 
waist) for one week to allow objective measurement of habitual physical activity 
and cardiorespiratory fitness. The accelerometer will be worn for the hours spent 
awake for the seven day period. The accelerometer is to be returned back to the 
University or picked up by study doctor (if practical) 
 
If we receive additional funding for this study, then you may be invited to attend for an MRI 
scan of your abdomen at Gartnavel Hospital. The scans would be arranged for a mutually 
convenient time.  
 
 For the MRI scan, you will be asked to wear a gown or you can bring a tracksuit 
(without zips) or pyjamas to change into. The MRI staff at the hospital will double 
check that you are safe to have the scan and take your consent. You will be asked 
to lie on a padded table that will slide you into the MRI scanner. The MRI scan is 
non-invasive and will capture images of your abdomen, particularly your liver. This 
scan will be able to tell us more specifically about any fat you may have in your 
liver and abdomen 
 
 
What are the possible disadvantages and risks of taking part? 
 Blood sampling may cause minor bruising, an inflammation of the vein or 
haematoma (a small accumulation of blood under the skin). Good practice, 
however, minimises this risk.  Some people may feel faint when they give blood. 
 
 The exercise tests will be at a maximal level and the possibility exists that, very 
occasionally, certain changes may occur during or shortly after the test. They 
include abnormal blood pressure, fainting or a change in the normal rhythm of the 
heartbeat.  At least two people will be present for all exercise tests (including the 
Study doctor) which will be undertaken in a room with all the necessary health and 
safety equipment. 
 
 The scan to measure the amount of fat in you liver will involve you lying still in a 
relatively confined space in the MRI scanner for 20-30 minutes. The scanner can 
be a bit noisy and some people who suffer from claustrophobia can find the 
confined space a bit unbearable. 
 
 There is a small possibility that taking part in this study will reveal a health problem 
that you already have such as high cholesterol, high blood pressure possible 
diabetes or angina.  If such a problem is revealed, with your permission, we will 
inform your GP to ensure that you receive appropriate treatment.  If necessary, a 
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clinical consultant physician (Professor Naveed Sattar) will supervise any follow-up 
care. Finally, if a condition such as diabetes is diagnosed, you may have to inform 
any insurance or mortgage companies you may take policies with in the future. 
 
 
What are the possible benefits of taking part? 
You will received a free health ‘MOT’ - the information gained during the study will allow 
us to give you detailed feedback about your blood pressure, cholesterol, blood sugar 
level, of “insulin resistance”, any fatty/thickness changes in the arteries of your neck, 
about your fitness levels and about your body fat. The knowledge gained from your 
participation may help develop screening tests that will help predict future risk of vascular 
disease in groups of people. Also, the knowledge gained will help guide future research 
investigating how to reduce this increased risk through lifestyle changes and may also 
help direct the development of new and drugs to prevent and treat groups at increased 
risk of vascular disease.  
 
 
What if something goes wrong? 
The chance of something going wrong is extremely small.  All of the procedures involved 
in this study are low risk. In the unlikely event that you are harmed due to someone's 
negligence, then you may have grounds for a legal action but you may have to pay for it.  
The University of Glasgow has in force a Public Liability Policy and Clinical Trials Policy 
which provides cover for negligent harm that may arise from participation. Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms may be available to you. 
 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential and only be handled by the individuals listed above or any staff that 
work under their supervision.  Any information about you which leaves the University will 
have your name and address removed so that you cannot be recognised from it. 
 
 
Who is organising and funding the research? 
This study is mainly being funded by Chest, Heart and Stroke Scotland, a charity that 
provides care and support throughout Scotland for people affected by Stroke, Heart 
disease and lung disease, as well as their families and other carers. They fund research 
into all aspects of prevention, diagnosis, treatment, rehabilitation and the social impact of 
chest, heart and stroke illness.   
  
 
What will happen to my samples after the study has finished? 
The blood samples that you provide for this study may be useful for future research into 
the prevention and treatment of diabetes and heart disease; this may involve analysis of 
certain genes associated with these diseases. Any use of your samples in future research 
will require further approval from a Research Ethics Committee and samples will be 
analysed in such a way that the results will not be directly traceable to you.  If you do not 
wish your samples to be used in future research, please indicate this on the consent form. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the West of Scotland (1) Research Ethics 
Committee. 
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Contact for Further Information 
You may ask any questions you like now or at any time about your rights as a participant 
in a research study or about the research study itself.  Dr Nazim Ghouri can be contacted 
by phone on 0141 3303076 or 07740782912 or e-mail n.ghouri@clinmed.gla.ac.uk, to 
discuss things or to meet in person.  
 
 
You will be given a copy of this information sheet and a signed consent form to 
keep for your records. 
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Volunteer Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project: A novel assessment of vascular 
disease, and its association with insulin resistance 
and adiposity in South Asians 
 
 Name of Researcher:_______________________________ 
 
   Please initial box 
 
1. I confirm that I have read and understand the 
information sheet dated 19th January 2010 for the above 
study and  
 have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to    
 withdraw at any time, without giving any reason, without my medical  
 care or legal rights being affected. 
 
3. I agree to take part in the above study. 
 
 
 
4. I agree to my GP being informed of my participation in the study.  
 
 
 
5. I agree for my samples to be used for future research into the 
prevention and treatment of diabetes and heart disease.  This 
may involve analysis of genes associated with these 
diseases. 
 
 
      
           
Name of Patient Date Signature 
 
    
Name of Person taking consent  Date Signature 
(if different from researcher) 
 
   
Researcher Date Signature 
 
 
1 for patient; 1 for researcher. 
 
Yes  
No 
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Appendix A2 - HEALTH SCREEN FOR STUDY VOLUNTEERS 
(Version 1, 14/9/09) 
 
Name: ……………………………………………………… Date of Birth: …………. 
 
Both parents of South Asian origin (Indian, Pakistani,  
Bangladeshi or Sri Lankan)     yes [ ] no [ ] 
Both parents of European origin    yes [ ] no [ ] 
 
It is important that volunteers participating in research studies are currently in good health and have 
had no significant medical problems in the past.  This is to ensure (i) their own continuing well-
being and (ii) to avoid the possibility of individual health issues confounding study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise  yes [ ] no [ ] 
(b)  attending your general practitioner    yes [ ] no [ ] 
(c) on a hospital waiting list    yes [ ] no [ ] 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP     yes [ ] no [ ] 
(b) attend a hospital outpatient department   yes [ ] no [ ] 
(c) be admitted to hospital      yes [ ] no [ ] 
 
3.   Have you ever had any of the following symptoms to a significant degree at rest or during 
exercise?  That is, have you had to consult a physician relating to any of the following? 
     Rest              Exercise 
(a)  Breathlessness  yes [ ] no [ ]  yes [ ] no [ ] 
(b)  Chest Pain  yes [ ] no [ ]   yes [ ] no [ ] 
(c)  Dizzy spells/Fainting yes [ ] no [ ]  yes [ ] no [ ] 
(d)  Diabetes  yes [ ] no [ ]   yes [ ] no [ ] 
(e)  Palpitations  yes [ ] no [ ]   yes [ ] no [ ] 
(f) Tightness in chest, jaw  
  or arm   yes [ ] no [ ]   yes [ ] no [ ] 
(g)  Other*   yes [ ] no [ ] 
 
*(Please specify) 
……………………………………………………………………..………………………. 
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4.    Do you have/or have had any muscle or joint injury which could affect your safety in 
performing exercise (e.g. cycling or running), strength testing or strength training?  
         yes [ ] no [ ] 
5. Have you ever had any of the following: 
(a) Convulsions/epilepsy     yes [ ] no [ ] 
(b) Asthma       yes [ ] no [ ] 
(c)  Eczema       yes [ ] no [ ] 
(d)  Diabetes      yes [ ] no [ ] 
(e) A blood disorder     yes [ ] no [ ] 
(g)  Digestive problems     yes [ ] no [ ] 
(h) Hearing problems     yes [ ] no [ ] 
(i) Disturbance of balance/co-ordination   yes [ ] no [ ] 
(j) Numbness in hands or feet    yes [ ] no [ ] 
(k) Disturbance of vision     yes [ ] no [ ] 
(l) Thyroid problems     yes [ ] no [ ] 
(m) Kidney or liver problems    yes [ ] no [ ] 
(n) Heart problems including murmurs   yes [ ] no [ ] 
(o) Any other health problems    yes [ ] no [ ] 
 (p) An allergy to soya protein or eggs   yes [ ] no [ ] 
 
6. Have any of your family (parents, grandparents, brothers, sisters, children, aunts, uncles, 
cousins) ever had any of the following: (if yes please give details below including age of first 
diagnosis if known) 
(a) Any heart problems     yes [ ] no [ ] 
(b) Diabetes      yes [ ] no [ ] 
(c)  Stroke       yes [ ] no [ ] 
(d)  Any other family illnesses    yes [ ] no [ ] 
 
7. Do you currently smoke     yes [ ] no [ ] 
 If yes, how many  < 10 per day  [      ] 10-20 per day  [     ] >20 per day  [     ] 
 If no, have you ever smoked    yes [ ] no [ ] 
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 If so, for how long did you smoke and when did you stop? …………………… 
 
8. How many units of alcohol do you typically drink in a week? …………………. 
 
If YES to any question, please describe briefly, including listing of current medication (e.g. to 
confirm whether problem was short-lived, insignificant or well controlled.) (Use a separate 
sheet if necessary) 
………………………………………………………………………………………………………... 
………………………………………………………………………………………………………...
…………….….……………………………………………………………………………………….
……………………………………………………………………………………………………...…
…………………………………..……………………………………………………………………
………………………………………………………………………………………………………
………………………………………………… 
 
Name and address of GP 
………………………………………………………………………………… 
     
…………………………………………………………………………………  
 
Signature:….…………………………………..   Date:……………….. 
 
 
Measurements 
 
Blood pressure  - Left arm (BEFORE MMode image RIGHT carotid)…………………..mm Hg  
 
Blood pressure  - Left arm (AFTER MMode image RIGHT carotid)…………………..mm Hg  
 
Blood pressure  - Left arm (BEFORE MMode image LEFT carotid)…………………..mm Hg  
 
Blood pressure  - Left arm (AFTER MMode image LEFT carotid)…………………..mm Hg  
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Appendix A3 - Food frequency questionnaire 
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Appendix A4 - Carotid ultrasound protocol 
Procedure  
 Switch the Acuson Sequoia on by pushing the button below the monitor on 
the left. 
To enter participant identifiers: 
a) Press Begin/End button in top left corner of control panel. 
b) Select “Start New Patient” on the soft key displayed on the base of the 
monitor. 
c) Enter subject initials from participant list in “Patient Name” field. 
d) Press “TAB” OR “Enter” to move to next field. 
e) Enter SA study number in “Patient ID” field. 
f) Leave “Study Type” as “SA study Trial”. 
g) Leave “Exam Preset” as “SA study Trial”. 
h) Enter date of birth. Age is calculated automatically. 
i) Enter sex (M for Male, F for Female). 
j) Enter sonographer ID number. 
1) Press “Begin Imaging” on the soft key displayed on the base of the monitor. 
2) Ensure subject is lying reclined and comfortably cushioned on the 
examination couch. 
3) Use wedge; ear-to-ear plane at 45 degrees to the horizontal; head turned to 
the contralateral side of scan. 
4) Apply ultrasound gel to neck. 
5) The left button on the screen scrolls through the examinations. Press 
“protocol” before pressing the left button on the screen to advance to the 
next stage of the examination. Each stage should be completed in turn: 
 
R_ICA_DOP: Doppler of right internal carotid artery: 
i) Use 4 cm depth setting (default). 
ii) Identify ICA. 
iii) Press “Cursor” key to position Doppler gate in entrance of ICA. 
iv) Press “Angle” knob and adjust angle to be parallel to blood flow.  
v) Press “PW” button. 
vi) Use trackball to adjust position to optimise trace. 
vii) Press “Gain/Frz/Run” to freeze image. 
viii) Rotate “Gain/Frz/Run” to scroll through strip if necessary, to obtain best 
available strip. 
ix) Press “Calipers On”. 
x) Use trackball to position caliper on peak of Doppler trace. 
xi) Double check that angle is set correctly. 
xii) Press “Image Store” to store image. 
xiii) N.B. If velocity is above 1.25m/s, note this and pass information to Kevin 
Deans as critical action limit. 
xiv) Press “Protocol” button and use left soft key to move to the next stage of 
the imaging protocol. 
RCCA_1:  
Identify the common carotid artery (CCA) region in RES4 (the arterial wall proximal 
to the dilatation), then: 
i) Press “RES” button. 
ii) RES (Regional expansion selection) 2 (2x2cm) box pops up. 
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iii) Move box to area of interest with trackball. 
iv) Press “RES” button again. 
v) Once real time image is satisfactory, press “Clip Store”. 
vi) Once clip has been stored, press “Gain/Frz/Run” to freeze image. 
vii) Rotate “Gain/Frz/Run” wheel to find optimal image where double line 
pattern is clearest. 
viii) To place a caliper mark: 
(1) Press “Calipers On” 
(2) Use trackball to move caliper to desired position. 
(3) On CCA image, place caliper mark at start of carotid bulb. 
ix) To store image, press “IMAGE STORE” 
x) Press “RES” again to leave “RES” mode. 
xi) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
RBUL_1:  
Identify the carotid bulb region in RES4 (the arterial wall between the 
dilatation and the flow divider), then image in RES2: 
i) Follow above procedure to store clip and image. 
ii) Place two caliper marks: one at start of the dilatation and one at level of 
flow divider. Left click (“Select” key) to anchor caliper. 
iii) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
RICA_1:  
Identify the right internal carotid (ICA) region in RES4 (the arterial wall distal 
to the flow divider) then image in RES2: 
i) Place caliper mark at level of flow divider. 
ii) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
R_MMODE:  
i) Take blood pressure using Omron sphygmomanometer. 
ii) Enter BP (SBP, DBP and HR) in relevant fields in laptop. 
iii) Return to right common carotid artery. 
iv) Press “RES” to magnify distal common carotid artery. 
v) Press “M-MODE”. 
vi) Use trackball to position M-line in B-mode part of the image. 
vii) When image is satisfactory, freeze image and rotate to find best image. 
viii) Store image in M-mode. 
ix) Repeat blood pressure measurement (using same arm throughout) and record 
in laptop. 
x) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
Repeat above steps for imaging the left carotid arterial wall segments: 
 
L_ICA_DOP: Left internal carotid artery Doppler 
i) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
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LCCA_1: Left common carotid artery, longitudinal section 
i) Place caliper mark at start of carotid bulb. 
ii) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
LBUL_1: Left carotid artery bulb, longitudinal section 
i) Place caliper marks at start of bulb and at level of flow divider. 
ii) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
LICA_1: Left internal carotid artery, longitudinal section 
i) Place caliper mark at level of flow divider. 
ii) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
 
L_MMODE:  
i) Take blood pressure using Omron sphygmomanometer and record SBP, DBP 
and HR values in laptop. 
ii) Return to left common carotid artery. 
iii) Press “RES” to magnify distal common carotid artery. 
iv) Press “M-MODE”. 
v) Use trackball to position M-line in B-mode part of the image. 
vi) When image is satisfactory, freeze image and rotate “Gain/Frz/Run” wheel 
to find best strip. 
vii) Store image in M-mode. 
viii) Repeat blood pressure measurement and record in laptop. 
ix) Press “Protocol” button and use left soft key to move to next stage of 
protocol. 
To review images: 
a) Press “REVIEW” 
b) Press “QUAD” button to alternate between viewing four images per screen or 
one image per screen. 
c) To delete any images, highlight image and press “DELETE”. 
d) A total of 16 images should be present (4 quad pages): 6 images, 6 clips, 2 
Dopplers and 2 M-modes. 
To end examination: 
a) Press “BEGIN/END” – returns user to demographic page. 
b) Press “START NEW PATIENT” soft key – closes examination and stores 
images on hard drive. 
c) Alternatively, press “STUDY/UTIL”. 
 
To copy studies to CD burner: 
a) Ensure other Acuson Sequoia instrument and switching device are both 
switched on. 
b) Insert blank CD-R into CD burner. 
c) Press “STUDY/UTIL” 
d) Select subjects to be copied to CD. Studies which have not been copied 
are highlighted with an asterisk. 
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e) Press “COPY to MDR”. 
f) Once studies have been copied to MDR, MDR display shows “Staging Files”. 
g) Press “Eject”. 
h) On ejecting CD, studies are burned to CD. 
i) Label CD with SA study study numbers and subject initials. 
 
Clean probe with Cutan wipes and T-spray cleaning solution only. 
To switch Acuson Sequoia off, push power switch. Do not unplug 
the instrument until the system has completely powered down 
and the screen is completely dark. 
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Appendix A5 – Carotid intima-media thickness-reader validation 
 
Table 1 Intra-reader reproducibility 
 
   Run (Mean of LCCA and RCCA, mm)    
Scan 1 2 3 4 5 6 7 8 9 10 Mean 
IMT 
(mm) 
Standard 
Deviation 
Coefficient 
Variance (%) 
1 0.548 0.535 0.521 0.562 0.5395 0.5315 0.534 0.5255 0.526 0.518 0.53405 0.013 2.3 
2 0.541 0.5425 0.554 0.52 0.519 0.508 0.523 0.5225 0.5255 0.535 0.52905 0.014 2.3 
3 0.4435 0.439 0.434 0.432 0.4495 0.438 0.4375 0.4415 0.434 0.379 0.4378 0.006 1.4 
4 0.651 0.65 0.6435 0.656 0.6175 0.6435 0.6295 0.6545 0.639 0.6435 0.6428 0.012 1.9 
5 0.385 0.3815 0.363 0.353 0.357 0.349 0.3645 0.339 0.334 0.3515 0.35775 0.016 4.6 
6 0.4975 0.496 0.475 0.482 0.4865 0.488 0.476 0.4875 0.481 0.469 0.48385 0.009 1.9 
7 0.4525 0.454 0.4535 0.441 0.456 0.4575 0.4535 0.438 0.4515 0.4495 0.4507 0.006 1.4 
8 0.555 0.5315 0.5515 0.5345 0.5375 0.512 0.5235 0.542 0.539 0.529 0.53555 0.013 2.4 
9 0.442 0.4515 0.429 0.4635 0.4755 0.45 0.455 0.433 0.4425 0.4455 0.44875 0.014 3.1 
10 0.5265 0.5265 0.516 0.501 0.4945 0.509 0.52 0.491 0.4925 0.4975 0.50745 0.014 2.8 
              
 
 
Table 2 Inter-reader reproducibility 
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Appendix A6 - Formulae for calculating predicted oxygen uptake (VO2pred) and 
additional speeds for gradient plateaux 
 
 
Speed equivalents 
 
4.5 km.h-1 = 75 m.min-1 
5.0 km.h-1 = 83.33 m.min-1 
5.5. km.h-1 = 91.67 m.min-1 
 
 
Calculating predicted oxygen uptake (VO2pred)  in ml.kg
-1.min-1 when gradient 
increasing and speed fixed 
 
VO2pred = 3.5 + 0.1 x speed (m.min
-1) + (gradient % x speed (m/min) x 1.8) 
 
 
Speed 4.5 km.h-1 
 
VO2pred  =  3.5 + 7.5   +  (gradient % x 75 x 1.8) 
  =  11     +  (gradient % x 135) 
 
 
Speed 5.0 km.h-1 
 
VO2pred  =  3.5 + 8.33   +  (gradient% x 83.33 x 1.8) 
  =  11.83    +  (gradient% x 150) 
 
 
Speed 5.5 km.hr-1 
 
VO2pred  =  3.5 + 9.17   +  (gradient% x 91.67 x 1.8) 
  =  12.67    +  (gradient% x 165) 
 
 
 
Calculating new speeds when maximum gradient attained 
 
 
Starting Speed 4.5 km.hr-1 
 
Gradient increment 2% 
 
Incremental ΔVO2pred = 2.7 ml.kg
-1.min-1 
 
New speed using max gradient of 24% (km.hr-1) = predicted O2 uptake – 3.5 
                       8.87 
 
 
Gradient increment 2.5% 
 
Incremental ΔVO2pred = 3.4 ml.kg
-1.min-1 
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New speed using max gradient of 25% (km.hr-1) =  predicted O2 uptake – 3.5 
                9.17 
 
 
Gradient increment 3% 
 
Incremental ΔVO2pred = 4-4.1 ml.kg
-1.min-1 
 
New speed using max gradient of 24% (km.hr-1) =  predicted O2 uptake – 3.5 
                8.87 
 
 
Starting Speed 5.0 km.hr-1 
 
Gradient increment 2% 
 
Incremental ΔVO2pred = 3 ml.kg
-1.min-1 
 
New speed using max gradient of 24% (km.hr-1) =  predicted O2 uptake – 3.5 
                8.87 
 
 
Gradient increment 2.5% 
 
ΔVO2pred = 3.7-3.8 ml.kg
-1.min-1 
 
New speed using max gradient of 25% (km.hr-1) =  predicted O2 uptake – 3.5 
                9.17 
 
 
Gradient increment 3% 
 
Incremental ΔVO2pred = 4.5 ml.kg
-1.min-1 
 
New speed using max gradient of 24% (km.hr-1) =  predicted O2 uptake – 3.5 
                8.87 
 
 
Starting Speed 5.5 km.hr-1 
 
Gradient increment 2% 
 
Incremental ΔVO2pred = 3.3 ml.kg
-1.min-1 
New speed using max gradient of 24% (km.hr-1) =  predicted O2 uptake – 3.5 
                8.87 
 
Gradient increment 2.5% 
 
Incremental ΔVO2pred = 4.1 ml.kg
-1.min-1 
 
New speed using max gradient of 25% (km.hr-1) =  predicted O2 uptake – 3.5 
                9.17 
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Gradient increment 3% 
 
Incremental ΔVO2pred = 4.9-5.0 ml.kg
-1.min-1 
 
New speed using max gradient of 24% (km.hr-1) =  predicted O2 uptake– 3.5 
                8.87 
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Appendix A7 
 
 
Exercise test Protocols 1-9
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Protocol 1 - Predicted Oxygen Consumption (VO2pred) - 4.5 km/hr + 2% / 2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
4.5 0 11.0 
4.5 2 13.7 
4.5 4 16.4 
4.5 6 19.1 
4.5 8 21.8 
4.5 10 24.5 
4.5 12 27.2 
4.5 14 29.9 
4.5 16 32.6 
4.5 18 35.3 
4.5 20 38.0 
4.5 22 40.7 
4.5 24 43.4 
4.8 24 46.1 
5.1 24 48.8 
 191 
Protocol 2 - Predicted Oxygen Consumption (VO2pred) - 4.5 km/hr + 2.5% / 
2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
4.5 0 11.0 
4.5 2.5 14.4 
4.5 5 17.8 
4.5 7.5 21.1 
4.5 10 24.5 
4.5 12.5 27.9 
4.5 15 31.3 
4.5 17.5 34.6 
4.5 20 38.0 
4.5 22.5 41.4 
4.5 25 44.8 
4.9 25 48.2 
5.2 25 51.6 
5.6 25 55.0 
6.0 25 58.4 
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 Protocol 3 - Predicted Oxygen Consumption (VO2pred) - 4.5 km/hr + 3% / 2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
4.5 0 11.0 
4.5 3 15.1 
4.5 6 19.1 
4.5 9 23.2 
4.5 12 27.2 
4.5 15 31.3 
4.5 18 35.3 
4.5 21 39.4 
4.5 24 43.4 
5.0 24 47.5 
5.4 24 51.5 
5.9 24 55.6 
6.3 24 59.6 
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 Protocol 4 - Predicted Oxygen Consumption (VO2pred) – 5.0 km/hr + 2% / 2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
5.0 0 11.8 
5.0 2 14.8 
5.0 4 17.8 
5.0 6 20.8 
5.0 8 23.8 
5.0 10 26.8 
5.0 12 29.8 
5.0 14 32.8 
5.0 16 35.8 
5.0 18 38.8 
5.0 20 41.8 
5.0 22 44.8 
5.0 24 47.8 
5.3 24 50.8 
5.7 24 53.8 
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Protocol 5 - Predicted Oxygen Consumption (VO2pred) - 5.0 km/hr + 2.5% / 
2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
5.0 0 11.8 
5.0 2.5 15.6 
5.0 5 19.3 
5.0 7.5 23.1 
5.0 10 26.8 
5.0 12.5 30.6 
5.0 15 34.3 
5.0 17.5 38.1 
5.0 20 41.8 
5.0 22.5 45.6 
5.0 25 49.3 
5.4 25 53.0 
5.8 25 56.7 
6.2 25 60.4 
6.6 25 64.1 
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Protocol 6 - Predicted Oxygen Consumption (VO2pred) - 5.0 km/hr + 3% / 2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
5.0 0 11.8 
5.0 3 16.3 
5.0 6 20.8 
5.0 9 25.3 
5.0 12 29.8 
5.0 15 34.3 
5.0 18 38.8 
5.0 21 43.3 
5.0 24 47.8 
5.5 24 52.3 
6.0 24 56.8 
6.5 24 61.3 
7.0 24 65.8 
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Protocol 7 - Predicted Oxygen Consumption (VO2pred) – 5.5 km/hr + 2% / 2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
5.5 0 12.7 
5.5 2 16.0 
5.5 4 19.3 
5.5 6 22.6 
5.5 8 25.9 
5.5 10 29.2 
5.5 12 32.5 
5.5 14 35.8 
5.5 16 39.1 
5.5 18 42.4 
5.5 20 45.7 
5.5 22 49.0 
5.5 24 52.3 
5.9 24 55.6 
6.2 24 58.9 
6.6 24 62.2 
7.0 24 65.5 
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Protocol 8 - Predicted Oxygen Consumption (VO2pred) - 5.5 km/hr + 2.5 % / 
2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
5.5 0 12.7 
5.5 2.5 16.8 
5.5 5 20.9 
5.5 7.5 25.0 
5.5 10 29.2 
5.5 12.5 33.3 
5.5 15 37.4 
5.5 17.5 41.5 
5.5 20 45.7 
5.5 22.5 49.8 
5.5 25 53.9 
5.9 25 58.0 
6.4 25 62.1 
6.8 25 66.2 
7.3 25 70.3 
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Protocol 9 - Predicted Oxygen Consumption (VO2pred) - 5.5 km/hr + 3% / 2min 
 
 
Speed (Km.hr-1) Gradient % Pred O2 uptake 
(ml.kg-1.min-1) 
5.5 0 12.7 
5.5 3 17.6 
5.5 6 22.6 
5.5 9 27.5 
5.5 12 32.5 
5.5 15 37.4 
5.5 18 42.4 
5.5 21 47.3 
5.5 24 52.3 
6.1 24 57.2 
6.6 24 62.2 
7.2 24 67.1 
7.7 24 72.1 
 
 
 
  
Appendix A8: Associations between HOMAIR and fasting glucose concentration with smoking status, alcohol consumption, years in 
education and SES.   
 
Predictor  
HOMA IR Fasting Glucose 
 
 Relative effect 
estimate (95% CI) 
p-value 
Relative effect 
estimate (95% CI) 
p-value 
Ethnicity  (European vs. South Asian)   1.67 (1.42, 1.96) <0.001 1.03 (1.01, 1.06) 0.017 
Years in Education  (per one year 
increase) 
 0.98 (0.96, 1.01) 0.191 1.00 (1.00, 1.01), 0.280 
SIMD Quintile (vs. 1st Quintile) 2 1.21 (0.82, 1.77) 0.334 1.01 (0.94, 1.08), 0.799 
 3 1.22 (0.85, 1.74) 0.279 1.02 (0.96, 1.08), 0.545 
 4 1.23 (0.87, 1.75) 0.238 0.98 (0.92, 1.04), 0.421 
 5 1.32 (0.95, 1.84) 0.100 1.01 (0.95, 1.07), 0.752 
   (0.569)  (0.322) 
Smoking Status (vs. non smoker) Ex-smoker 1.26 (1.02, 1.56) 0.030 1.03 (1.00, 1.07), 0.088 
 Current 1.02 (0.79, 1.31) 0.909 1.03 (0.99, 1.08), 0.144 
   (0.091)  (0.119) 
Alcohol Consumption (units per week) 
(vs. non-drinker) 
≤20 0.92 (0.68, 1.23) 0.561 1.01 (0.96, 1.07), 0.574 
 >21 0.86 (0.60, 1.22) 0.390 1.02 (0.96, 1.09), 0.476 
   (0.690)  (0.769) 
Values are presented with 95% confidence intervals (95% CI) and p values, with p values for the overall effect of categorical variables given in parenthesis. 
